UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended February 2928, ~~2024~~2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: ~~333~~000-~~265368~~56737

MEDINOTEC, INC.

(Exact name of registrant as specified in its charter)

Nevada		36-4990343
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Northlands Deco Park | 10 New Market Street | Stand 299 Avant Garde Avenue

North Riding | Johannesburg | South Africa 2169

(Address of principal executive offices) (Zip Code)

+27 87 330 2301

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act: ~~None~~Common Stock, par value $0.001 per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed fourth fiscal quarter: $39,~~662~~157,~~854~~135

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 11,733,750 shares as of ~~June~~May 128, ~~2024~~2025.

A picture containing text, clipart

Description automatically generated

TABLE OF CONTENTS

PART I		PAGE
ITEM 1.	BUSINESS	1
ITEM 1A.	RISK FACTORS	24
ITEM 1B.	UNRESOLVED STAFF COMMENTS	53
ITEM 1C.	CYBERSECURITY	53
ITEM 2.	PROPERTIES	54
ITEM 3.	LEGAL PROCEEDINGS	54
ITEM 4.	MINE SAFETY DISCLOSURES	54
PART II
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	55
ITEM 6.	[RESERVED]	55
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	55
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	6261
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	6261
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	62
ITEM 9A.	CONTROLS AND PROCEDURES	63
ITEM 9B.	OTHER INFORMATION	64
ITEM 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	64
PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	65
ITEM 11.	EXECUTIVE COMPENSATION	69
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	70
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	71
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	73
PART IV
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES	74
ITEM 16.	FORM 10-K SUMMARY	74
SIGNATURES		75

Table of Contents

FORWARD-LOOKING STATEMENTS

Except for statements of historical fact, some information in this document contains “forward-looking statements” that involve substantial risks and uncertainties. You can identify these forward-looking statements by words such as “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. The statements that contain these or similar words should be read carefully because these statements discuss our future expectations, contain projections of our future results of operations or of our financial position, or state other forward-looking information. We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able accurately to predict or control. Further, we urge you to be cautious of the forward-looking statements which are contained in this registration statement because they involve risks, uncertainties and other factors affecting our operations, market growth, service, products and licenses. The factors listed in the sections captioned “Risk Factors” and “Description of Business,” as well as other cautionary language in this registration statement and events in the future may cause our actual results and achievements, whether expressed or implied, to differ materially from the expectations we describe in our forward-looking statements. We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict all those risks, nor can we assess the impact of all of those risks on our business or the extent to which any factor may cause actual results to differ materially from those contained in any forward-looking statement. The forward-looking statements in this registration statement are based on assumptions management believes are reasonable. However, due to the uncertainties associated with forward-looking statements, you should not place undue reliance on any forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and unless required by law, we expressly disclaim any obligation or undertaking to publicly update any of them in light of new information, future events, or otherwise. The occurrence of any of the events described as risk factors or other future events could have a material adverse effect on our business, results of operations and financial position. Since our common stock is considered a “penny stock,” we are ineligible to rely on the safe harbor for forward-looking statements provided in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”).

As used in this Annual Report on Form 10-K, unless the context otherwise requires, the terms the “Company,” “Registrant,” “we,” “us,” “our,” “Medinotec,” “Medinotec Group of Companies” or “MDNC” refer to Medinotec, Inc., a Nevada corporation, and its wholly owned subsidiaries.

ii3

Table of Contents

PART I

ITEM 1.

BUSINESS

Company Overview

Medinotec Inc. was registered on April 26, 2021, in the State of Nevada. With an effective date of April 26, 2022, we acquired DISA Medinotec Propriety Limited, a South African corporation, from Minoan Medical Proprietary Limited ("Minoan"), a company incorporated in South Africa, and owner of all the capital stock of DISA Medinotec Propriety Limited. We accomplished the acquisition pursuant to the terms and conditions of a Share Exchange Agreement under common control with Minoan whereby we acquired all the capital stock of DISA Medinotec Proprietary Limited in exchange for the issuance of stock at par value and the transfer of the outstanding loan account.

This Purchase was concluded between Minoan and a local newly established investment vehicle of Medinotec Inc. called Medinotec Capital Proprietary Limited in South Africa after Medinotec Inc. registered the company as a shelf company by injecting $10,000 into it on December 18, 2021. Medinotec Capital Proprietary Limited serves as the acquisition vehicle for Medinotec Inc on the continent of Africa.

Combined these companies now form the Medinotec Group of Companies.

Our History

Prior to the above, in 2015, DISA Vascular ~~Distribution~~2015, an an innovative medical device company that specialized in vascular technology for the treatment of coronary artery disease, was established. It was subsequently renamed DISA Medinotec Proprietary Limited. DISA Medinotec Proprietary Limited was situated in Cape Town, South Africa and had been developing stents for the international market since 1998. It has since produced high-quality medical devices through in-depth research and development capabilities (“R&D”) and a total commitment to patient care. Today, the products are sold via a network of distributor partners both in South Africa and internationally.

A professional team consisting of our CEO and CFO was recruited to implement and execute the strategy, and an infrastructure of a large manufacturing facility was established, substantially increasing our manufacturing and warehousing capabilities.

Various distributors were appointed, and rights obtained to grow sales internationally, especially in Namibia and Mauritius, as well as the Middle East, Europe, South America, and portions of Asia. We have started establishing various networks to export and distribute our products in North America and other highly regulated countries such as, Australia, Japan, and China. The FDA approval that was granted for the Trachealator in November 2021 together with the concluded private placement allowed for the roll out in the United States which started during the 2024 fiscal year. ~~During this period, 501 units were sold in the United States.~~ In addition, we are finalizing multiple patent applications in several territories, which we believe will give us the ability not only to maintain our intellectual property but also to market our products aggressively.

The manufacture of medical devices for the treatment of vascular and airway diseases is now performed in our facility in Johannesburg, South Africa. Raw materials and components used in manufacture are sourced from a number of local and international suppliers to ensure continuity of supply while maintaining high quality and reliability. Procedures and processes are in place to ensure that these materials meet the regulatory requirements and comply towith specifications, and suppliers are regularly evaluated to monitor their quality performance.

The core values of care, learning, continuous improvement, innovation, outstanding delivery, and relationship building are important to the success of our business. The quality of the manufactured products is achieved through careful selection of suppliers and the maintenance of good manufacturing practices, thereby mitigating risk.

Table of Contents

Employees

As of February 2928, ~~2024~~2025, the Medinotec Group of ~~Companies~~ Companies employed 5451 employees, which consists of full-time employees, ~~part-time~~and ~~employees as well as~~ independent contractors.

§• Commercial team: Within the ~~group~~Group of ~~companies~~Companies the Commercial team representing the products currently consists of 26 individuals responsible for all aspects of the sales process, including pricing, marketing, transportation and logistics, product development and general customer service and training.

§• Sales team: The team is organized by both region and end-market and comprises a group of experienced and dedicated team members who understand the industry and who are experts in their various medical fields. The team is led out of the Johannesburg head office and is regionally positioned in the major medical markets across South Africa. As the Company makes decisions to enter or expand its presence in certain markets or regions, it expects to continue to add dedicated team members to support that growth,. ~~the~~The company currently has seventeen dedicated sales members in the United States and this number is expected to increase as the sales grow and regulatory and administrative hurdles are cleared to allow further revenue expansion.

§• Marketing team: This team coordinates all new and existing customer outreach efforts and identifies emerging market trends and new product opportunities. This includes producing exhibits for trade shows and exhibitions, manufacturing product overview materials, participating in both regional and international industry meetings and other trade associations and managing advertising efforts in trade journals.

§• Transportation Warehouse and Logistics team: The team manages domestic and international shipments and product deliveries by directing inbound and outbound ocean vessels and flights, supervising equipment maintenance, coordinating with freight carriers to ensure equipment availability, ensuring compliance with shipping regulations and strategically planning for future growth. This team also ensures storage and shipping happens in accordance with the quality requirements of each product.

§• Technical team: The team services and maintains all major equipment utilized in manufacturing.

§• Customer Services team: This team is dedicated to creating an exceptional customer experience and making it easy to do business with us. It aims to accomplish this by consistently exceeding customer expectations, continually improving service performance, offering efficient and timely responses to customer needs, being available to customers 24/7, and providing customers with personal points of contact.

These functions are supported by various back-office functions including, but not limited to, R&D, Quality, Finance, Admin and Regulatory staff.

Attracting the right talent is vital to the success of the Medinotec Group of Companies, and the contribution they make to the business is highly valued. Our focus on attracting the most competent and suitable people to operate in a rewarding work environment is a priority, particularly in the highly competitive labor market in which we operate.

The ~~below~~ table below shows the approximate number of employees and independent contractors, the employment status as full or part time, and the employer within the Medinotec Group of Companies. None of our employees are represented by a labor union with respect to their employment with us. We have not experienced any work stoppages, and we consider our relations with our employees to be good.

Employer	Number of full-time employees			Number of part-time employees		Number of independent contractors
Medinotec Inc.		2*	*		1—		1614
Medinotec Capital Proprietary Limited*		2*	*		2—		—
DISA Medinotec Proprietary Limited		33			—		—
Total		3537			3—		1614

* 2 Executives employed by Medinotec Inc. and Medinotec Capital Proprietary Limited are the same individuals.

Table of Contents

Group Contractors

DISA Medinotec Proprietary Limited successfully secured multiple distribution contracts from renowned international medical device companies, collectively referred to as the Cardiology distribution business. These contracts were awarded following adjudication by independent international third-party medical device companies. The introduction to these esteemed companies was facilitated by Minoan Medical Proprietary Limited, the previous distributor, before DISA Medinotec assumed responsibility. This transition underscores DISA Medinotec's strategic prowess in expanding its portfolio and underscores the collaborative efforts within the medical device distribution sector. These distribution products currently and in the future are expected to add to the product group of the business and help to achieve increased revenues, which consists of more mature but also profitable products that will complement our in house developed products. The Company appointed DISA Life Sciences, a South African based sub-distributor, which already distributes the in house manufactured brands of Medinotec within the market territory of South Africa. This sub-distributor will facilitate sales into the territory of South Africa while the principle focus of the business unit remains the development of products for which it owns the IP, while the distributor will perform the sales and marketing functions in this territory.

The Trachealator product obtained FDA approval in in November 2021, which allowed the Company to sell this product into the United States. Since the Company had no prior sales channels or or infrastructure in the United States, management found it prudent to plan a roll out of the product with a distributor that had an established network and infrastructure. For this business, the Company partnered with a company called Innovative Outcomes and entered into a revolving credit facility to a maximum of $750,000. Innovative Outcomes would use this facility to grow both their own distribution network and infrastructure and also allow for the Company to utilize this network and infrastructure. However, during the quarter ending November 30, 2023, there was a material change in strategic focus where the Company would require its products to be marketed to niche surgical units, Innovative Outcomes would be servicing the wound care clinic market only which meant that the future growth of the combined network ~~and~~ and infrastructure would not be a strategic match between the two entities. It was therefore decided to separate the network and infrastructure developed and for each company to pursue its strategic focus. The note receivable will continue on the same terms and ~~become~~became payable ~~later~~ induring the 2024 financial year, but the Company decided to provide full impairment against this receivable on November 30, 2023. This ~~decision~~ decision was made in prudence due to the fact that the receivable is ~~not~~no longer backed by any Trachealator revenue streams ~~anymore~~ and does not ~~change~~ change that Innovative Outcomes will still be liable for payment of this in the future ~~Interest will accrue as normal until maturity date~~. Should payments be received this provision will be reversed with the same amount of cashflow received.

Two of the most valuable assets the Medinotec Group of Companies has isare its long-term customer relationships and its strong distribution and marketing network. Through its distribution partnership, the Group has a network of over 100 sales representatives, who cover approximately 60% of all hospital ~~theatre~~operating ~~floors~~room onfloors on a weekly basis in South Africa. The Group plans to replicate such a network in the US.

The Group has historical reliance on two ~~related~~companies ~~parties~~ for sales into South Africa: there is reliance on DISA Life Sciences Proprietary Limited (“Disa Life Sciences”) as a customer; and for exports out of South Africa there was historical reliance on Minoan Medical (a related party). These relationships provide the ~~Group~~ Group with more than 100 sales representatives in the South African Market.

Sales between the Medinotec Group and DISA Life Sciences will continue into the future due to the vast distribution arm of DISA Life Sciences within South Africa. The Group’s expectation is to reduce reliance on the South African markets for customers and accounts as the Group endeavors to expand and enter into international first world markets. However, there is no guarantee that our plan will result in a decrease in reliance on DISA Life Sciences for customers and accounts. As with any expansion effort, there are barriers to entry and outside factors, such as regulatory approval, competition, among others, that may prevent us from entering such markets. As such, there is a risk that the concentration of customer issue will remain an ongoing issue unless we are successful in overcoming barriers to entry, competing with those in our markets and achieving regulatory approvals, none of which can be guaranteed.

The Medinotec Group of Companies operate in countries where the market is dominated by certain players, and this creates a sales concentration risk which also causes an accounts receivable concentration risk.

Seasonality

Sales reflect the cyclical nature of the business, as the number of procedures incorporating our products does decrease in the summer holiday months of December and January within the South African market, which is currently the predominant market in the Medinotec Group of Companies.

Table of Contents

Reliance on Other Parties

The Medinotec Group of Companies in the past focused solely on product development and manufacturing and therefore outsourced its sales function to two ~~parties~~companies, namely, Minoan Medical Proprietary Limited (a related party) and DISA Life Sciences. This was done to preserve funds for R&D and manufacturing and to ensure the products that ~~get~~are developed are launched effectively.

§• DISA Life Sciences is, as per management’s best estimation, one of the top 5 medical device distributors in South Africa and has a far reaching sales and marketing component to their business,. DISA Medinotec partnered with DISA Life Sciences to create a market for the products in South Africa, due to the reach of this distributor, DISA Medinotec was able to reach its budgets and break even scenarios on products much faster than it would have attempting to launch on their own. DISA Life Sciences uses its own sales force and certain sub-contractors to penetrate the South African market. After we took exports in house, the DISA Life Sciences relationship consists of supplying products in South Africa.

Please refer to the related party footnotes in the financial statements and as disclosed in the Section of this Annual Report, entitled, “Certain Relationships and Related Transactions, and Director Independence” where the nature and flow of transactions between ~~each~~related ~~of these~~ parties have been disclosed in in detail.

Our Business Strategy

As we are currently operating in various markets, the below provides a brief overview of the Company structure as well as each individual ~~entities~~entity’s role within the Company:

Medinotec Inc The company was incorporated in Nevada in April of 2021. Currently, this company houses the directorship and management of the business and owns the subsidiary, Medinotec Capital Proprietary Limited, which in turn wholly owns DISA Medinotec Proprietary Limited. Medinotec Inc. facilitates all sales into the United States.

	Medinotec Capital (Pty) Ltd

	This company was established and incorporated by Medinotec Inc. to establish an investment holding company on the continent of Africa. The intention in the future will be that the same structure gets established for any continent on which Medinotec Group of Companies would like to expand into. Consolidating all African investments under one holding company simplifies the transfer pricing policies inter group and would ensure a lower risk of breaching any transfer pricing regulations set by African regulators

Disa Medinotec (Pty) Ltd This is the operational company acquired by Medinotec Capital in March of 2022. This company manufactures and develops the products that are sold to Medinotec Inc. It is a medical device manufacturing and distribution company with distribution channels predominately in South Africa, but also in the Middle East, South America, Europe and portions of Asia, with plans to enter the markets in ~~North America and other FDA comparable~~ countries such as Australia, Japan and China that have very strict regulatory approval processes.

Table of Contents

Our objective is to become one of the significant industry players within the next five years. We plan to achieve this by:

1. growing our product range; 2. building our competences; and 3. ~~through~~ making strategic acquisitions.

Our strategy includes investing in the entire value chain, ranging from the importation of raw materials, manufacturing capabilities and the marketing and selling of products, through to the distribution of our products to customers via our sales network.

A high-level overview of our strategy follows onin ~~page~~the 410-K, ~~which~~ which is followed by a discussion on how we implement this strategy.

A group of surgeons performing an operation

Description automatically generated

5(Image depicting two healthcare professionals in surgical attire are preparing to intubate a patient in a medical setting. Source: Shutterstock)

Table of Contents

Text

Description automatically generated

Table of Contents

Our Strategic Differentiators

We attribute our success to the following key strengths:

§• Commitment to innovation: We are dedicated to continuing to develop patentable products and offerings through R&D.

§• Experienced management team: The members of the Company’s management team bring considerable experience to the dynamic environment in which we operate. Their expertise covers a range of disciplines, including industry-specific operating and technical knowledge. The Company has assembled an agile, creative, and responsive team that can quickly adapt to changing market conditions.

§• Extensive geographic footprint: We believe that the strategic location of our facilities and logistics capabilities contribute to our customer retention rates and our ability to reach broader market segments.

§• Low-cost operating structure: We focus on building and operating facilities with low operating costs to enable us to better manage market downturns.

§• Strong relationships with customers: We have a long and enviable track record of timely delivery of products, which contributes to a reputation for dependability. Our extensive network of technical resources and other expertise enables us to collaborate with customers to develop product offerings to improve their satisfaction.

§• Extensive knowledge of setting up distribution channels: We have various exclusive distribution agreements in place with distributors to ensure these distributors include our products into an extensive product mix, which includes some of the most innovative and cutting-edge technologies available today.

§• Focus on safety and wellbeing: We focus on the safety of our employees and our patients and maintain safe and responsible operations. We are known in the communities in which we operate as a preferred employer and as a responsible corporate citizen.

The Three Pillars of our Strategy

Innovate and Grow our Product Range

DISA Medinotec Proprietary Limited established itself as a highly successful company that has been investing heavily in creating its own IP, as well as the R&D and manufacturing techniques involved in producing unique niche medical devices, thereby creating a value base that is ready to enter advanced high-value markets in North America.

The approach, agility and excellent production capabilities have allowed DISA Medinotec Proprietary Limited to capitalize on key medical trends, while an in-depth market knowledge and understanding have enabled anticipation of market needs well in advance. This, combined with accelerated product development, innovation, and speed to market, with a focus on cost reduction, equipment upgrades and low-cost facilities, has proved to be a recipe for success.

We currently have three products that are commercially available and a rich pipeline of developmental projects. We currently derive most of our profits by selling these products in South Africa, leaving ample room to grow the basket offering that sales personnel take to the market. Our plan is also to constantly innovate and enhance our product range to ensure our competitiveness.

The products are generally targeted at more complex, specialized surgical cases and are specifically relevant in medical centers of excellence. During 2018, DISA Medinotec Proprietary Limited recognized the need to become a significant player in manufacturing in reaction to the risk of price sensitivity.

710

Table of Contents

DISA Medinotec Proprietary Limited currently specializes in niche products within the disciplines of cardiology and respiratory interventions in which we are involved in medical device design, development, manufacture, all supported by a well-trained and educated sales and distribution channel. The specialty areas include:

§• Interventional Cardiology, which involves surgery performed on the heart and vessels to correct life-threatening conditions. The surgery is performed by minimally invasive intravascular methods depending on the condition to be corrected.

§• Interventional Endolaryngeal Endoscopy, which involves balloon dilation to treat suitable airway stenosis by ENT surgeons and anesthetists.

The focus of our expansion is on markets with surgical centers of excellence, including the Middle East, Europe, and the US, with the aim of:

§• increasing the number of surgeons endorsing and using our products, not necessarily through sales, but through skills transfer; §• increasing the number of procedures conducted; and §• solidifying key opinion leader support and publications related to the use of our products during procedures.

In addition, we appointed and trained various distributors in the Middle East, Europe, portions of Asia and South America, with several training initiatives also held in the USA where FDA approval have been granted for the Trachealator following the 510(k) substantially equivalence process for Class II medical devices. This has enabled us to start sales in the USA.

The Medinotec Group’s growth plan is determined by the surgical devices market, which is currently the main contributor to sales. ~~The sector is expected to achieve a compound annual growth rate (“CAGR”) of nearly 6.5% during the period 2017-2025. (Source: Mordor Intelligence.)~~ Moreover, healthcare in developing countries – our primary target market – is undergoing rapid changes. The growing population in these countries is likely to lead to increased demand for healthcare, including medical devices. The growing burden of diseases and innovative medical treatments currently, according to management’s estimate, accounts for nearly two-thirds of the rise in spending.

North America is expected to continue dominating ~~the~~ the overall market for medical supplies and investment opportunities. The US holds the largest market share in the region due to the superior regulation of surgical devices and a growing awareness among the population of an alternative approach for procedures in the treatment of injuries, and for chronic disease management. Our sales in the United States for the fiscal year was $~~553~~678,~~967~~105, which represents 117% of total sales. This is up from $21553,~~467~~967 in the prior fiscal year, which represented 211% of total sales.

Key Market Trends and Our Response to These

There is currently a massive drive for minimal ~~invasive~~ invasive procedures done at lower costs, which in turn decreases hospitalization and the cost of procedures and ~~theatre~~operating room time. As ~~this~~ this is the primary market for our devices, i.e., minimally invasive procedures, it is important for us to be at the cutting-edge of ~~technological~~ technological developments at the correct price point to remain relevant. It is also important to diversify product offerings to ensure that all the products used during a procedure can be supplied by one service provider. The price of these devices is also expected to fall given the entry of many new players in the market.

Another market driver is the growing population in developing countries for healthcare and procedures, which has increased significantly in recent years as previously mentioned.

Major shifts in industry market share have occurred in connection with product problems, physician advisories, safety alerts, results of clinical trials to support superiority claims, and publications about products, reflecting the importance of product quality, product efficacy and quality systems in the medical device industry.

811

Table of Contents

In the current environment of managed care, economically motivated customers, consolidation among healthcare providers, increased competition, and declining reimbursement rates, we have been increasingly required to compete on the basis of price. In order to continue to compete effectively, we must continue to create or acquire advanced technology, incorporate this technology into proprietary product offerings, obtain regulatory approvals in a timely manner, maintain high-quality manufacturing processes, and successfully market these products.

Government and private sector initiatives to limit the growth of healthcare costs, including price regulation, competitive pricing, bidding and tender mechanics, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements, are continuing in many countries in which the Medinotec Group does business, including the US.

These initiatives put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, private healthcare insurance and managed-care plans have attempted to control costs by limiting the amount of reimbursement they will pay for particular procedures or treatments, tying reimbursement to outcomes, shifting to population health management, and other mechanisms.

Hospitals, which purchase our technology, are also seeking to reduce costs through a variety of mechanisms, including, for example, centralized purchasing, and in some cases, limiting the number of vendors that may participate in the purchasing program. Hospitals are also aligning interests with physicians through employment and other arrangements, such as gainsharing, where a hospital agrees with physicians to share any realized cost savings resulting from changes in practice patterns such as device standardization. This has created an increased level of price sensitivity among customers for our products.

A picture containing room, scene, hospital room

Description automatically generated

(Image depicting a team of surgeons performing an operation. Source: Shutterstock)

The next logical step for us would be to secure investment opportunities and additional distributor relationships through the North American territory and to further deploy this for growth in our distribution channels.

912

Table of Contents

Our Competitor Landscape

The Medinotec Group of companies operates in highly competitive markets that are characterized by a number of large, multinational players as well as a number of small, regional or local distributors. Some of the major players include Johnson & Johnson, Boston Scientific, Cook Medical, Cordis, B. Braun, Teleflex, Medtronic, Merit Medical, Endotec, Conmed and Cadence.

Competition is based on price, consistency and quality of product, site location, distribution capability, customer service, reliability of supply, breadth of product offering and technical support. The principal competitive factors in these markets are product features, value-added solutions, reliability, clinical evidence, reimbursement coverage, and price.

We compete with many companies having significantly more capital resources, larger research laboratories and more extensive distribution systems. As such, there are no assurances that we will be able to compete and gain market share.

Build our Competencies

Our investment in R&D ~~includes~~has included the development of a state-of-the-art production facility in Johannesburg, South Africa. This facility, ~~allows~~designed ~~for~~to asignificantly ~~significant~~enhance ~~increase in~~ capacity and output, within an ISO 7 cleanroom. ~~The~~environment, ~~facility~~ also ~~has~~features ~~increased~~expanded laboratory space, including a “dry” laboratory for microscopy, mechanical testing, prototyping, and experimentation, and a “wet” laboratory for pressure testing, weighing, ~~experimentation~~liquid ~~with liquids~~ experimentation, and 3D printing. Additionally, ~~as well as~~ a workshop ~~containing~~is equipped for turning, milling, grinding, and other ~~equipment~~processes ~~necessary~~required for ~~building~~ custom machinery ~~and~~ ~~performing~~and ~~repairs~~prototype ~~or creating prototypes~~development.

AThe facility's large packaging area and a dedicated EtO sterilizer ~~facility~~ ~~provide~~have ~~the~~enabled ~~capacity~~in-house ~~to perform~~ sterilization, onsupporting ~~our products. Our~~ operations ~~are~~ governed by the ISO 13485 Quality Management System. Our ~~products are also~~ CE-Marked products, with IP protection, have benefited from expertise in advanced medical manufacturing techniques, including balloon forming, heat and adhesive bonding, device coating, catheter laminating, and more. This has allowed for the commissioning of the latest balloon-forming manufacturing equipment to increase production capabilities for interventional balloon catheter products.

WeWhile ~~have~~this ~~expertise~~investment inhas ~~numerous~~been ~~innovative~~an ~~medical~~integral ~~manufacturing~~part of ~~techniques,~~our ~~including~~growth ~~balloon forming~~strategy, ~~several~~we ~~heat~~are ~~and~~temporarily ~~adhesive~~shifting ~~bonding~~focus ~~techniques,~~away ~~device~~from ~~coating,~~further ~~grinding,~~expansion ~~catheter laminating and many others. Many~~ of the ~~products~~production ~~incorporate~~facility. ~~high-performance~~Instead, ~~medical~~our ~~balloons.~~strategic focus Aswill anow ~~result,~~center on the ~~latest~~other ~~balloon-forming~~two ~~manufacturing equipment~~pillars ~~has~~of ~~been~~our ~~procured~~strategy ~~and~~as ~~commissioned~~these inpriorities ~~the~~are ~~new~~aligned ~~manufacturing~~with ~~facility~~our vision to ~~assist~~drive ingrowth ~~increasing~~through innovation ~~production~~and ~~capabilities~~strategic ofalignment ~~interventional balloon~~with ~~catheter~~key ~~products~~partners.

~~The~~By ~~Medinotec~~concentrating ~~Group~~on ofthese ~~Companies~~focus ~~plans~~areas, tothe ~~further~~Medinotec ~~invest~~Group inof ~~strategic~~Companies ~~capital~~aims ~~projects~~ to ~~introduce~~maximize ~~innovative technologies~~impact, ~~efficiency~~accelerate ~~improvements~~innovation, and ~~capacity~~leverage ~~expansion~~our low-cost base in ~~key~~South ~~growth~~Africa to strengthen our position ~~categories.~~as ~~This~~a ~~will~~leading bemed-tech ~~implemented~~company ~~through:~~globally.

§ Focusing on processes, from sales management to customer relationships. § Creating new channels and brand availability. § Expanding growth strategy through strategic partners. § Identifying quick-return capital projects.

By leveraging off our low-cost base in South Africa we aim to become one of the leading med-tech companies in the world.

Table of Contents

Make Strategic Bolt-on Acquisitions

While strategic bolt-on acquisitions remain a consideration in our business plan, we currently have no active due diligence processes underway and no imminent acquisition transactions at this time.

Table of Contents

Our Implementation Plan

Any business strategy requires a plan that outlines a roadmap for implementation. The Medinotec Group of Companies’ plan is to continue to ensure quality manufacturing of our current products, ongoing investment into our own IP, and planned acquisitions to ensure the financial stability of current operations, the longevity of our organization and a smooth integration process for new businesses we may acquire. The key drivers in our plan that support the business strategy are as follows:

§• Increase our presence and product offering in specialty product end-markets. In the past, we have signed various exclusive distribution agreements across multiple territories to enhance our product basket and reach.

§• Our R&D and business development teams work together to enhance existing product offering. These teams also pursue opportunities to acquire new product offerings through business acquisitions and distributorships that are expected to increase our presence and market share in certain specialty product markets and/or allow us to enter new markets. We manage a robust pipeline of new products and business relationships in various stages of development and are also in various stages of expanding capabilities to improve product offerings across our various platforms.

§• Further develop value-added capabilities to maximize margins. We expect to continue investing in ways to increase the value we provide to customers by growing our product offerings, improving our supply chain management, upgrading our IT, and enhancing our customer service model. We are also exploring other ways to expand our reach and our products to provide incremental value to our customers, including new acquisitions to vertically integrate ~~its~~our supply chain and to obtain more of the gross profit share of the entire customer experience.

§• Optimize product mix and keep operating costs low. We continue to actively manage our product mix as we seek to maximize profit margins. This requires us to use our proprietary expertise in balancing key variables, such as procurement and processing capacity, transportation availability, customer requirements and pricing. Additionally, we undertake continuous improvement efforts to increase the effectiveness and efficiency of our production and distribution facilities.

§• Effectively position logistic capabilities and supply chain network to meet customers’ needs. We continue to strategically position our supply chain to deliver according to our customers’ needs. We believe that our supply chain network and logistic capabilities are a competitive advantage that enables us to provide superior service to customers.

§• The strategic location of our distribution centers enables us to service major customers within 48 hours (this includes certain deliveries to rural and outlying areas in South Africa, which have limited road access and infrastructure). Additionally, our in-house delivery capabilities allow for direct deliveries and last-minute route adjustments to support our customers.

§• Evaluate expansion opportunities and other acquisitions. We expect to continue leveraging our reputation, procurement, distribution capabilities and infrastructure to increase our product offerings, as well as to explore other opportunities to expand our reserve base and sell new products.

§• We will pursue acquisitions of value-adding products and technologies. We will prioritize acquisitions that will provide us with opportunities to realize synergies, which include entering new geographic markets, acquiring attractive customer contracts, and improving operations.

§• Maintain balance sheet strength and flexibility. We intend to maintain financial strength and flexibility to enable us to better manage the business through industry downturns and pursue acquisitions and new growth opportunities as they arise. The business has good cash-producing prospects and this, together with our entrepreneurial mindset, ensures that we can quickly pursue opportunities that are time sensitive.

§• Carry sufficient levels of inventory to meet the product delivery needs of customers. We aim to carry sufficient inventory, and to provide payment terms to customers in the normal course of business to meet the operational demands of our customers. Due to the location of our distribution centers in relation to the US, Europe, and the Far East, we require our distributors to carry at minimum three (3) months of inventory on fast moving items to avoid supply chain pressures.

§• Training and skills development: Our continued investment into the healthcare landscape through training and academic development assists in retaining and maintaining the necessary skills base within southern Africa. Training and skills development in healthcare is an intrinsic and necessary part of our growth strategy. We use a state-of-the-art training facility at our Johannesburg head office, which includes the latest cardiology simulators, to assist young surgeons and health professionals to develop their procedural skills. We also have a full array of non-occlusive balloon dilation technology for training purposes and for hands-on product technical training.

1114

Table of Contents

Product Distribution

We have appointed various distributors to grow sales internationally, especially in Europe, North America, South America, Middle East, portions of Asia as well as Namibia and Mauritius.

We are currently represented in approximately 29 31 countries, with product registration in progress for an additional 158 countries. We currently have 2528 appointed distributors to represent our products globally. All exports are managed directly out of South Africa by an export manager.

We have had several training initiatives held in the US where FDA approval has been granted for the Trachealator following the 510(k) substantially equivalence process for Class II medical ~~devices.~~ ~~During the past financial year 501 units of the Trachealator have been sold in the USA.~~devices

We intend to complete our various networks and obtain regulatory approvals to be able to export and distribute our product to countries such as Australia, Japan and China.

Through the operating subsidiary DISA Medinotec Proprietary Limited, we ship our products to customers directly by freight or by air and through our network of in-house and courier partners. Recent market trends have resulted in more product volumes being transported by high-efficiency road freight.

Our distribution centers in Johannesburg, South Africa and New York, United States of America are strategically located to provide access to road and air freight. We also continually explore ways of optimizing our network to ensure that the product remains close to the point of end use. This approach allows us to provide excellent customer service and positions us to take advantage of opportunistic sales.

Product Manufacturing – Quality Assurance and Regulatory Requirements

Quality Management

The safety and quality of our medical devices is assured through rigorous documented procedures and an accredited Quality Management System (“QMS”), which was established in accordance with the requirements of ISO13485, the European Union Medical Device Regulation 2017/745, the US FDA 21 CFR 820 regulations, and the various applicable acts and guidelines legislated by the South African regulatory authorities.

Our QMS is implemented through the Medinotec Group of Companies’ policies, procedures and work instructions followed and utilized by all departments. We also maintain an active post-market surveillance program, which enables product performance to be regularly assessed and to be reported to the regulatory authorities if any incident/malfunction occurs that results in severe injury to the patient or death.

Additionally, we maintain quality standards relevant to the storage and distribution of our products. These include technical/quality agreements with our suppliers. Since we import raw materials, all manufacturing of the products is performed in DISA Medinotec South Africa’s clean room facilities, and all instructions and quality manuals are written to convert a series of raw materials into finished goods against the applicable quality assurance standards and internal procedures. No manufacturing steps are outsourced at the moment.

Compliance to all procedures is monitored via an internal audit system and augmented by audits conducted annually by European and American notified bodies.

Table of Contents

International Quality Regulations

Many products require CE marking before they can be sold in the European Union. CE marking indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. It is required for products manufactured anywhere in the world that are then marketed in the European Union.

Table of Contents

Most of our products carry the CE Mark, ensuring conformity to the legal requirements of the European Union. The valid CE certificates for the devices concerned have been issued in compliance with the Medical Device Directive 93/42/EEC and these devices could initially be placed on the market until May 2024, but an extension has been granted till the end of 2027 due to the European Notified Bodies being unable to handle the volume of the applications.

We are currently in the process of ensuring compliance with the new and very demanding Medical Device Regulation (MDR) 2017/745 with the Trachealator ~~being~~ already being certified under this regulation. The Technical Files for the remaining products are currently being reviewed by DEKRA.

DEKRA is a global testing, inspection, and certification organization. In Europe, DEKRA is recognized as a Notified Body for medical devices, meaning it is authorized by the European Union to assess whether medical devices comply with EU regulations and standards. This involves evaluating the design, manufacturing process, and quality management systems of medical devices to ensure they meet the required safety and performance criteria before they can be marketed in the EU. DEKRA's role includes conducting conformity assessments, issuing CE certifications, and performing post-market surveillance to ensure ongoing compliance.

FDA certification via the 510(k) substantially equivalence process for Class II medical devices for the Trachealator has been obtained and sales ~~has~~have started in the US during the past financial year. For two cardiac catheters, we are in the process of obtaining the required FDA certification for our devices, thus enabling us to market and sell our products in the US.

In addition, we are subject to numerous and increasingly stringent environmental laws and regulations concerning, among other things, the generation, handling, storage, transportation, treatment and disposal of toxic and hazardous substances, the discharge of pollutants into the air and water and the cleanup of contamination. We are required to maintain and comply with environmental permits and controls for some of our operations, and these permits are subject to modification, renewal, and revocation by the issuing authorities. Our environmental compliance may increase in the future because of changes in environmental laws and regulations or increased manufacturing activities at any of our facilities. We could incur significant costs or liabilities because of any failure to comply with environmental laws, including fines, penalties, third-party claims, and the costs of undertaking a clean-up on-site or at a site to which any waste materials were transported. In addition, we are planning to grow in part by acquisition, and our diligence may not have identified environmental impacts from historical operations at sites we may acquire in the future. We have an extensive health and safety program. This also stipulates how we handle waste materials and staff safety in the cleanroom facility. Our health and safety costs are included in our compliance costs.

	The Medinotec Group of Companies for the Years Ended		~~The Medinotec Group of Companies for the Years Ended~~
	February 29, 2024		February 29, 2023
	February 28, 2025		February 29, 2024
Compliance cost	$	~~186~~526,~~338~~603	$	~~218~~186,~~694~~338

It should be noted that as we approach market and sales readiness with our products our compliance costs are increased to facilitate the path to sell products into new territories and to ensure legal and statutory compliance in these markets. The fluctuations in annual and quarterly compliance costs can be attributed to these new markets being prepared for sales activities.

Table of Contents

Medical Device Regulation

Regulatory body approvals and market acceptance play a material role in the success of our business plan. The approval process of the governing bodies for example FDA/CE is lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our products it will have a material impact on our business, we may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities;. ifIf we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired even if our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. Regulatory approvals are aligned with our operating segments, with U.S. Food and Drug Administration (FDA) requirements primarily applicable to our operations within the United States, while also relevant in certain non-European international markets. The Conformité Européenne (CE) marking, historically required for European market access, is now being replaced by the European Union’s new regulatory framework under the Medical Device Regulation (EU MDR) and In Vitro Diagnostic Regulation (IVDR), collectively referred to as the EU’s FDR (Future Device Regulation), which governs our activities in Europe and certain other international jurisdictions

Table of Contents

Regulation of Medical Devices in Europe

Medical devices placed on the market in the European Economic Area, or EEA must meet the relevant essential requirements laid down in Annex I of Directive 93/42/EEC concerning medical devices ("the Medical Devices Directive"). The most fundamental essential requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical matter. Compliance with a standard developed to implement an essential requirement also creates a rebuttable presumption that the device satisfies that essential requirement.

To demonstrate compliance with the essential requirements laid down in Annex I to the Medical Devices Directive, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Conformity assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience in respect of similar products already marketed. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate to sterility or metrology), a conformity assessment procedure requires the intervention of a Notified Body. Notified bodies are often separate entities and are authorized or licensed to perform such assessments by government authorities. The notified body would typically audit and examine a product’s technical dossiers and the manufacturers’ quality system. If satisfied that the relevant product conforms to the relevant essential requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE Mark to the device, which allows the device to be placed on the market throughout the EEA. Once the product has been placed on the market in the EEA, the manufacturer must comply with requirements for reporting incidents and field safety corrective actions associated with the medical device.

In order to demonstrate safety and efficacy for their medical devices, manufacturers must conduct clinical investigations in accordance with the requirements of Annex X to the Medical Devices Directive ("MDD"), Annex 7 of the Active Implantable Medical Devices Directive ("AIMDD"), and applicable European and International Organization for Standardization standards, as implemented or adopted in the EEA member states. Clinical trials for medical devices usually require the approval of an ethics review board and approval by or notification to the national regulatory authorities. Both regulators and ethics committees also require the submission of serious adverse event reports during a study and may request a copy of the final study report.

Table of Contents

On April 5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the E.U. Medical Devices Directive and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member States, the regulations would be directly applicable, i.e., without the need for adoption of EEA member State laws implementing them, in all EEA member States and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable, and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. The Medical Device Regulation became applicable in May 2021. The new regulations:

•

strengthen the rules on placing devices on the market and reinforce surveillance once they are available;

•

establish explicit provisions on manufacturers’ responsibilities for the follow-up of the quality, performance, and safety of devices placed on the market;

• improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; • set up a central database to provide patients, healthcare professionals, and the public with comprehensive information on products available in the E.U.; and

•

strengthen the rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.

Table of Contents

In the European Union, member states are responsible for enforcing the EU’s medical device rules and for ensuring that only compliant medical devices are placed on the market or put into service in their jurisdictions. They have the power to suspend the marketing and use, or demand the recall, of unsafe or non-compliant devices. They also have the power to bring enforcement action against companies or individuals for breaches of the device rules. Non-compliance may also result in Notified Bodies revoking any certificate of conformity that they have issued for a device or the manufacturer’s quality system.

We are subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of:

•

design, development, and manufacturing;

•

product standards;

•

product safety;

•

product safety reporting;

•

marketing, sales, and distribution;

•

packaging and storage requirements;

•

labeling requirements;

•

content and language of instructions for use;

•

clinical trials;

•

record keeping procedures;

Table of Contents

•

advertising and promotion;

•

recalls and field corrective actions;

•

post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;

•

import and export restrictions;

•

tariff regulations, duties, and tax requirements;

•

registration for reimbursement; and

•

necessity of testing performed in country by distributors for licensees.

The time required to obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from FDA requirements.

Table of Contents

Regulation of Medical Devices in South Africa

In South Africa, medical device manufacturing is regulated by the South African Health Products Regulatory Authority (“SAHPRA”), with guidelines published in the Government Gazette No. 40480 in 2016, which refer to licensing of medical devices establishments and the registration required to ensure an acceptable level of safety, quality, and performance. DISA Medinotec Proprietary Limited is registered with SAHPRA and possesses the above-described licenses and registrations for all our products.

Federal, State, and Foreign Fraud and Abuse and Physician Payment Transparency Laws.

In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws may restrict our business practices if our products will be reimbursable under federal healthcare programs. These laws include, without limitation, foreign, federal, and state anti-kickback and false claims laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.

The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs.

Violation of the AKS also triggers liability under the Civil Monetary Penalties Law (CMPL). The CMPL carries penalties of up to $50,000 per kickback, in addition to three times the amount of the remuneration. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid. Liability under the federal Anti-Kickback Statute may also arise because of the intentions or actions of the parties with whom we do business.

The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes “any request or demand” for money or property presented to the U.S. government. The federal civil False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the federal civil False Claims Act.

Table of Contents

In addition, private parties may initiate “qui tam” whistleblower lawsuits against any person or entity under the federal civil False Claims Act in the name of the government and share in the proceeds of the lawsuit. Penalties for federal civil False Claim Act violations include fines for each false claim, plus up to three times the amount of damages sustained by the federal government and, most critically, may provide the basis for exclusion from the federally funded healthcare program. The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious or fraudulent and, unlike the federal civil False Claims Act, requires proof of intent to submit a false claim. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $13,946 to $27,894 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid, and other federal healthcare programs.

The Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier.

The Health Insurance Portability and Accountability Act of 1996 ("HIPAA") also created additional federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

Table of Contents

Many foreign countries have similar laws relating to healthcare fraud and abuse. Foreign laws and regulations may vary greatly from country to country. For example, the advertising and promotion of our products is subject to E.U. directives concerning misleading and comparative advertising and unfair commercial practices, as well as other EEA Member State legislation governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals. Also, many U.S. states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.

Data Privacy and Security Laws.

In the future, we may also be subject to various federal, state, and foreign laws that protect personal information including certain patient health information, such as the E.U. General Data Protection Regulation (“GDPR”) and the California Consumer Privacy Act (“CCPA”), and restrict the use and disclosure of patient health information, such as HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), in the U.S.

HIPAA established uniform standards governing the conduct of certain electronic healthcare transactions and requires certain entities, called covered entities, to comply with standards that include the privacy and security of Protected Health Information (“PHI”). HIPAA also requires business associates, such as independent contractors or agents of covered entities that have access to PHI in connection with providing a service to or on behalf of a covered entity, of covered entities to enter into business associate agreements with the covered entity and to safeguard the covered entity’s PHI against improper use and disclosure.

The HIPAA privacy regulations cover the use and disclosure of PHI by covered entities as well as business associates, which are defined to include subcontractors that create, receive, maintain, or transmit PHI on behalf of a business associate. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, or to request restrictions on the use or disclosure of PHI. The security regulations establish requirements for safeguarding the confidentiality, integrity, and availability of PHI that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify any individual whose PHI is breached according to the specifications set forth in the breach notification rule. The HIPAA privacy and security regulations establish a uniform federal “floor” and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI as defined under HIPAA.

Table of Contents

HIPAA requires the notification of patients, and other compliance actions, in the event of a breach of unsecured PHI. If notification to patients of a breach is required, such notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, we would be required to report the improper use or disclosure to HHS which would post the violation on its website, and to the media. Failure to comply with the HIPAA privacy and security standards can result in civil monetary penalties up to $68,928 per violation, not to exceed $2.07 million per calendar year for non-compliance of an identical provision.

HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities, and their business associates for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.

Table of Contents

In addition, California enacted the CCPA, effective January 1, 2020, which, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for “protected health information” maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context.

In the EEA, we may become subject to laws which restrict our collection, control, processing, and other use of personal data (i.e. data relating to an identifiable living individual) including the GDPR (and any national laws implementing the GDPR). As part of our operations, we process personal data belonging to data subjects in the EEA, including employees, contractors, suppliers, distributors, service providers, customers, patients, or clinical trial participants. For patients or clinical trial participants, we process special categories of personal data like health and medical information. We need to ensure compliance with the GDPR (and any applicable national laws implementing the GDPR) in each applicable EEA jurisdiction.

Healthcare Reform.

The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.

We expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.

Our Key Products

Medinotec’s innovative surgical and healthcare products are market leaders and meet high quality standards. These are as follows with the Trachealator being one of our most sought-after and innovative offerings.

Table of Contents

The Trachealator

The Trachealator has changed the way that tracheal, and, to a degree, bronchial stenosis is managed in extremely ill patients. While there are multiple causes of tracheal stenosis, it is estimated that thousands of cases are reported every year. Multiple, safe, serial dilations of the trachea are often curative and the Trachealator is currently in our opinion as management the only device that is non-occlusive and which allows the procedure to be done with the patient fully awake and un-sedated.

The Trachealator received its CE Mark in 2019 and is currently sold in various markets across Europe, Middle East, South America and portions of Asia and has been used successfully on thousands of patients. The FDA approval through the 510(k) substantially equivalence process for Class II medical devices was obtained in November 2021. In May of 2021 in recognition of the technology advancement in the device, it was awarded a Gold Medal in the Medical Design Excellence Awards.

The Trachealator received the CE Mark of approval by a European notifying body (DEKRA). CE Marking is a qualification mandatory for any product to be sold in countries of the European Union.

The USA recognizes only an FDA approval to accept products in its market – a 510(k) accreditation that was obtained in November 2021 for the Trachealator and sales has since commenced in the USA.

Table of Contents

From prior experience, an FDA certificate and CE Mark are widely accepted by other countries in the world as a valid accreditation for entry into their markets; however, the medical device approval process differs for each country and territory in the world and each may have additional requirements over and above CE mark and FDA accreditation, or may even require their own quality standards. Since the business plan is drafted mainly around the USA and European markets the CE marking and planned future FDA submissions, entry into other markets will only be investigated if the expected launch of our product candidates does not commercialize in the United States and Europe and each entry will be assessed on its own merits and requirements.

For example, Australia, Japan and China have their own quality accreditation systems (TGF, JIS & CFDA respectively) and do not accept CE marking and/or an FDA certificate.

A close-up of a tube

Description automatically generated

Several medical equipment in a room

Description automatically generated

~~Fig. 2:~~ The Trachealator.

Close-up of a human body

Description automatically generated

A close-up of a wire

Description automatically generated

19The Trachealator

Table of Contents

The Cape Cross PTCA Catheter

The Medinotec Group of Companies also designed and developed a range of semi-compliant coronary PTCA ~~balloon~~ catheters known as the Cape Cross, which attained a CE Mark and are marketed ~~around~~ around the world and in South Africa, becoming a widely used interventional balloon in the market.

A PTCA ~~balloon~~ catheter ~~(also known as a Plain Old Balloon Angioplasty [“POBA”] catheter)~~ is inserted either from the groin or the arm and threaded through the blood vessels, through the aorta into the heart. The cardiac surgeon and/or interventional cardiologist will move the catheter to the blocked artery (plaque). The balloon part of the catheter is inflated to open the blockage in the artery, after which the balloon is deflated, and the entire catheter withdrawn and removed. If this procedure is not effective enough to open the artery, a coronary stent will be placed inside the diseased area of the artery.

A close up of a plane

Description automatically generated

~~Fig. 3.~~ The Cape Cross PTCA Catheter.

Cape Cross Non-Compliant (“NC”) Catheter

On the back of the Cape Cross, the Cape Cross NC Catheter was developed for post dilation purposes. The product has become a mainstay of our cardiology range. It is CE Marked and widely used in South Africa. After a stent is placed in an artery, it is followed up by moving a NC catheter to the site where the stent was placed. The NC catheter balloon part is then inflated inside the stent. This is done to “seat” the stent inside the artery wall. In other words, if the stent was not optimally placed, the NC Catheter can be used to make the stent fit “snugly” against the artery wall to avoid dislodgement and movement of the stent after placement.

Close-up of a person's fingers

Description automatically generated with low confidence

A close-up of a fire extinguisher

Description automatically generated with medium confidence

Diagram

Description automatically generated

~~Fig. 4.~~ The Cape Cross Non-Compliant (“NC”) Catheter.

2023

Table of Contents

Aortic Valve Dilation Balloon Catheter ~~(Developmental)~~

The Aortic Perfusion and Dilation Catheter is a non-occlusive perfusion balloon to allow the expansion of the aortic valve without impeding the cardiac output.

~~It is currently in the mid stages of research and development.~~ This catheter could ~~potentially~~ be used to post dilate the artificial valve in TAVI (Transcatheter Aortic Valve Implantation) without the need for pacing.

A clinical study was conducted in 2022, as part of the development of the Technical File documentation which is currently undergoing examination by our Notified Body (DEKRA).

Submission for FDA certification via the 510(k) ~~substantially~~ substantially equivalence process iswas ~~currently~~made ~~underway~~on May 31, ~~with~~2024. ~~submission~~FDA ~~expected~~clearance bywas ~~the~~obtained ~~end~~on ofMarch ~~April~~11, ~~2024~~2025, after the financial year end.

The Micro CTO Catheter (Developmental)

We have developed a highly specific niche ~~CTO~~ CTO (Chronic Total Occlusion) catheter balloon range with diameters of 0.70 to 1.25 mm, as a size range extension to the current Cape ~~Cross~~ Cross Rx PTCA ~~Balloon~~ Catheter.

These micro-balloon catheters address an extremely specific market need for difficult coronary cases and will further cement our position as one of the premier specialized coronary balloon catheter manufacturers. The Technical File was submitted to our Notified Body at the end of July 2023, and is currently undergoing examination.

The process of obtaining FDA certification for the full range of Cape Cross PTCA catheters via the 510(k) substantial equivalence process commenced in January 2024 ~~and the expected submission date is July 2024~~.

The Tracheal Stent (Developmental)

We are currently in the initial stages of ~~development~~ development of a new self-expanding, temporary, silicone tracheal stent to be used in conjunction with the Trachealator ~~balloon~~ in the treatment of tracheal stenosis.

The complimentary nature of this product will further build on our know-how in the field of advanced airway management, and we look forward to its further design and testing over the upcoming months.

Product Development Pipeline

The following distinct and finite developmental phases / stages are applicable to all our product pipeline, namely:

R&D

Pre-production prototyping

Testing

Production

Clinical trials

MDR/CE Mark accreditation

Local marketing & selling

International sales outside the US

FDA 510 (k) approval

10)

Sales to the United States.

2124

Table of Contents

The products described have reached the following stages:

Trachealator:	The Company is pleased to report that, since sales commenced, it has supplied 940 Trachealators, both in private and academic hospitals throughout the United States of America. FDA clearance and CE certification was obtained.	The Company is pleased to report that, since sales commenced, it has supplied 501 Trachealators, both in private and academic hospitals throughout the United States of America. FDA listing and CE registration was obtained.
Cape Cross PTCA Catheter:	Application for FDA 510(k) clearance in progress with external consultants. Final submission pending. CE certification under the MDD has been obtained, and is still valid under Regulation (EU) 2023/607. CE certification under the MDR is in progress.
Cape Cross NC Catheter:	Application for FDA 510(k) clearance in progress with external consultants. Final submission pending. CE certification under the MDD has been obtained, and is still valid under Regulation (EU) 2023/607. CE certification under the MDR is in progress.
Lamprey Suction Dissector:		The progress of this product's development has been temporarily suspended to prioritize the pursuit of products with greater economic viability.
Aortic Valve Dilation Balloon Catheter (OutFlo):	FDA clearance was obtained on March 11, 2025, after the financial year end.
Aortic Valve Dilation Balloon Catheter (Outflo):		R&D, Testing, Pre-Production Prototyping, Testing, Production, Clinical Trials, Application for MDR CE Mark Accreditation has been submitted. Application for FDA 510(k) clearance in progress with external consultants. Final submission pending.
Micro CTO Catheter:	R&D, Testing, Pre-Production Prototyping, Clinical Trials MDR/CE Mark accreditation application was submitted in July 2023.
Micro CTO Catheter:		R&D, Testing, Pre-Production Prototyping, Clinical Trials MDR/CE Mark accreditation application was submitted in July 2023.
Tracheal Stent:	R&D
Tracheal Stent:		R&D
Epistaxis Catheter:	R&D, Testing, Pre-Production Prototyping, Testing, Production, Clinical Trials – FDA 510(k) exempted (Class I product)
Epistaxis Catheter:		R&D, Testing, Pre-Production Prototyping, Testing, Production, Clinical Trials – FDA 510(k) exempted (Class I product)

Intellectual Property

Medinotec Group of Companies currently holds various product registration certificates and operating licenses, which allow us to operate as an importer of raw materials for the manufacture of medical devices and an exporter and distributor of these products within the territories we service. We also hold various patents, trademarks, and other intangible proprietary rights that are considered material to the business and its ability to compete effectively with other companies.

Medinotec Group of Companies pursues a policy of obtaining patent protection in the US, China, Europe, Middle East, and Australia for patentable subject matter in our products and attempt to review third-party patents and patent applications to the extent publicly available to develop an effective patent strategy. This assists in avoiding the infringement of third-party patents, helps identify licensing opportunities and monitors the patent claims of others.

Due to the Trachealator being fairly new, patent applications for the Trachealator have been filed in the following countries or regions: USA, European Union, ~~Canada,~~ China, Australia, Korea and South Africa. All other products are either not novel enough to file a patent or not yet developed far enough to start filing processes.

The status of these applications is listed below:

1)	USA:	~~The~~Patent ~~official~~No. ~~notice~~12,036,376, ofB2 ~~allowance~~ has been ~~issued~~granted byon ~~the~~July ~~United~~16, ~~States~~2024. ~~Patents~~This ~~and~~patent ~~Trademark~~is ~~Office~~valid –until ~~Attorney~~April ~~Docket~~28, ~~number : CU 74801-CH-BSE-DG~~2040.
2)	China:	Patent No. 201880086558.2 has been granted on ~~the~~March ~~31st~~31, of2023. ~~March~~This ~~2023~~patent is valid until December 12, 2038.
3)	South Korea:	Patent No. 10-2635372 has been granted on ~~the~~February ~~5th~~5, of2024. ~~February~~This ~~2024~~patent is valid until September 4, 2040.
4)	European Union:	~~Awaiting~~Intention ~~examination~~to ~~report~~ grant: ~~Application~~EP No3768363 / November 11, 2024. :This ~~18903920~~patent is valid until December 12, 2038.0
5)	~~Canada~~South Africa:	~~Awaiting~~Patent ~~examination~~No. ~~Report~~2020/02618 :has ~~Application~~been Nogranted on July 27, 2022. ~~3086610~~This patent is valid until July 27, 2040.
6)	~~South Africa~~Australia:	~~Patent~~Acceptance ~~has~~to ~~been~~be ~~granted~~advertised, in2018406682, ~~June~~November ~~2022~~14, –2024. ~~Application~~This :patent ~~2020~~is /valid ~~02618~~until December 12, 2038.
7)	Australia:	Awaiting examination report – Application No. : 2018406682

No patents have been licensed from third parties.

2225

Table of Contents

Trade Secrets

With respect to some of our products, Medinotec Group of Companies rely principally on trade secrets, rather than patents, to protect proprietary processes, methods, documentation, and other technologies, as well as certain other business information.

Although the Medinotec Group of Companies seek patents from time to time as discussed above, patent protection for other industrial and specialty products requires a costly federal registration process with an uncertain outcome that would place confidential information in the public domain.

The Medinotec Group of Companies also relies on trade secrets, expertise, continuing technological innovations, and licensing opportunities to develop, maintain and strengthen our competitive position. We strive to protect our trade secrets indefinitely through the use of confidentiality agreements and other security measures, understanding that these efforts may prove to be ineffective.

Research and Development

All R&D is conducted within the Medinotec Group of Companies, which employs the necessary engineers, and technical and support personnel. The in-house technical expertise includes biomedical engineering and product design. The R&D team focuses primarily on developing new products and supporting existing products.

Condition of Physical Assets and Insurance

Parts of the Medinotec Group of Companies are capital intensive and require ongoing capital investment for the replacement, modernization and/or expansion of equipment and facilities. We therefore maintain insurance policies against property loss and business interruption and insure against other risks that are typical in the operation of the business, in amounts that we believe to be reasonable. Where costs are deemed to be commercially unviable, we self-insure. Such insurance, however, contains exclusions and limitations on coverage, particularly with respect to environmental liability and political risk. There can thus be no assurance that claims would be paid under such insurance policies in connection with a particular event.

Primary Customers

Medinotec Group of Companies primary customers include hospitals, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations (“GPOs”). We also benefit from strong and long-standing relationships with customers in each of the industrial and specialty products end markets we serve.

Third Party Coverage and Reimbursement

Healthcare providers that purchase medical devices generally rely on third-party payors, including private payors, such as indemnity insurers, employer group health insurance programs and managed care plans, to reimburse all or part of the cost of the products. As a result, demand for our products is and will continue to be dependent in part on the coverage and reimbursement policies of these payors.

Possible reductions in, or eliminations of, coverage or reimbursement by third-party payors, or denial of, or provision of uneconomical reimbursement for new products may affect our customers’ revenue and ability to purchase our products. Any changes in the healthcare ~~regulatory~~regulation, payment or enforcement landscape relative to our customers’ healthcare services have the potential to significantly affect our operations and revenue.

Additional Information

The public may read and copy any materials the Company files with the SEC in the SEC’s Public Reference Section, Room 1580, 100 F Street N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Section by calling the SEC on 1-800-SEC-0330. Additionally, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, which can be found at http://www.sec.gov.

2326

Table of Contents

Item 1A.

Risk Factors.

You should carefully consider the risks described below together with all of the other information included in this Annual Report before making an investment decision with regard to our securities. The statements contained in or incorporated herein that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, you may lose all or part of your investment. In addition to other information in this registration statement and in other filings we make with the Securities and Exchange Commission, the following risk factors should be carefully considered in evaluating our business as they may have a significant impact on our business, operating results and financial condition. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered as a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods.

SUMMARY OF RISK FACTORS

~~Our~~The ~~business~~following is ~~subject~~a tocondensed ~~numerous~~summary ~~risks~~of ~~and~~the ~~uncertainties,~~principal ~~including~~risks ~~those~~associated ~~highlighted~~with inour ~~the~~business. ~~section~~These ~~titled~~risks ~~“Risk~~represent ~~Factors”,~~the ~~that~~key ~~represent~~ challenges ~~that~~and uncertainties we face, inand ~~connection~~they ~~with the~~are ~~successful~~described ~~implementation~~in ofgreater detail ~~our strategy. Any investment~~ in the ~~business~~“Risk atFactors” ~~its~~section ~~current~~of ~~stage~~this ~~can~~report. beInvesting ~~deemed to be extremely speculative~~ in ~~nature.~~our ~~The~~securities ~~occurrence~~involves ofa ~~one~~high ordegree ~~more~~ of ~~the~~risk, ~~events~~and ~~or circumstances described in~~ the ~~section titled “Risk Factors,”~~occurrence ~~alone~~of orany inof ~~combination~~these ~~with~~factors ~~other~~could ~~events~~materially orand ~~circumstances,~~adversely ~~may~~affect ~~have an adverse effect on~~ our business, ~~cash flows,~~ financial condition, ~~and~~ results of operations~~. Such risks include~~, ~~but~~or ~~are~~stock ~~not limited to:~~price.

Financial Risks: We carry substantial debt, may need additional financing, and face exposure to interest rate changes, accounting rule shifts, and tax regulation updates, all of which could impact financial flexibility and results.

Operational Challenges: Our success depends on product development, supply chain continuity, and competitive positioning. Industry consolidation, pricing pressures, IT disruptions, and foreign exchange volatility pose risks to our operations and profitability.

Customer and Market Exposure: We rely heavily on a limited number of customers, including DISA Life Sciences, which increases the risk of revenue concentration. Inadequate insurance coverage and internal control weaknesses may further exacerbate operational vulnerabilities.

Management and Governance: Our business depends on a small number of key personnel, many of whom are located outside the U.S. Concentrated voting power among founders and limited public-company experience heighten governance and compliance risks.

Regulatory and Legal: Delays in obtaining regulatory approvals, potential product liability, compliance with marketing and reimbursement rules, IP protection, and evolving environmental and data privacy laws all pose significant risks. Violations could lead to penalties or legal action.

Geopolitical and Regional Risks: Political and economic instability in South Africa—such as load-shedding, exchange controls, and FATF grey-listing—may impair operations. Broader geopolitical tensions and trade disputes also affect supply chains and market access. Geopolitical and trade risks due to tariffs and trade wars.

Market and Securities Risks: Our shares trade on the OTCQX market and are considered penny stocks, which may limit liquidity. Future equity issuances could dilute existing shareholders, and share prices may fluctuate significantly due to external factors

Details of the above risks are as follows:

Table of Contents

Risks Related to our Financial Position and Need for Capital

•

The Medinotec Group of Companies’ substantial leverage and debt service obligations could adversely affect the business.

•

The Medinotec Group of Companies may need additional financing – any limitation on our ability to obtain such additional financing could have a material adverse effect on the business, financial condition, and results of operations.

•

Future changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse or unexpected revenue fluctuations and affect the reported results of operations within The Medinotec Group of companies.

Risks Related to Our Business Operations


	•	Consolidation in the healthcare industry could have an adverse effect on revenues and results of operations of the Medinotec Group of Companies.

•

Healthcare industry cost-containment measures could result in reduced sales of the Medinotec Group of Companies medical devices and medical device components.

•

The continuing development of many of our products and offerings depends on our maintaining strong relationships with healthcare professionals, and these professionals are external to the Medinotec Group of Companies.

•

Products in the development pipeline of The Medinotec Group of Companies may not come to market or fail to commercialize.

Table of Contents

	•	The Medinotec Group of Companies operate in a highly competitive industry and may be unable to compete effectively.

	•	Reduction or interruption in supply or other manufacturing difficulties may adversely affect operations and related product sales within the Medinotec Group of Companies.

•

The Medinotec Group of Companies rely on the proper function, security and availability of our IT systems and data to operate the business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect the business, results of operations, financial condition, cash flows, reputation, or competitive position.

•

The Medinotec Group of Companies business model is concentrated around developing countries with higher growth rates, although this model also causes forex risk exposure which may cause adverse or unexpected revenue fluctuations and affect the reported results of operations.

•

The Medinotec Group of Companies insurance program may not be adequate to cover future losses.

•

The Medinotec Group of Companies future growth is dependent upon the development of new products and line extensions, which requires significant research and development, clinical trials and regulatory approvals, all of which are very expensive and time-consuming and may not result in a commercially viable product.

• If the Medinotec Group of Companies fails to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate and investors’ views of us. • We have limited experience in marketing and sales and are in the early stages of building our sales channels in the life science market and internationally • We rely on a limited number of subcontractors to manufacture, assemble, package and production test our products, and the failure of any of these third-party subcontractors to deliver products or otherwise perform as requested could damage our relationships with our customers, decrease our sales and limit our growth. • We distribute commodity medical products on behalf of multinational manufacturers for a substantial portion of our sales, and our failure to maintain and further develop these relationships could harm our business. • We have identified material weaknesses in our internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner, which could have an adverse impact on our business.

2528

Table of Contents

	•	We have limited experience in marketing and sales and are in the early stages of building our sales channels in the life science market and internationally

	•	We rely on a limited number of subcontractors to manufacture, assemble, package and production test our products, and the failure of any of these third-party subcontractors to deliver products or otherwise perform as requested could damage our relationships with our customers, decrease our sales and limit our growth.

	•	We distribute commodity medical products on behalf of multinational manufacturers for a substantial portion of our sales, and our failure to maintain and further develop these relationships could harm our business.

	•	We have identified material weaknesses in our internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner, which could have an adverse impact on our business.

Risks Related to Management, Personnel and Control Persons

•

The Medinotec Group of Companies depends on our senior management personnel and may not be able to retain or replace these individuals or recruit additional personnel, which could harm our business.

•

If the Medinotec Group of Companies are unable to find, train and retain key personnel, including new showroom employees that reflect our brand image and embody our culture, we may not be able to grow or sustain our operations.

•

The Medinotec Group of Companies’ largest shareholder, officer and director, Dr. Gregory Vizirgianakis, has substantial control over us and our policies and will be able to influence corporate matters.

•

The Medinotec Group of Companies’ officers and directors are located outside of the U.S., so it will be difficult to effect service of process and enforcement of legal judgments upon our officers and directors.

•

The Medinotec Group of companies’ officers and directors have limited experience managing a public company.

Risk Associated ~~With~~with Legal and Regulatory Matters

	•	The Medinotec Group of Companies are subject to extensive medical device regulation that may impede or hinder the approval process for our products and, in some cases, may not ultimately result in approval or may result in the recall or seizure of previously approved products.

	•	Failure to obtain clearance or authorization for our medical devices, or other delays in the development of our medical devices, would adversely affect our ability to grow our business.
	•	Modifications to our products may require new 510(k) clearances, de novo submissions, or pre-market approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.
	•	Failure to obtain clearance or authorization for our medical devices, or other delays in the development of our medical devices, would adversely affect our ability to grow our business. We may be liable if the FDA or other U.S. enforcement agencies determine we have engaged in the off-label promotion of our products or have disseminated false or misleading labeling or promotional materials.

•

Healthcare policy changes may have a material adverse effect on the Medinotec Group of Companies.

•

The Medinotec Group of Companies is subject to environmental laws and regulations and the risk of environmental liabilities, violations, and litigation.

•

Claims made against the Medinotec Group of Companies from time to time can result in litigation that could distract management from our business activities and result in significant liability or damage to our brand.

• The Medinotec Group of Companies’ failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject it to penalties and adversely impact its reputation, business, results of operations, financial condition, and cash flows. • Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on the business, results of operations, financial condition and cash flows.29

Table of Contents

•

The Medinotec Group of Companies’ failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject it to penalties and adversely impact its reputation, business, results of operations, financial condition, and cash flows.

•

Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on the business, results of operations, financial condition and cash flows.

•

The Medinotec Group of Companies may not be able to protect our intellectual property rights effectively.

•

Security breaches, loss of data and other disruptions could also compromise sensitive information related to the business, preventing it from accessing critical information or expose us to liability, which could adversely affect the business and reputation.

•

Changes in tax laws or exposure to additional income tax liabilities could have a material impact on the Medinotec Group of Companies, the results of operations, financial conditions and cash flows.

•

The failure to comply with anti-corruption laws could materially affect the Medinotec Group of Companies and result in civil and/or criminal sanctions.

•

Laws and regulations governing international business operations could adversely impact the Medinotec Group of Companies.

•

As an Emerging Growth Company under the Jobs Act, the Medinotec Group of Companies are permitted to rely on exemptions from certain disclosures requirements.

•

Because we are a “Smaller Reporting Company,” we may take advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less company information than they would receive from a public company that is not a Smaller Reporting Company.

Risks Associated with Political Instability and Regional Issues

•

Geopolitical and trade risks due to tariffs and trade wars

•

South Africa Specific Risk of stable power supply

•

South Africa Specific Risk of Political instability may affect the Medinotec Group of Companies ability to operate effectively.

•

South Africa Specific Risk that BEE requirements may restrict growth opportunities and limit the Medinotec Group of Companies’ ability to attract key talent.

•

South Africa Specific Risk that South African authorities may disallow or delay a transfer of funds from South Africa to the United States

• South Africa Specific Risk of ~~Being~~being Grey listed by the FATF- Financial Action Task Force • Medinotec faces heightened geopolitical and trade risks due to South African international relations, as potential revocation of AGOA benefits, increased tariffs, and stricter import regulations on South African goods could significantly impact the cost, compliance, and competitiveness of its U.S.-bound medical exports.

Table of Contents

Risks Relating to Our Securities

•

If the Medinotec Group of Companies undertakes future offerings of our common stock, shareholders will experience dilution of their ownership percentage.

•

If a market for the Medinotec Group of Companies' common stock does not develop, shareholders may be unable to sell their shares.

•

The Medinotec Group of Companies’ common stock price may be volatile and could fluctuate widely in price which could result in substantial losses for investors.

•

If securities analysts do not initiate coverage or continue to cover the Common Stock or publish unfavorable research or reports about the business, this may have a negative impact on the market price of the Common Stock of the Medinotec Group of Companies.

Table of Contents

•

Because we are subject to the “Penny Stock” rules and our shares are quoted on the over-the-counter bulletin board, the level of trading activity in the Medinotec Group of Companies’ stock may be reduced.

•

If the Medinotec Group of Companies issues shares of preferred stock with superior rights than the common stock, it could result in a decrease in the value of our common stock and delay or prevent a change in control.

•

The Medinotec Group of Companies does not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.

•

Provisions in the Nevada Revised Statutes and our Bylaws could make it very difficult for an investor to bring any legal actions against the Medinotec Group of companies’ directors or officers for violations of their fiduciary duties or could require us to pay any amounts incurred by our directors or officers in any such actions.

Risks Related to our Financial Position and Need for Capital

The Medinotec Group of Companies’ substantial leverage and debt service obligations could adversely affect the business.

As of February 2928, ~~2024~~2025, the consolidated Medinotec Group of Companies had approximately $~~827~~1,~~454~~505,047 of current liability obligations and $1,~~809~~033,~~655~~097 of long-term liabilities outstanding.

The long-term debt relates to the non-current portion of the operating lease liability, deferred tax liabilities as well as an unsecured loan from the related party Minoan Medical, which was the prior shareholder of DISA Medinotec Proprietary Limited. The Medinotec Group of Companies has a period of 3 years post the Initial Public Offer ("IPO”) date of 31 March 2023 to repay the loan, during these 3 years the loan will carry interest at the prevailing prime lending rate of the time. The prevailing prime lending rate as of February 2928, ~~2024~~2025, in South Africa is 11.7500%.

The interest charged for the year ended February 2928, ~~2024~~2025, for the consolidated Medinotec Group of Companies was $~~277~~176,~~230~~416 and a 1% movement in the interest rates constitutes a a value of $2316,~~594~~038 on an annual basis.

From time to time the Group utilized trade finance to assist with funding of orders for raw materials with longer lead and shipping times the interest spent on trade finance for the year ended February 2928, ~~2024~~2025 for the consolidated Medinotec Group of Companies was $3528,~~317~~126 and $4835,~~230~~317 for the year ended February 2829, ~~2023~~2024. Trade Finance carries a charge of prime plus 1% therefore 12.7500%, at February 2928, ~~2024~~2025. aA 1% movement ~~would~~in the interest rate would equate to $2,~~770~~344 for the year ending February 2928, ~~2024~~2025. Trade finance is use specific and linked to inventory ordering therefore no forecast will be disclosed for an expected change in annual utilization and the quarter and six-month sensitivity adjustments are disclosed on the current orders financed by trade finance at the time.

As of February 29, 2024, the related party loan for the consolidated Medinotec Group of Companies had a balance of $1,769,957 with an interest charge of $236,873 per annum at the prevailing prime interest rate of 11.75% at that date. A 1% movement in the interest rates constitutes a value of $20,159.31

Table of Contents

As of February 28, 2025, the related party loan for the consolidated Medinotec Group of Companies had a balance of $940,277 with an interest charge of $141,748 per annum at the prevailing prime interest rate of 11.00% at that date. A 1% movement in the interest rates constitutes a value of $12,886.

The Medinotec Group of Companies has the option to settle earlier, and settlement can be in cash or any form of equivalent. It is currently the intention of management to settle the loan in equity at some point in the future, since the agreement allows the Medinotec Group Companies to settle the amounts either in equity or in cash. If equity is used, the impact on cashflow would be zero.

If we elect to settle the loan in cash: Cash reserves available in February ~~2024~~2025 in the Consolidated Medinotec Group of Companies were $2,~~808~~769,~~910~~686 and the loan account outstanding at the same time was $1940,~~769,957~~277. Therefore, if settled today it would constitute 6334% of available cash.

The interest rate chargeable is a guideline determined by the South African Reserve Bank and gets utilized by financial institutions to determine the financial gain they may derive from a loan. The Prime rate is therefore at arm’s length and justifiable rate that can be applied to a loan within the borders of the Republic of South Africa.

Table of Contents

We may also incur additional indebtedness in the future. This could have adverse consequences, including the following:

	•	making it more difficult for us to satisfy our financial obligations;
	•	increasing vulnerability to adverse economic, regulatory and industry conditions;
	•	placing us at a disadvantage to our competitors that are less leveraged;
	•	limiting the ability to compete and flexibility in planning for, or reacting to, changes in the business and the industry in which we operate;
	•	limiting the ability to borrow additional funds for working capital, capital expenditures, acquisitions and general corporate or other purposes; and
	•	exposing us to greater interest rate risk since the interest rate on floating rate borrowings is variable.

Our debt service obligations require us to use a portion of the operating cash flow to pay interest and principal on indebtedness instead of for other corporate purposes, including funding the future expansion of the business, acquisitions, and ongoing capital expenditures, which could impede growth. If operating cash flow and capital resources are insufficient to service debt obligations, we may be forced to sell assets, seek additional equity or debt financing or to restructure our debt, which could harm long-term business prospects.

Our failure to comply with the terms of our indebtedness could also result in an event of default which, if not cured or waived, could result in the acceleration of all its debt. Ifand ~~this~~impact ~~occurs,~~our weability ~~may~~to ~~lose~~operate ~~all~~as ofa ~~our~~going ~~assets and go out of business~~concern.

Management evaluated the Company’s ability to continue as a going concern in accordance with ASC 205-40 and concluded that, based on current cash, projected operations, and available funding, there is no substantial doubt about the Company’s ability to meet its obligations for at least 12 months from the issuance of these financial statements.

Our expansion plans may require additional capital and we may need capital to operate our business in response to circumstances caused by the risks in conducting business in this industry. The raising of additional capital could result in dilution to stockholders. In addition, there is no assurance that we will be able to obtain additional capital if we need it, or that if available, it will be available to us on favorable or reasonable terms. Any limitation on our ability to obtain additional capital as and when needed could have a material adverse effect on the business, financial condition and results of operations.

Table of Contents

A change in accounting standards or practices or a change in existing taxation rules or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. This also applies to new standards, practices, and rules.

Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. The fact that we operate in multiple territories and have a worldwide footprint heightens this risk in specific territories.

Risks Relating to Business Operations

Consolidation in the healthcare industry could have an adverse effect on revenues and results of operations of the Medinotec Group of Companies.

Many healthcare companies, including healthcare systems, distributors, manufacturers, providers, and insurers, are consolidating or have formed strategic alliances. As the healthcare industry consolidates, competition to provide goods and services to industry participants will become more intense. Further, this consolidation creates larger enterprises with greater negotiating power, which they can use to negotiate price concessions. If we must reduce our prices because of industry consolidation, or if we lose customers as a result of consolidation, the business, financial condition, results of operations and cash flows could be adversely affected.

Table of Contents

Healthcare industry cost-containment measures could result in reduced sales of the Medinotec Group of Companies medical devices and medical device components.

Most of our customers and the healthcare providers to whom our customers supply medical devices, rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all the cost of the procedures in which medical devices that incorporate components we manufacture or assemble are used.

The continuing efforts of governmental authorities, insurance companies and other payers of healthcare costs to contain or reduce these costs could lead to patients being unable to obtain approval for payment from these third-party payers.

If third-party payer payment approval cannot be obtained by patients, sales of finished medical devices that include our components may decline significantly and our customers may reduce or eliminate purchases of these components.

The cost-containment measures that healthcare providers are instituting, both in the US and outside of the US could harm our ability to operate profitably.

If we fail to maintain our working relationships with healthcare professionals, many of our products may not be launched and marketed in line with the needs and expectations of the professionals who use and support our products, which could cause a decline in earnings and profitability.

The research, development, marketing and sale of many of our new products depends on our maintaining working relationships with healthcare professionals, relying on them to provide considerable knowledge and experience regarding the development, marketing and sale of products. Physicians assist us as researchers, product consultants, inventors, and public speakers.

Any failure to maintain these relationships and expand our network to include new professionals in the territories we enter will have a negative impact on our financial success.

Table of Contents

Products in the development pipeline of The Medinotec Group of Companies may not come to market or fail to commercialize.

We will, at any time, have several innovative products in the R&D phase. However, some of these projects may fail to come to market for a number of reasons, which could include competitors releasing a similar product at the same time, a lack of viability in terms of production costs or projected sales, or low/no acceptance in the market, failures on safety and efficacy measures, among other factors.

The Medinotec Group of Companies operate in a highly competitive industry and may be unable to compete effectively.

We compete in medical markets throughout the world, which are characterized by rapid changes resulting from technological advances and scientific discoveries. In the product lines in which we compete, we face competition ranging from large companies with multiple business lines to small, specialized manufacturers that offer a limited selection of niche products. Development by other companies of new or improved products, processes, technologies, or the introduction of reprocessed products or generic versions when our proprietary products lose their patent protection may make existing or planned products less competitive.

We believe our ability to compete depends upon many factors both within and beyond our control, including product performance and reliability, product technology and innovation, product quality and safety, breadth of product lines, product support services, customer support, cost-effectiveness and price, reimbursement approval from healthcare insurance providers, and changes to the regulatory environment.

Table of Contents

Competition may increase as additional companies enter our markets or modify their existing products to compete directly with ours. In addition, academic institutions, governmental agencies, and other public and private research organizations also may conduct research, seek patent protection, and establish collaborative arrangements for discovery, research, clinical development and marketing of similar products.

These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring necessary product technologies. From time to time we have lost, and may in the future lose, market share in connection with product problems, physician advisories, safety alerts and publications about our products, which highlights the importance of product quality, product efficacy and quality systems to the business.

In the current environment of managed care, consolidation among healthcare providers, increased competition, and declining reimbursement rates, we have been increasingly required to compete on the basis of price. Further, our continued growth and success depend on our ability to develop, acquire and market new and differentiated products, technologies, and intellectual property. As a result, we also face competition for marketing, distribution, and collaborative development agreements, establishing relationships with academic and research institutions and licenses to intellectual property.

In order to continue to compete effectively, we must continue to create, invest in or acquire advanced technology, incorporate this technology into its proprietary products, obtain regulatory approvals in a timely manner, and manufacture and successfully market our products. Given these factors, we cannot guarantee that we will be able to compete effectively or continue its current level of success.

Reduction or interruption in supply or other manufacturing difficulties may adversely affect operations and related product sales within the Medinotec Group of Companies.

The supply of products requires timely delivery and exact planning due to most of our raw material either being manufactured by suppliers or imported. These suppliers/strategic partners require a sufficient amount of quality components and materials and are highly exacting and complex, due in part to strict regulatory requirements.

We have generally been able to obtain adequate supplies of such finished goods, raw materials, components, and services. However, for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials, goods, and services needed to fill our supply chain are obtained from various sole suppliers.

Table of Contents

Although we work closely with our suppliers to ensure continuity of supply while maintaining high quality and reliability, the supply of these goods, components, raw materials, and services may be interrupted or insufficient. In addition, due to the stringent regulations and requirements of regulatory agencies, regarding the manufacture and import/export of our products, we may not be able to quickly establish additional or replacement sources. In addition, a reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to supply products in a timely or cost-effective manner and could result in lost sales.

Other disruptions in the supply chain process or product sales and fulfilment systems for any reason, including equipment malfunction, failure to follow specific protocols and procedures, supplier facility shut-downs, defective raw materials, wars and conflict, natural disasters such as hurricanes, tornadoes or wildfires, property damage from riots, and other environmental factors and the impact of epidemics or pandemics, such as Covid-19, and actions by businesses, communities and governments in response, could lead to launch delays, product shortage, unanticipated costs, lost revenues and damage to our reputation. For example, in the past we have experienced an information technology (“IT”) systems interruption that affected our customer ordering, distribution, and manufacturing processes. Furthermore, any failure to identify and address manufacturing problems prior to the release of products to customers could result in quality or safety issues.

These disruptions are exacerbated by global economic uncertainty and heightened geopolitical tensions, such as the Russian war on Ukraine, between the United States and China as well as Brexit and conflicts in the Middle East, which can also have an impact on several factors influencing prices, exchange rates, and interest rates, all of which can affect our business in turn.

Table of Contents

In addition, several key components are manufactured or sterilized at a particular facility, with limited alternate facilities. If an event occurs that results in damage to or closure of one or more of such facilities, such as the damage caused by natural disasters, power outages, civil unrest, and other factors, we may be unable to manufacture or sterilize the relevant products at the previous levels or at all. Because of the time required to approve and license a manufacturing or sterilization facility, a third-party may not be available on a timely basis to replace production capacity in the event manufacturing or sterilization capacity is lost.

In order to manage any supply chain risk, we have identified key and crucial components in our manufacturing lines that we deem not to be readily available, and we have vetted 2-3 trusted suppliers, which we believe mitigates the risk of becoming overly reliant on a specific supplier. Despite this precaution, there is no assurances that we will be able to secure the materials needed in the event these sources are unable to fulfil orders. Any failure in the supply chain would result in a lack of inventory and ~~the~~an inability to sell ~~product~~products. For all other non-key materials, we find that ~~these~~ these are readily available from a variety of suppliers and therefore, the risk of sourcing them is minimal or non-existent.

We are increasingly dependent on sophisticated IT systems to operate the business, including to process, transmit and store sensitive data, and many of our products and services include integrated software and IT that collects data regarding patients or connects to its systems.

Like other multi-national corporations, we could experience, and in the past have experienced, attempted or actual interference with the integrity of, and interruptions to, our IT systems, as well as data breaches, such as cyber-attacks, malicious intrusions, breakdowns, interference with the integrity of our products and data or other significant disruptions.

Furthermore, we rely on third-party vendors to supply and/or support certain aspects of our IT systems. These third-party systems could also become vulnerable to cyber-attack, malicious intrusions, breakdowns, interference, or other significant disruptions, and may contain defects in design or manufacture or other problems that could result in system disruption or compromise the information security of our own systems.

In addition, we continue to grow in part through new business acquisitions and, as a result, may face risks associated with defects and vulnerabilities in their systems, or difficulties or other breakdowns or disruptions in connection with the integration of the acquisitions into its own IT systems.

Table of Contents

Our worldwide operations mean that we are subject to laws and regulations, including data protection and cybersecurity laws and regulations, in many jurisdictions. Any data security breaches, cyber-attacks, malicious intrusions or significant disruptions could result in actions by regulatory bodies and/or civil litigation, any of which could materially and adversely affect the business, results of operations, financial condition, cash flows, reputation or competitive position.

In addition, our IT systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving legal and regulatory standards, the increasing need to protect patient and customer information, changes in the techniques used to obtain unauthorized access to data and information systems, and the IT needs associated with changing products and services.

There can be no assurance that the process of consolidating, protecting, upgrading, and expanding systems and capabilities, continuing to build security into the design of products, and developing new systems to keep pace with continuing changes in information processing technology will be successful or that additional systems issues will not arise in the future.

Table of Contents

If our IT systems, products or services or sensitive data are compromised, patients or employees could be exposed to financial or medical identity theft or suffer a loss of product functionality. We could lose existing customers, have difficulty attracting new customers, have difficulty preventing, detecting, and controlling fraud, be exposed to the loss or misuse of confidential information, have disputes with customers, physicians, and other healthcare professionals, suffer regulatory sanctions or penalties under federal laws, state laws, or the laws of other jurisdictions, experience increases in operating expenses or an impairment in our ability to conduct operations, incur expenses or lose revenues as a result of a data privacy breach, product failure, IT outages or disruptions, or suffer other adverse consequences including lawsuits or other legal action and damage to reputation.

During the years ended February 2928, ~~2024~~2025, and February 2829, ~~2023~~2024, we did not, to our knowledge, experience any cybersecurity incidents or breaches that materially impacted or are reasonably likely to materially impact our business, performance or results.

Foreign exchange risk refers to the losses that an international financial transaction may incur due to currency fluctuations. Also known as currency risk, forex risk and exchange-rate risk, it describes the possibility that an investment’s value may decrease due to changes in the relative value of the involved currencies. Investors may experience jurisdiction risk in the form of foreign exchange risk. Foreign exchange risk arises when a company engages in financial transactions denominated in a currency other than the currency where that company is based. Any appreciation/depreciation of the base currency or the depreciation/appreciation of the denominated currency will affect the cash flows emanating from that transaction. Foreign exchange risk can also affect investors who trade in international markets, and businesses engaged in the import/export of products or services to multiple countries.

Our business of import/exports of raw materials and goods exposes us to foreign exchange risk by having account payables and receivables affected by currency exchange rates. This risk originates when a contract between us and our suppliers specifies exact prices for goods or services, as well as delivery dates. If a currency’s value fluctuates between when the contract is signed and the delivery date, it could cause a loss for one of the parties.

Our business model is concentrated around developing countries with higher growth rates which causes greater exposure to forex risk which may cause adverse or unexpected revenue fluctuations and affect the reported results of operations. Usually, the attractive growth rates of these developing countries ~~offsets~~offset the long term forex implications of their volatile currencies.

Table of Contents

There are three types of foreign exchange risk that we are exposed to:

	•	Transaction risk: This is the risk that we face when we are buying a product from a company located in another country. The price of the product will be denominated in the selling company's currency. If the selling company's currency were to appreciate versus the buying company's currency, then the company doing the buying will have to make a larger payment in its base currency to meet the contracted price.
	•	Translation risk: A parent company owning a subsidiary in another country could face losses when the subsidiary's financial statements, which will be denominated in that country's currency, is translated back to the parent company's currency.
	•	Economic risk: Also called forecast risk, this refers to when market value is continuously impacted by an unavoidable exposure to currency fluctuations.

We continually assess our foreign exchange risks and implement varying strategies based on the current economic conditions to implement hedging strategies to mitigate that risk. This usually involves forward contracts, options, and other exotic financial products that, if done properly, can protect us from unwanted foreign exchange moves during periods of high volatility. We may also impose a strategy of not hedging due to the costs involved outweighing the benefits. We then leave exposures unhedged until market conditions and costs justify proceeding with a hedging strategy into the future.

The long-term strategy is to make certain strategic investments that will generate revenue in first-world, stable currencies to offset the impacts of cost of sales imports in developing currencies.

Table of Contents

The Medinotec Group of Companies operate in countries where the market is dominated by certain players and this creates a sales concentration risk which also causes an accounts receivable concentration risk.

Accounts receivable concentration risk is the level of revenue risk a portfolio holds as a result of relying on a small pool of customers. High customer concentration occurs when any single customer accounts for 20% or more of revenue. Much like anything, there are benefits and risks associated with high customer concentration.

The Group has historical reliance on two parties for sales into South Africa: there is reliance on DISA Life Sciences as a customer; and for exports out of South Africa there was historical reliance on Minoan Medical Proprietary. These relationships provide the Group with more than 100 sales representatives in the South African Market.

Sales between DISA Life Sciences and the Medinotec Group will continue into the future due to the vast distribution arm of DISA Life Sciences within South Africa. The Medinotec Inc. Group’s expectation is to reduce reliance on the South African markets for customers and accounts as the Group endeavors to expand and enter international first world markets. However, there is no guarantee that our plan will result in a decrease in reliance on DISA Life Sciences for customers and accounts. As with any expansion effort, there are barriers to entry and outside factors, such as regulatory approval, competition, among others, that may prevent us from entering such markets. As such, there is a risk that the concentration of customer issue will remain an ongoing issue unless we are successful in overcoming barriers to entry, competing with those in our markets and achieving regulatory approvals, none of which can be guaranteed.

Please refer to the related parties and entities section for a more detailed discussion on each function and the relationships involved as well as any arm’s length disclosures.

These relationships have the upside of:

	•	Developing long-term relationships with fewer large customers
	•	Less contractual agreements and overheads per dollar
	•	Greater focus on customer service and customer needs
	•	Work with large customers similarly to partners

Table of Contents

These relationships also pose the following risks and downsides:

• Loss can devastate revenue, profit, and cash flow • Holds pricing and negotiating leverage, which can decrease revenue • Diverts disproportionate ~~amount~~amounts of resources away from smaller customers • Causes difficulty diversifying over time • Can decrease the value of a company

Due to the nature of the territories that we operate in, it will be impossible to eliminate concentration risk. However, we do plan to diversify into a larger product basket and increase our international footprint, either by growing operations into other territories or alternatively acquiring more business share in other geographical territories.

The Medinotec Group of Companies insurance program may not be adequate to cover future losses.

We have elected to combine a mix of self-insurance and insured risks for most of the insurable risks across our company. We made this decision based on cost and availability factors in the insurance marketplace.

We continue to maintain a directors and officers liability insurance policy with third-party insurers that provides coverage for our directors and officers. This policy also covers product liability claims to a limited extent. We also maintain a detailed stock throughput policy to ensure inventory is ensured against losses and fire risk. All other assets fall into the category of self-insurance.

Table of Contents

We continue to monitor the insurance marketplace to evaluate the value of obtaining insurance coverage for other categories of losses in the future. Although we believe, based on historical loss trends, that our self-insurance program accruals and existing insurance coverage will be adequate to cover future losses, historical trends may not be indicative of future losses.

Risks associated with insurance plans include:

•

Insurance costs could increase significantly, or the availability of insurance may decrease, either of which could adversely impact our financial condition;

•

Deductible or retention amounts could increase, or our coverage could be reduced in the future and to the extent losses occur, there could be an adverse effect on our financial results depending on the nature of the loss and the level of insurance coverage we maintained;

•

Insurance may not be available to us at an economically reasonable cost, or our insurance may not adequately cover our liability in connection with claims brought against us; and

•

As our business inherently exposes us to claims, we may become subject to claims for which we are not adequately insured. Unanticipated payment of a large claim may have a material adverse effect on our business.

The absence of sufficient third-party insurance coverage for other categories of losses increases our exposure to unanticipated claims and these losses could have a materially adverse impact on the business, results of operations, financial condition, and cash flows.

The Medinotec Group of Companies future growth is dependent upon the development of new products and line extensions, which requires significant research and development, clinical trials, and regulatory approvals, all of which are very expensive and time-consuming and may not result in a commercially viable product.

In order to develop new products and improve current product offerings through our strategic partnerships with other principals, we focus our research and development programs largely on the development of, or obtaining the exclusive distribution rights to, next-generation and technology offerings across multiple programs and opportunities.

Table of Contents

As a part of the regulatory process of obtaining marketing clearance from the respective countries’ regulators for new products, we and our strategic partners conduct and participate in numerous clinical trials with a variety of study designs, patient populations and trial endpoints. Unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us or partners related to us, by our competitors or by third parties, or the market’s perception of this clinical data, may adversely impact our ability to obtain product approvals from the regulators, our position in, and share of, the markets in which we participate and our business, financial condition, results of operations or future prospects.

If the Medinotec Group of Companies fails to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate and investors’ views of us.

Our failure to maintain the effectiveness of our internal controls in accordance with the requirements of best practices could have a material adverse effect on the business. It could lose investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on the price of the Common Stock. In addition, if our efforts to comply with new or changed laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and the business may be harmed.

We have limited experience in marketing and sales and are in the early stages of building our sales channels in the life science market and internationally.

We may not be able to market, sell or distribute our current and future products effectively enough to support our planned growth. Currently, we sell our products through a combination of direct sales efforts and partnerships with distributors across all our key markets. During ~~2022~~2025, our distributors accounted for a significant portion of our total revenue. We are in the process of broadening and diversifying our sales channels across all markets. In the future, if we fail to maintain good relationships with, or fail to successfully motivate any of our large distributors, our revenue may decline. If we do not diversify our sales channels and effectively utilize our direct sales force, we will continue to be susceptible to risks associated with having a large percentage of revenue concentrated with a limited number of distributors.

Competition for employees capable of selling expensive medical devices within the pharmaceutical and biotechnology industries is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our products and limit our revenue growth and potential profitability.

Table of Contents

In addition, the time and cost of establishing a specialized sales, marketing and customer service force for a particular product or service may be difficult to justify considering the revenue projected to be generated by such additional personnel and resources. We also intend to add additional distribution partners in the life science market, and if we are unable to do so successfully, it will adversely impact on our ability to increase the revenue from our product offerings.

We rely on distributors for the sale of our products abroad and are entering into new agreements for the United States. We intend to continue to grow our business internationally and in the United States and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. We exert limited control over existing distributors under our agreements with them, and if their sales and marketing efforts for our products in their particular region are not successful, our business would be materially and adversely affected. Locating, qualifying, and engaging additional distribution partners with local industry experience and knowledge will be necessary in at least the short to mid-term to effectively market and sell our platform in certain countries outside the United States. We may not be successful in finding, attracting, and retaining distribution partners, or we may not be able to enter into such arrangements on favorable terms.

Most of our distribution relationships are non-exclusive and permit such distributors to distribute competing products. As such, our distributors may not commit the necessary resources to market our products to the level of our expectations or may choose to favor marketing the products of our competitors. Some of our distribution relationships are exclusive where the company is forced to rely on their efforts. Our distribution partners may compete against our inside sales force for sales opportunities. If current or future distributors do not perform adequately, offer competitive products, compete with our own sales staff, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth.

Table of Contents

We rely on a limited number of subcontractors to manufacture, assemble, package and production test our products, and the failure of any of these third-party subcontractors to deliver products or otherwise perform as requested could damage our relationships with our customers, decrease our sales and limit our growth.

While we design and market our products and conduct test development in-house, we do not manufacture, assemble, package and production test the vast majority of components of our products, and we must rely on third-party subcontractors to perform these services. If these subcontractors do not provide us with high-quality products, services and production and production test capacity in a timely manner, or if one or more of these subcontractors terminates its relationship with us, we may be unable to obtain satisfactory replacements to fulfill customer orders on a timely basis, our relationships with our customers could suffer, our sales could decrease, and our growth could be limited.

In addition, the consolidation of foundry subcontractors, as well as the increasing capital intensity and complexity associated with fabrication in smaller process geometries has limited the diversity of our suppliers and increased our risk of a "single point of failure." The lack of diversity of suppliers could also drive increased prices and adversely affect our results of operations, including our product gross margins.

We currently do not have long-term supply contracts with any of our third-party subcontractors. Therefore, they are not obligated to perform services or supply products to us for any specific period, in any specific quantities or at any specific price, except as may be provided in a particular purchase order. None of our third-party subcontractors has provided contractual assurances to us that adequate capacity will be available to us to meet future demand for our products. Our subcontractors may allocate capacity to the production of other companies' products while reducing deliveries to us on short notice. Other customers that are larger and better financed than we are or that have long- term agreements with these subcontractors may cause these subcontractors to reallocate capacity to those customers, thereby decreasing the capacity available to us.

Table of Contents

Other significant risks associated with relying on these third-party subcontractors include:

	•	reduced control over product cost, delivery schedules and product quality;

	•	potential price increases;

	•	inability to achieve sufficient production, increase production or test capacity and achieve acceptable yields on a timely basis;

	•	increased exposure to potential misappropriation of our intellectual property;

	•	shortages of materials used to manufacture products; and

	•	capacity shortages.

We distribute commodity medical products on behalf of multinational manufacturers for a substantial portion of our sales, and our failure to maintain and further develop these relationships could harm our business.

We act as a distributor on behalf of multinational firms, and we depend on these third-party contracts for cardiac commodity product inventory to consumers. Our distribution efforts for these other products, some of which are competitive with our own commodity products such as our Cape Cross NC and Cape Cross products, currently do and are expected to account for most of our net sales in the near future. These relationships are mostly non-exclusive and terminable upon a certain number of days’ notice. The loss of, or business disruption at, one or more of these firms or a negative change in our relationship with them, or a disruption to any one of our sales channels could have a material adverse effect on our business. If we do not maintain our relationship with these product suppliers or develop relationships with other firms for inventory to sell, the growth of our business may be adversely affected, and our business may be harmed. If we are required to obtain additional or alternative distribution agreements or arrangements in the future, we cannot be certain that we will be able to do so on satisfactory terms or in a timely manner. Our inability to enter into satisfactory distribution agreements may inhibit our ability to implement our business plan or to establish markets necessary to expand the distribution of products successfully.

Table of Contents

We may not be able to successfully implement our growth strategy for our own branded products as a result of the distribution efforts we engage in of outside product offerings we distribute for.

We believe that our future success depends, in part, on our ability to implement our growth strategy of leveraging our existing brand and products to drive increased sales. Our ability to implement this strategy depends, among other things, on our ability to:

	•	enter distribution and other strategic arrangements with third-party retailers and other potential distributors of our products successfully compete in the product categories in which we choose to operate;

	•	successfully compete in the product categories in which we choose to operate;

	•	introduce new and appealing products and successfully innovate our existing products;

	•	develop and maintain consumer interest in our brand; and

	•	increase our brand recognition and loyalty.

We may not be able to implement this growth strategy successfully. Our planned marketing expenditures may not result in increased total sales or generate sufficient levels of consumer interest or brand awareness, and our high rates of sales and income growth may not be sustainable over time. Our sales and results of operations will be negatively affected if we fail to implement our growth strategy or if we invest resources in a growth strategy that ultimately proves unsuccessful.

Table of Contents

We have identified material weaknesses in our internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner, which could have an adverse impact on our business.

Since becoming a public company, ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis has been, and will continue to be, costly and a time-consuming effort. In addition, the rapid changes in our operations and corporate structure have created a need for additional resources within the accounting and finance functions in order to produce timely financial information and to ensure the level of segregation of duties customary for a U.S. public company.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States (“GAAP”). Our management is also required, on a quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any changes and material weaknesses identified. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in our annual or interim consolidated financial statements might not be prevented or detected on a timely basis, as occurred with our interim consolidated financial statements in 2023, which were then restated and corrected in amended Quarterly Reports on Form 10-Q prior to the filing of this Annual Report on Form 10-K. As described in Item 9A of this Annual Report on Form 10-K, there were several material weaknesses identified in our internal control over financial reporting.

We are working to remediate our material weaknesses as soon as practicable. Our remediation plan, which is continuing to be developed, can only be accomplished over time, and these initiatives may not accomplish their intended effects. Failure to maintain our internal control over financial reporting could adversely impact our ability to report our financial position and results from operations on a timely and accurate basis or result in misstatements. Likewise, if our financial statements are not filed on a timely basis, we could be subject to regulatory actions, legal proceedings or investigations by ~~Nasdaq~~FINRA, the SEC or other regulatory authorities, which could result in a material adverse effect on our business and/or we may not be be able to maintain compliance with certain of our agreements. Ineffective internal controls could also cause investors to lose confidence in our financial reporting, which could have a negative effect on our stock price, business strategies and ability to raise capital.

Table of Contents

Even after the remediation of our material weaknesses, our management does not expect that our internal controls will ever prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. No evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the business will have been detected.

Risks Related to Management, Personnel and Control Persons

The Medinotec Group of Companies depends on our senior management personnel and may not be able to retain or replace these individuals or recruit additional personnel, which could harm our business.

Our future success is substantially dependent on the continued service of Dr. Gregory Vizirgianakis, our Founder, President, Chief Executive Officer and a member of our board of directors, and Pieter van Niekerk, our Chief Financial Officer, Treasurer and a member of our board of directors. Dr. Vizirgianakis and Mr. van Niekerk have extensive experience both with our company and in our industry and are familiar with our business, systems, and processes. Their loss would be catastrophic to our product offerings and ability to manage our business effectively, as we will likely not be able to find suitable individuals to replace them on a timely basis or at all.

Table of Contents

We depend on several key management, executive, sales and marketing, and technical personnel. The loss of the services of one or more key employees could delay the achievement of business objectives. Our success will also depend on our ability to attract and retain additional highly qualified executives, management, sales and marketing and technical personnel to meet its growth goals. We further face intense competition for qualified personnel, many of whom are often subject to competing employment offers, and we do not know whether we will be able to attract and retain such personnel.

Our success depends in large part on the continued service of the senior management team. In particular, the continued service of this group of individuals is critical to our vision, strategic direction, culture, products, and business plan. We do not maintain key-man insurance for any of the senior management team, and thus the loss of any of our executives, even temporarily, or any other member of senior management, could harm the business.

Dr. Gregory Vizirgianakis, our Founder, President, Chief Executive Officer and a member of our board of directors, and his brother, Stavros Vizirgianakis, also a member of our board of directors, together control our company with an 81% vote on all matters regarding shareholder approval by virtue of his ownership in our common stock.

Gregory and Stavros Vizirgianakis have not agreed to vote their shares together. If they decide to vote together on any matter, they are able to exercise significant influence over our company, including the election of directors, the approval of significant corporate transactions, and any change of control of our company. They could prevent transactions, which might be in the best interests of the other shareholders. Their interests may not necessarily be in the best interests of the shareholders in general. The rest of our shareholders will be considered minority shareholders and these will have little say in the direction of the Company as a result of their holdings.

Table of Contents

Our officers and directors are located outside of the United States and reside in South Africa. As a result, it may be difficult to effect service of process within the United States and enforce judgments of the US courts obtained against our executive officers and directors. Particularly, our shareholders may not be able to:

	•	Effect service of process in the U.S. on any of our officers and directors;
	•	Enforce judgments obtained in U.S. courts against our officers and directors based upon the civil liability provisions of the U.S. federal securities laws;
	•	Enforce, in a court outside of the U.S., judgments of U.S. courts based on the civil liability provisions of the U.S. federal securities laws; and
	•	Bring an original action in a court in South Africa to enforce liabilities against any of our officers and directors based upon the U.S. federal securities laws.

The Medinotec Group of companies’ officers and directors have limited experience managing a public company.

Our officers and directors have limited experience managing a public company. Consequently, we may not be able to raise any funds or run our public company successfully. Our executive officer’s and director’s lack of experience of managing a public company could cause you to lose some or all of your investment.

Table of Contents

Risk Associated with Legal and Regulatory Matters

The Medinotec Group of Companies are subject to extensive medical device regulation that may impede or hinder the approval process for our products and, in some cases, may not ultimately result in approval or may result in the recall or seizure of previously approved products.

The medical technology industry is regulated extensively by governmental authorities, principally the FDA, and state regulatory agencies with oversight of various aspects of drug and device distribution, sale, and use. The regulations are very complex, have become more stringent over time, and are subject to rapid change and varying interpretations. Regulatory restrictions or changes could limit our ability to carry on or expand our operations or result in higher than anticipated costs or lower than anticipated sales. The FDA and other federal and state governmental agencies regulate numerous elements of our business, including:

	•	product design and development;
	•	pre-clinical and clinical testing and trials;
	•	product safety;
	•	establishment registration and product listing;
	•	labeling and storage;
	•	marketing, manufacturing, sales, and distribution;
	•	pre-market clearance or approval;
	•	servicing and post-marketing surveillance, including reporting of deaths or serious injuries and malfunctions that, if they recurred, could lead to death or serious injury;
	•	advertising and promotion;
	•	post-market approval studies;
	•	product import and export; and
	•	recalls and field-safety corrective actions.

Table of Contents

Before we can market or sell a new regulated product or a significant modification to an existing product in the United States, we must obtain either clearance under Section 510(k) of the FDCA, grant of a de novo classification request, or approval of a pre-market approval, or PMA, application from the FDA, unless an exemption from pre-market review applies. In the 510(k) clearance process, the FDA must determine that a proposed device is “substantially equivalent” to a legally marketed “predicate” device (in most cases Class II devices, with a few exceptions), with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. Class III devices approved under the PMA process cannot serve as predicates. Clinical data are sometimes required to support substantial equivalence. In the de novo process, the FDA must determine that general and special controls are sufficient to provide reasonable assurance of the safety and effectiveness of a device, which is low to moderate risk and has no predicate (in other words, the applicant must justify the “down-classification” to Class I or II for a new product type that would otherwise automatically be placed into Class III, but is lower risk). The PMA process requires an applicant to demonstrate the safety and effectiveness of the device based on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing, and labeling data.

The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. Products that are approved through a PMA application generally need FDA approval before they can be modified. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k). The 510(k), de novo, and PMA processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA’s 510(k) clearance process usually takes from 3 to 12 months, but may take longer. The FDA’s stated goal is to review de novo classification requests within 150 days, 50% of the time, but in reality the process for many applicants generally takes even longer, up to a year or more. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or longer, from the time the application is submitted to the FDA until an approval is obtained. The process of obtaining regulatory clearances, approvals, and emergency use authorization to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances, approvals, or authorizations on a timely basis, or at all for our proposed products.

Table of Contents

If the FDA requires us to go through a lengthier, more rigorous examination for marketing authorization of our medical devices or future modifications to our medical devices than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline or to not increase in line with our forecasts. In addition, the FDA may determine that future products will require the more costly, lengthy, and uncertain PMA process. Although we do not market any devices under PMA, the FDA may demand that we obtain a PMA prior to marketing certain of our future products. Further, even with respect to those future products where a PMA is not required, we cannot assure you that we will be able to obtain the 510(k) clearances with respect to those products.

The FDA can delay, limit, or deny clearance, approval, or authorization of a device for many reasons, including:

	•	we may not be able to demonstrate that our products are safe and effective for their intended users;
	•	the data from our clinical trials may be insufficient to support clearance, approval, or authorization; and
	•	the manufacturing process or facilities we use may not meet applicable requirements.

In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our products under development. Any delay in, or failure to obtain or maintain, clearance or approval for our products under development could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny of us, could dissuade some customers from using our products and adversely affect our reputation and the perceived safety and efficacy of our product. Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as fines, civil penalties, injunctions, warning letters, recalls of products, delays in the introduction of products into the market, refusal of the FDA or other regulators to grant future clearances or approvals, and the suspension or withdrawal of existing clearances or approvals by the FDA or other regulators. Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and negatively impact our reputation, business, financial condition and operating results. Furthermore, any operations or product applications outside of the United States will subject us to various additional regulatory and legal requirements under the applicable laws and regulations of the international markets we enter. These additional regulatory requirements may involve significant costs and expenditure and, if we are not able to comply with any such requirements, our international expansion and business could be significantly harmed.

Table of Contents

Failure to obtain clearance or authorization for our medical devices, or other delays in the development of our medical devices, would adversely affect our ability to grow our business.

Commercialization of our medical devices may require an Emergency Use Authorization (EUA), FDA clearance of a 510(k) premarket notification submission, or authorization of a de novo submission. The process for submitting and obtaining FDA clearance of a 510(k), authorization of a de novo submission, or EUA can be expensive and lengthy. The FDA’s review process can take several months or longer, and we may not be able to obtain FDA clearance, de novo authorization, or Emergency use Authorization for our medical devices on a timely basis, if at all. The FDA’s refusal of, or any significant delays in receiving 510(k) clearance, de novo authorization, or Emergency use Authorization of our medical devices, would have an adverse effect on our ability to expand our business.

FDA approval ~~have~~has been granted for the ~~Trachealtor~~Trachealator following the 510(k) substantially equivalence process for Class II medical devices. We have no such FDA approval with respect to the ~~reset~~rest of our medical devices and we have not performed any clinical testing of our medical devices, which will likely be required before the device can be marketed. Even if a clinical trial is completed, there can be no assurance that the data generated during a clinical trial will meet the safety and effectiveness endpoints or otherwise produce results that will lead the FDA to grant marketing clearance, approval, or authorization. In addition, any other delays in the development of our medical devices, for example, unforeseen issues during product validation, would have an adverse effect on our ability to commercialize our medical devices.

Table of Contents

Modifications to our products may require new 510(k) clearances, de novo submissions, or pre-market approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.

FDA approval has been granted for the Trachealator following the 510(k) substantially equivalence process for Class II medical devices. Any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires a new 510(k) clearance or, possibly, a de novo or PMA. The FDA requires every manufacturer to make this determination in the first instance, and provides some guidance on decision making, but the FDA may review any manufacturer’s decision at any time. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications, de novo submissions or PMAs for modifications to our previously cleared or approved products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.

We may be liable if the FDA or other U.S. enforcement agencies determine we have engaged in the off-label promotion of our products or have disseminated false or misleading labeling or promotional materials.

Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including laws and regulations prohibiting marketing claims that promote the off-label use of our products or that make false or misleading statements. Healthcare providers may use our products off-label, as the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine. FDA also could conclude that a performance claim is misleading if it determines that there are inadequate non-clinical and/or clinical data supporting the claim. If the FDA determines that our promotional materials or training promote of an off-label use or make false or misleading claims, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fines, and criminal penalties. It is also possible that other federal, state, or foreign enforcement authorities might take action if they determine that our promotional or training materials promote an unapproved use or make false or misleading claims, which could result in significant fines or penalties. Although our policy is to refrain from statements that could be considered off-label promotion of our products or false or misleading, the FDA or another regulatory agency could disagree. Violations of the FDCA may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which may lead to costly penalties and may adversely impact our business. Recent court decisions have impacted FDA’s enforcement activity regarding off-label promotion in light of First Amendment Considerations; however, there are still significant risks in this area, in part due to the potential for False Claims Act exposure. In addition, the off-label use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend and could result in substantial damage awards against us and harm our reputation.

Table of Contents

Healthcare policy changes may have a material adverse effect on the Medinotec Group of Companies.

In response to perceived increases in healthcare costs in recent years, there have been and continue to be proposals by several governments, regulators, and third-party payers globally, including the US federal and state governments, to control these costs and, more generally, to reform healthcare systems.

Certain of these proposals could, among other things, limit the prices we are able to charge for products or the amounts of reimbursement available for our products, and could also limit the acceptance and availability of such products.

The adoption of some or all of these proposals could have a material adverse effect on the business, results of operations, financial condition and cash flows. If we experience decreasing prices for our goods and services and we are unable to reduce expenses, there may be a materially adverse effect on the business, results of operations, financial condition and cash flows.

Table of Contents

The Medinotec Group of Companies is subject to environmental laws and regulations and the risk of environmental liabilities, violations, and litigation.

We are subject to numerous US and non-US environmental, health and safety laws and regulations concerning, among other things, the health and safety of employees; the generation, storage, use and transportation of hazardous materials; emissions or discharges of substances into the environment; investigation and remediation of hazardous substances or materials at various sites; chemical constituents in medical products; and end-of-life disposal and take-back programs for medical devices.

Our operations and those of certain third-party suppliers involve the use of substances subject to these laws and regulations, primarily those used in manufacturing and sterilization processes. If we or our suppliers violate these environmental laws and regulations, facilities could be shut down and violators could be fined, criminally charged, or otherwise sanctioned.

Furthermore, environmental laws outside of the US are becoming more stringent, resulting in increased costs and compliance burdens. Certain environmental laws also assess liability on current or previous owners or operators of real property for the costs of investigation, removal or remediation of hazardous substances or materials at their properties or at properties which they have disposed of hazardous substances. In addition to clean-up actions brought by governmental authorities, private parties could bring personal injury or other claims due to the presence of, or exposure to, hazardous substances. The ultimate cost of site clean-up and timing of future cash outflows is difficult to predict, given the uncertainties regarding the extent of the required clean-up, the interpretation of applicable laws and regulations, and alternative clean-up methods.

The costs of complying with current or future environmental protection and health and safety laws and regulations, or liabilities arising from past or future releases of, or exposures to, hazardous substances, may exceed our estimates, or have a material adverse effect on the business, results of operations, financial conditions, and cash flows.

Finally, in some jurisdictions around the world, culture and practice encourages reuse of disposable products when the product is clearly labelled for single use. Such reuse may expose us to liability in these jurisdictions.

As a company with expanding operations, we increasingly face the risk of litigation and other claims against us. We have no such claims at present. Litigation and other claims may arise in the ordinary course of our business and include employee claims, commercial disputes, landlord-tenant disputes, intellectual property issues, product-oriented allegations and slip and fall claims. These claims can raise complex factual and legal issues that are subject to risks and uncertainties and could require significant management time. Litigation and other claims against us could result in unexpected expenses and liabilities, which could materially affect our operations and our reputation.

In addition, the medical device industry is characterized by extensive litigation and, from time to time, we are the subject of various claims. Regardless of the outcome, such claims are expensive to defend and divert management and operating personnel from other business issues. A successful claim or claims against us could result in payment of significant monetary damages and/or injunctive relief.

Table of Contents

Our devices, products and therapies are purchased principally by hospitals or physicians that typically bill various third-party payers, such as governmental healthcare programs, private insurance plans and managed care plans, for the healthcare services provided to their patients.

Table of Contents

The ability of customers to obtain appropriate reimbursement for products and services from third-party payers is critical because it affects which products customers purchase and the prices they are willing to pay. As a result, our devices, products, and therapies are subject to regulation regarding quality and cost for reimbursement and regulation of health goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud.

Many territories have similar laws that apply to reimbursement by state and other funded programs as well as in some cases to all payers. In certain circumstances, insurance companies attempt to bring a private cause of action against a manufacturer for causing false claims.

In addition, our strategic investments position the company as a manufacturer of FDA-approved devices reimbursable by federal healthcare programs. We are thus subject to the Physician Payments Sunshine Act, which requires us to annually report certain payments and other transfers of value our company makes to US-licensed physicians or US teaching hospitals. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.

We are also subject to risks relating to changes in government and private medical reimbursement programs and policies, and changes in legal regulatory requirements in the US and around the world. Implementation of further legislative or administrative reforms to these reimbursement systems, or adverse decisions relating to coverage of / or reimbursement for our products by administrators of these systems, could have an impact on the acceptance of and demand for our products and the prices that customers are willing to pay for them.

Quality is extremely important to us and our customers due to the impact of our products on patients, and the serious and potentially costly consequences of product failure. We are thus exposed to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices.

In addition, many products are used in intensive care settings with seriously ill patients. Component failures, manufacturing nonconformance, design defects, off-label use, or inadequate disclosure of product-related risks or product related information with respect to our products, if they were to occur, could result in an unsafe condition or injury to, or death of, a patient.

This could lead to recall of, or issuance of a safety alert relating to, our products, and could result in product liability claims and lawsuits, including class actions, which could ultimately result, in certain cases, in the removal from the body of such products and claims regarding costs associated therewith. Due to the strong brand recognition of Medinotec name and our brands, a material adverse event involving one of our products could result in reduced market acceptance and demand for all products within that brand and could harm our reputation and ability to market products in the future.

Should we fall short of these standards and our products become subject to recalls or safety alerts, our reputation could be damaged, we could lose customers and revenue and results of operations could decline. Our success also depends on the ability to manufacture to exact specifications for precision engineered components, sub-assemblies and finished devices from multiple materials. If components fail to meet these standards or fail to adapt to evolving standards, our reputation, competitive advantage, and market share could be harmed.

In certain situations, we may undertake a voluntary recall of products or temporarily shut down production lines based on performance relative to our own internal safety and quality monitoring and testing data. Any of the foregoing problems, including future product liability claims or recalls, regardless of their ultimate outcome, could harm our reputation and have a material adverse effect on the business, results of operations, financial condition, and cash flows.

4447

Table of Contents

The Medinotec Group of Companies may not be able to protect our intellectual property rights effectively.

Patents, trademarks and other intangible proprietary rights are and will be essential to the business and our ability to compete effectively with other companies. During normal day-to-day trade, we also rely on trade secrets, know-how, continuing technological innovations, strategic alliances, and licensing opportunities to develop, maintain and strengthen our competitive position.

We pursue a policy of obtaining patent protection in both the US and overseas for patentable subject matter of our proprietary devices and attempt to review third-party patents and patent applications to the extent publicly available to develop an effective patent strategy, avoid infringement of third-party patents, identify licensing opportunities and monitor the patent claims of others.

We also operate in an industry that is susceptible to significant intellectual property litigation. This litigation is expensive, complex, and lengthy and its outcome is difficult to predict. Future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel.

In addition, we may have to take legal action in the future to protect our patents, trade secrets, or know-how or to assert our intellectual property rights against claimed infringement by others. Any such legal action could be costly and time consuming and no assurances can be made that any lawsuit will be successful.

The invalidation of key patents or proprietary rights that we own, or an unsuccessful outcome in lawsuits to protect intellectual property, could have a material adverse effect on the business, financial condition, and results of operations. In the event that the right to market any of our products is successfully challenged, or if we fail to obtain a required license or are unable to design around a patent, the business, financial condition, and results of operations could be compromised.

In the ordinary course of business, we collect and store sensitive data, including patient health information, personally identifiable information about employees, intellectual property, and proprietary business information. We manage and maintain applications and data utilizing on-site and off-site systems. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information.

The secure processing, storage, maintenance, and transmission of this critical information is vital to operations and business strategy, and we devote resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our IT and infrastructure may be vulnerable to attacks by hackers, viruses, breaches, or interruptions due to employee error or malfeasance, terrorist attacks, hurricanes, fire, flood, other natural disasters, power loss, computer systems failure, data network failure, internet failure, or lapses in compliance with privacy and security mandates. Any such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties.

Unauthorized access, loss or dissemination could also interrupt operations, including the ability to receive and ship orders from customers, bill our customers, provide customer support services, conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business and damage our reputation, any of which could adversely affect the business.48

Table of Contents

Changes in tax laws or exposure to additional income tax liabilities could have a material impact on the Medinotec Group of Companies, the results of operations, financial conditions and cash flows.

We are subject to income taxes, as well as non-income-based taxes, in South Africa, and other jurisdictions in which we operate, as well as jurisdictions such as the United States, in which we intend to have operations. The tax laws in these could change on a prospective or retroactive basis, and any such changes could adversely affect us and our effective tax rate.

Taxation regulation in territories around the world can also change very quickly, which may mean that all the implications for businesses may not have been fully thought through by the regulating authorities before final guidelines and laws are issued. Furthermore, any changes made by tax authorities, together with other legislative changes, to the mandatory sharing of company information (financial and operational) with tax authorities on both a local and global basis, could lead to disagreements between jurisdictions with respect to the proper allocation of profits between such jurisdictions. We therefore continuously monitor changes to tax regulation and double tax treaties between the territories in which we operate. We also maintain a comprehensive transfer pricing policy to govern the flow of funds between various tax territories.

We are further subject to ongoing tax audits in the various jurisdictions in which we operate. We regularly assess the likely outcomes of these audits to determine the appropriateness of our tax provisions. However, there can be no assurance that we will accurately predict the outcomes of these audits, which could have a material impact on the business, financial condition, results of operations, and cash flows.

While we have recorded reserves for potential payments to various tax authorities related to uncertain tax positions, the calculation of such tax liabilities involves the application of complex tax regulations in many jurisdictions. Therefore, any dispute with a tax authority may result in payment that is significantly different from our estimates. If the payment proves to be less than the recorded reserves, the reversal of the liabilities would generally result in tax benefits being recognized in the period when we determine the liabilities to be no longer necessary. Conversely, if the payment proves to be more than the reserves, we would incur additional charges, and these could have a materially adverse effect on the business, financial condition, results of operations, and cash flows.

The failure to comply with anti-corruption laws could materially affect the Medinotec Group of Companies and result in civil and/or criminal sanctions.

FCPA and similar anticorruption laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business. Because of the predominance of government-administered healthcare systems in many jurisdictions around the world, many of our customer relationships are with governmental entities and are therefore potentially subject to such laws.

We also participate in public-private partnerships and other commercial and policy arrangements with governments around the globe. Global enforcement of anti-corruption laws has increased in recent years, including investigations and enforcement proceedings leading to assessment of significant fines and penalties against companies and individuals.

Our international operations create a risk of unauthorized payments or offers of payments by one of our employees, consultants, sales agents, or distributors. The business maintains policies and programs to implement safeguards to educate employees and agents on these legal requirements, and to prevent and prohibit improper practices. However, existing safeguards and any future improvements may not always be effective, and employees, consultants, sales agents, or distributors may engage in conduct for which we could be held responsible.

In addition, regulators could seek to hold us liable for conduct committed by companies in which we invest or that we acquire. Any alleged or actual violations of these regulations may subject us to government scrutiny, criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt the business, adversely affect our reputation and result in a material adverse effect on the business, results of operations, financial condition, and cash flows.

4649

Table of Contents

Laws and regulations governing international business operations could adversely impact the Medinotec Group of Companies.

The US Department of the Treasury’s Office of Foreign Assets Control (“OFAC”), and the Bureau of Industry and Security at the US Department of Commerce (“BIS”) administer certain laws and regulations that restrict US persons and, in some instances, non-US persons, in conducting activities, transacting business with or making investments in certain countries, governments, entities and individuals subject to US economic sanctions.

Our international operations subject us to these laws and regulations, which are complex, restrict business dealings with certain countries, governments, entities, and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced, or interpreted in a manner that materially impacts our operations. From time to time, certain subsidiaries have limited business dealings in countries subject to comprehensive sanctions.

Certain of our subsidiaries sell medical devices, and may provide related services, to distributors and other purchasing bodies in such countries. These business dealings represent an insignificant amount of our consolidated revenues and income but expose us to a heightened risk of violating applicable sanctions regulations. Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment.

We have established policies and procedures designed to assist with compliance with such laws and regulations. However, there can be no assurance that these will prevent us from violating these regulations in every transaction in which we may engage. As such a violation could adversely affect our reputation, business, financial condition, results of operations and cash flows.

As an Emerging Growth Company under the Jobs Act, the Medinotec Group of Companies are permitted to rely on exemptions from certain disclosures requirements.

We qualify as an "emerging growth company" under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

	•	have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;
	•	comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);
	•	submit certain executive compensation matters to shareholder advisory votes, such as "say-on-pay" and "say-on-frequency;" and
	•	disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive's compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an "emerging growth company" for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1 billion, (ii) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

Until such a time, however, we cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

4750

Table of Contents

We are a “smaller reporting company” as defined in the Exchange Act. As a smaller reporting company, we may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. To the extent we take advantage of any reduced disclosure obligations, it may make it harder for investors to analyze the Company’s results of operations and financial prospectus in comparison with other public companies.

Risks Associated with Political Instability and Regional Issues

Geopolitical and Trade Risks due to tariffs and trade wars

Medinotec Inc. operates in a challenging geopolitical and trade environment that exposes the company to several risks that could adversely affect our financial performance and operations.

The U.S. has recently imposed significant tariffs on imports from South Africa and other nations, with tariffs ranging up to 30% on a variety of goods, including machinery, vehicles, and precious metals. This has raised concerns regarding the future of the African Growth and Opportunity Act (AGOA), which has previously provided preferential trade benefits, including duty-free access to the U.S. market for South African goods. Should these benefits be revoked, we could face increased export costs and reduced demand for our products in the U.S., which represents a significant market for our business.

At the May 21, 2025 Oval Office meeting, U.S. President Donald J. Trump and South African President Cyril Ramaphosa met, but no changes to the imposed tariffs were announced.

While the South African government is exploring the possibility of negotiating a bilateral trade agreement with the U.S., the outcome and timeline of these discussions are uncertain. As a result, the tariffs and the potential loss of AGOA benefits could significantly disrupt our U.S. market strategy and increase the costs of our exports to the U.S.

The current global trade tensions, including the tariffs imposed by the U.S., have led to a ripple effect in other markets, including Europe. European governments may respond with retaliatory tariffs or other trade measures, potentially increasing the cost of medical device products we distribute from European suppliers. These price increases could have an adverse impact on our business, as we may be unable to offset the rising costs without passing them onto customers. Since we are locked into agreements with our suppliers for the distribution of their products in South Africa, our ability to mitigate these cost increases is limited.

South Africa is experiencing significant political instability, with tensions rising within the ruling coalition government. The potential collapse of the government of national unity and the uncertainty surrounding fiscal policies, such as increases in VAT or other tax rates, could disrupt business operations. In particular, such instability may lead to regulatory changes, higher operating costs, or interruptions to our manufacturing activities in South Africa.

While Medinotec Inc. cannot directly influence these political developments, we are closely monitoring the situation and assessing potential risks to our operations. We are also considering contingency plans to manage any disruptions that could arise from governmental changes or civil unrest.

While we are not large enough to directly engage with policymakers, we are actively monitoring developments related to trade tariffs and political instability in South Africa. We will continue to adapt our strategies based on emerging trends and adjust our risk management approach accordingly.

Table of Contents

For our self-manufactured products, we are actively exploring options to diversify our supply chain, which will help reduce exposure to any disruptions caused by tariff changes or political instability. However, for our agency business, where we distribute products for multinational medical device companies, we are reliant on our suppliers and their pricing decisions, which limit our ability to mitigate the impact of potential tariff-induced cost increases.

Despite these efforts, the interconnected nature of these risks means that their cumulative impact could be more significant than anticipated, potentially affecting our financial results and operational stability.

South Africa Specific Risk of Unstable Power Supply

Electricity demand in South Africa is extremely high and energy plants do not meet the demand. Therefore, there are frequent rolling black outs that are handled by a schedule of “load shedding” during which the supply and demand of electricity is balanced out to prevent the entire power grid from collapsing. This results in unstable energy sources and frequent production halts for our company. DISA Medinotec has a backup generator big enough to sustain the entire production facility in case of a power outage. In addition, South Africa is also a very solar capable country due to the weather being warm with sub-tropical like conditions. Therefore, we are looking into solar power as a means to run our production facilities more efficiently in the longer run.

South Africa Specific Risk of Political instability May Affect the Medinotec Group of Companies’ ability to operate effectively.

Political instability in the countries in which we operate, including South Africa, where episodes of violent civil unrest (riots) have further destabilized the country’s economy and resulted in extensive damage to commercial property, and may cause increased uncertainty about our ability to exist in this environment. This may adversely affect investor confidence as well as our business planning, operations and our market capitalization.

This risk extends to global economic uncertainty and heightened geopolitical tensions, such as those in involved in the Russian war on Ukraine, between the United States and China as well as Brexit, which can also have an impact on several factors influencing commodity prices, exchange rates, and interest rates, all of which can affect our business in turn.

South Africa Specific Risk that Broad-based Black Economic Empowerment (“BEE”) requirements may restrict growth opportunities and limit the Medinotec Group of Companies’ ability to attract key talent.

In South Africa, the correction of inequalities amongst the key demographic groups of the country as a result of Apartheid is regulated by the Broad-based Black Economic Empowerment Act 53 of 2003. This is a legislative framework for the promotion of BEE that seeks to advance economic transformation and enhance the economic participation of Black people in the South African economy. Companies failing to meet the requirements of the Act and its associated codes may be at risk of not being able to attract investment and may also face more limited opportunities for growth (both organic and acquisitive) and failure to attract, recruit and retain key candidates and suitably qualified personnel.

South Africa Specific Risk that South African authorities may disallow or delay a transfer of funds from South Africa to the United States

The Central Reserve Bank of South Africa oversees the flow of currency in and out of the republic of South Africa and the South African Revenue services oversee all transfer pricing issues. The Medinotec Group of Companies has transfer pricing bench marking in place for future planned transactions between its South African subsidiaries and Medinotec Inc., its U.S. parent company, and makes use of an external exchange control advisor to ensure any cross-border transactions complies with the requirements of both the Reserve Bank and the South African Revenue services. This is an approval process for the flow of funds and therefore may cause timing delays to transfer funds cross border but does not mean that it is disallowed entirely. We have successfully concluded a Private Placement during May of 2022 to the value of $ 3.3 million in the name of Medinotec Inc., which raise provided enough cashflow to fund our expected American operations and therefore we do not foresee that in the near future there will be intercompany or cross border dependence for operational activities. We believe that once Medinotec Inc. establishes its own sales network the company is expected to become self-sustaining. If for some reason there is a time delay and the funding raised during the private placement is not enough, to realize the business plan of the parent, the operating subsidiary in South Africa would be its only source of cashflow to sustain the Medinotec Group of Companies.

4852

Table of Contents

Allowable cash flows and their expected timelines are disclosed in the following table:

Method	Description	Normal Time Delay Experienced
Management fees	Restricted to an amount that the business would need to prove that the services rendered by the Medinotec Group Internationally to the local company is at an arm’s length amount. If this cannot be proven authorities will disallow the charge and in certain instances levy fines and penalties	If these charges are proven to be at arm’s length, flow of funds can happen within a one-week time frame.
Loans	Restricted to arm’s length terms and would need to apply for formal approval to the authorities.	The application may be accepted or declined and would require 6-10 weeks before approval will be obtained.
Dividends	Dividends may be declared from time to time depending on the fact that the company declaring these dividends are liquid and solvent.	Since Medinotec Inc. is the registered owner of the business in South Africa dividends may be declared at a Board meeting and these can be paid to the parent entity. A dividends withholdings tax of 20% would apply and the funds may then exit the country. The timeline to ensure compliance and transfer the funds will be 2-3 weeks.

It is important to note that the above-mentioned table is the only three options to externalize funds out of South Africa. The time delays mentioned are based on prior experience and guidance from expert advisors. The authorities do have the final decision-making powers on any transaction and therefore time delays may become material and can have a material impact on the business and its ability to function especially when a dispute arises from interactions with the regulators. Management fees and loans can easily be declined by authorities whereas dividends are less likely to be declined.

Our entire business plan is based on the successful private placement that was concluded, and this funding is expected to facilitate two years of funding required before any funding would be needed from the South African subsidiaries, therefore this leaves some time to obtain regulatory approvals in advance if the business plan roll out in the United States is slower than expected. If the Central Reserve Bank declines or imposes any restrictions including time delays for approvals for flow of funds it may have a material impact on the business operations of the Group and may delay its roll out in the American Markets until a follow up capital raise or alternatively debt finance can be obtained on an international level. It is important to note that this successful raise of money does not guarantee that we will obtain regulatory approval in the USA for product candidates that fall outside the Trachealator product which already obtained FDA approval in November 2021. In addition to this it also does not guarantee successful commercializing of any products in the United States of America.

South Africa Specific Risk of South Africa Being Grey listed by the FATF- Financial Action Task Force

The FATF- Financial Action Task Force is a global inter-governmental body, that promotes policies and sets international standards relating to the combating of money laundering, terrorist financing, and the financing of the proliferation of weapons of mass destruction. There are currently 39 members of the FATF; 37 jurisdictions including South Africa and 2 regional ~~organisations~~organizations (the Gulf Cooperation Council and the European Commission). There are a further 31 international and regional ~~organisations~~organizations which are Associate Members or Observers of the FATF and participate in its work. South Africa is the only African member of FATF, but other African jurisdictions participate through FATF Regional Bodies like the Eastern and Southern Africa Anti-Money Laundering Group (ESAAMLG) who are associate members of FATF.

The FATF grey list refers to the FATF’s practice of publicly identifying countries with strategic Anti- Money Laundering and Countering the Financing of Terrorism (AML/CFT) deficiencies. The FATF maintains two such lists: I. jurisdictions under “increased monitoring” that are actively working with the FATF to address strategic deficiencies in their regimes” and II. “high-risk jurisdictions subject to a call for action” that are not actively engaging with the FATF to address these deficiencies.

4953

Table of Contents

South Africa did poorly in its 2021 mutual evaluation, which was conducted in 2019 when many institutions (especially law-enforcement agencies) were at their weakest following state capture. Whilst no country is fully compliant with all 40 FATF Recommendations and all 11 effective immediate outcomes, South Africa was deemed to have too many weaknesses in its legal framework (being deemed to be inadequately compliant with 20 of FATF’s recommendations) in all 11 effectiveness immediate outcomes. South Africa was put under a one-year observation period in October 2021, giving the country time to address 67 Recommended Actions. South Africa made significant progress during the observation period, passing two major Amendment Acts in 2022, and strengthening its institutions. A January 2023 assessment of SA’s progress found that South Africa had made significant and positive progress, reducing the 67 Recommended Actions to 8 strategic deficiencies, where more progress is required.

The most significant implication to a country that is ~~greylisted~~grey-listed is the reputational damage to the country, as its effectiveness in combatting financial crimes like corruption and money-laundering as well as terror financing are deemed to be below international standards. The second and related implication arises from consequential action taken regarding cross-border transactions, particularly possible action taken by foreign banks that provide correspondent banking services. It should be noted that FATF does not require enhanced due diligence measures to be applied, but rather that all jurisdictions take account of it in their risk analysis. The same FATF statement quoted above notes:

“The FATF does not call for the application of enhanced due diligence measures to be applied to these jurisdictions. The FATF Standards do not envisage de-risking, or cutting-off entire classes of customers, but call for the application of a risk-based approach. Therefore, the FATF encourages its members and all jurisdictions to take into account the information presented below in their risk analysis.” However, despite the FATF requirement, selected institutions are expected to undertake more enhanced monitoring, for their own business reasons, or as may be required by their own laws (eg EU directives). Hence institutions based in a ~~greylisted~~grey-listed country that engages in cross-border trade and other activities may be subject to higher levels of customer due diligence by financial institutions outside of that country. In practice, this means ~~being~~ being more thorough processing and vetting clients and understanding the sources of their funds. However, if a country has demonstrated ~~that~~ that it has taken strong and credible steps to prevent or get out of ~~greylisting~~grey listing, the costs of ~~greylisting~~grey listing will likely be reduced. In the case of South Africa, none of the items on the action plan relate directly to preventive measures in respect of the financial sector, reflecting significant progress since the mutual evaluation in the application of a risk-based approach to the supervision of banks and insurers. National Treasury, therefore, expects that if South Africa continues to make significant improvements in effectiveness and swiftly exits ~~greylisting~~ grey listing, it will have a limited impact on financial stability and costs of doing business with South Africa, particularly if South Africa moves speedily to get out of ~~greylisting~~grey listing.

Companies in South Africa, responding to the ~~greylisting~~grey-listing will require context-specific solutions depending on the broader impact of the ~~greylisting~~grey listing on their plans around aspects such as strategic expansions, capital raising, and any general increased cost of doing business. Medinotec trades in a highly regulated environment already and applies high levels of due diligence and financial ~~contol~~control therefore the additional costs of compliance expected to be incurred due to the ~~greylisting~~grey listing is in our opinion minimal, this assessment may however change based on Government’s response into the future. This status may however make it harder for the business to raise capital in the future, Generally, it takes from one to three years for countries to address the deficiencies and to be taken off the grey list, something that occurs after a final, on-site assessment ~~when~~ when both FATF and the relevant country believe that all elements of the action plan have been largely or fully addressed. The South ~~African~~ African Government communicated that it plans to address the eight (8) areas of strategic deficiencies identified by the FATF, by no later than the end of January 2025 and that government has an intention to exit the grey list as fast as possible. There may, however , be unplanned delays.

Despite the progress the South African Government is making on addressing deficiencies, it is still unclear how long this designation will remain in place and what ramifications, if any, the designation will have for the Company.

Table of Contents

Risks Relating to Our Securities

If the Medinotec Group of Companies undertakes future offerings of our common stock, shareholders will experience dilution of their ownership percentage.

Generally, existing shareholders will experience dilution of their ownership percentage in the company if and when additional shares of common stock are offered and sold. In the future, we may be required to seek additional equity funding in the form of private or public offerings of our common stock. In the event that we undertake subsequent offerings of common stock, your ownership percentage, voting power as a common shareholder, and earnings per share, if any, will be proportionately diluted. This may, in turn, result in a substantial decrease in the per-share value of your common stock.

Table of Contents

If a market for our common stock does not develop, stockholders may be unable to sell their shares

Our common stock is quoted under the symbol “MDNC” on the OTCQX operated by OTC Markets Group, Inc., an electronic inter-dealer quotation medium for equity securities. We were approved for trading in March 2023, and we do not have an active trading market. We can provide no assurances that an active trading market will ever occur, and you may have issues selling your securities in our company.

The Medinotec Group of Companies’ common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.

The market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including:

	•	new products and services by us or our competitors;
	•	government regulation of our products and services;
	•	intellectual property disputes;
	•	additions or departures of key personnel;
	•	sales of our common stock;
	•	our ability to integrate operations, technology, products and services;
	•	our ability to execute our business plan;
	•	operating results below expectations;
	•	loss of any strategic relationship;
	•	industry developments;
	•	economic and other external factors; and
	•	period-to-period fluctuations in our financial results.

You should consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the above.

In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

The trading market for the Common Stock will depend on the research and reports that securities analysts publish about our business and us. We do not have any control over these analysts. There is no guarantee that securities analysts will cover the Common Stock. If securities analysts do not cover the Common Stock, the lack of research coverage may adversely affect our market price.

Table of Contents

If we are covered by securities analysts, and the stock is the subject of an unfavorable report, the stock price and trading volume would likely decline. If one or more of these analysts ceases to cover our company or fails to publish regular reports on us, we could lose visibility in the financial markets, which could cause the stock price or trading volume to decline.

Table of Contents

The Securities and Exchange Commission has adopted regulations which generally define "penny stock" to be any listed, trading equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock, the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules which may increase the difficulty Purchasers may experience in attempting to liquidate such securities.

If the Medinotec Group of Companies issues shares of preferred stock with superior rights to the common stock, it could result in a decrease in the value of our common stock and delay or prevent a change in control of us.

Our board of directors is authorized to issue up to 20,000,000 shares of preferred stock. Our board of directors has the power to establish the dividend rates, liquidation preferences, voting rights, redemption and conversion terms and privileges with respect to any series of preferred stock. The issuance of any shares of preferred stock having rights superior to those of the common stock may result in a decrease in the value or market price of the common stock. Holders of preferred stock may have the right to receive dividends, certain preferences in liquidation and conversion rights. The issuance of preferred stock could, under certain circumstances, have the effect of delaying, deferring, or preventing a change in control of us without further vote or action by the stockholders and may adversely affect the voting and other rights of the holders of common stock.

The Medinotec Group of Companies does not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.

We do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting it at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will occur only if our stock price appreciates.

Members of our board of directors and our officers will have no liability for breaches of their fiduciary duty of care as a director or officer, except in limited circumstances, pursuant to provisions in the Nevada Revised Statutes and our Bylaws as authorized by the Nevada Revised Statutes. Specifically, Section 78.138 of the Nevada Revised Statutes provides that a director or officer is not individually liable to the company or its shareholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that (1) the director’s or officer’s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and (2) his or her breach of those duties involved intentional misconduct, fraud or a knowing violation of law.

Table of Contents

This provision is intended to afford directors and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach of the duty of care by a director or officer. Accordingly, you may be unable to prevail in a legal action against our directors or officers even if they have breached their fiduciary duty of care.

Table of Contents

In addition, our Bylaws allow us to indemnify our directors and officers from and against any and all costs, charges and expenses resulting from their acting in such capacities with us. This means that if you were able to enforce an action against our directors or officers, in all likelihood, we would be required to pay any expenses they incurred in defending the lawsuit and any judgment or settlement they otherwise would be required to pay. Accordingly, our indemnification obligations could divert needed financial resources and may adversely affect our business, financial condition, results of operations and cash flows, and adversely affect prevailing market prices for our common stock.

ITEM 1B.

UNRESOLVED STAFF COMMENTS

This information is not required for smaller reporting companies.

ITEM 1C.

CYBERSECURITY

Cybersecurity Risk Management and Strategy

We rely on our information technology to operate our business. As such, we have policies and processes designed to protect our information technology systems, some of which are managed by third parties, and resolve issues in a timely manner in the event of a cybersecurity threat or incident.

We have designed our business applications and hosting services to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. We seek to further mitigate cybersecurity risks through a combination of monitoring and detection activities, use of anti-malware applications, employee training, quality audits and communication and reporting structures, among other processes. We engage a third-party consultant to assist us with our cybersecurity risk management framework, including the monitoring and detection of cybersecurity threats and responding to any cybersecurity threats or incidents.

The Company maintains an ongoing partnership with a third-party cybersecurity service provider, which facilitates continuous communication through regular electronic updates and periodic onsite engagements. This collaboration ensures alignment in key areas of cybersecurity, including threat detection, vulnerability management, and incident response.

We have implemented internal communication protocols designed to promptly escalate any cybersecurity incidents to the appropriate personnel responsible for evaluating their significance and potential materiality. Upon identification of an incident, the matter is assessed in coordination with our cybersecurity service provider. Relevant information is then communicated to the Board of Directors, which is responsible for determining whether public disclosure is required under applicable securities laws. This process is intended to support timely and accurate reporting in accordance with the Company’s disclosure obligations.

Cybersecurity Governance

~~Our~~The Company’s cybersecurity program is supported by a third-party consultant team, iswhich ~~managed~~provides byexpertise ~~our~~in monitoring, threat detection, and risk mitigation. This team operates under the oversight of senior leadership, specifically the Chief Executive Officer and an Independent Director. Inwith ~~addition~~relevant experience. Together, they ~~management~~are ~~updates~~responsible for managing the ~~board,~~relationship aswith ~~necessary,~~the ~~regarding~~cybersecurity ~~any~~consultants ~~material~~and ensuring that cybersecurity ~~incidents,~~risk asmanagement ~~well~~remains asaligned ~~any~~with ~~incidents~~the ~~with~~Company’s ~~lesser~~overall ~~impact~~strategic ~~potential~~objectives and risk tolerance.

Our cybersecurity program is informed by industry-recognized best practices, including the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF), which guides our efforts across key domains such as risk identification, protection, threat detection, incident response, and recovery. This framework helps ensure consistency and effectiveness in our cybersecurity approach and supports compliance with evolving regulatory expectations.

Cybersecurity oversight is also integrated into the Company’s broader corporate governance structure. Management provides updates to the Board of Directors at least quarterly, or more frequently as necessary in response to immediate threats or incidents. These updates cover any material cybersecurity events, as well as incidents of lesser impact that may indicate emerging risks or operational vulnerabilities. The Board, in exercising its oversight responsibilities, evaluates the potential impact of such incidents on the Company’s operations, financial condition, and disclosure obligations.

Table of Contents

This governance framework is designed to ensure that the Company remains responsive to the dynamic cybersecurity landscape, maintains regulatory compliance, and protects the integrity of its information systems and data assets.

Our management team is responsible for assessing and managing our material risks from cybersecurity threats.

Risks from Cybersecurity threats

Although cybersecurity risks have not materially affected us, including our business strategy, results of operations or financial condition, to date, we face numerous and evolving cybersecurity threats in our business. For more information about the cybersecurity risks we face, see the risk factor entitled "The Medinotec Group of Companies rely on the proper function, security and availability of our IT systems and data to operate the business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect the business, results of operations, financial condition, cash flows, reputation, or competitive position." in Item 1A. Risk Factors.

During the years ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024, we did not, to our knowledge, experience any cybersecurity incidents or breaches that materially impacted or are reasonably likely to materially impact our business, performance or results.

Table of Contents

ITEM 2.

PROPERTIES

Currently, we do not own any real estate. Our principal executive offices and manufacturing facility are located at Northlands Business Park at 170-171 Bush Telegraph Avenue, North ~~riding~~Riding, Johannesburg, South Africa. We have entered into a lease for this 8,783 square foot facility. We also rent office space in Melville, New York under a short-term rental agreement. We believe that our properties are adequate for our current needs, but growth potential may require larger facilities due to the anticipated addition of personnel.

• The lease term: Three years commencing August 1, 2023 until July 31, 2026.

• Rent is approx.: $2,546 per month (Excluding Value Added Taxes)

• Rates taxes and Levies are billed in addition to the Rent

• DISA Medinotec pays its own utility bills to the local service providers

We do not have any policies regarding investments in real estate, securities, or other forms of property.

Please refer to related party footnotes in the financial statements and as disclosed in the Section of this Annual Report, entitled, “Certain Relationships and Related Transactions, and Director Independence” for the related party effects of the lease.

We are also currently renting office and storage space in Long Island, New York ~~with the following terms attached to the lease:~~.

• The lease term: Twelve months commencing July 1, 2023 until June 30, 2024.

• Rent is approx.: $1,601 per month

ITEM 3.

LEGAL PROCEEDINGS

From time to time, the Company may become involved in various legal proceedings in the ordinary course of its business and may be subject to third-party infringement claims.

In the normal course of business, the Company may agree to indemnify third parties with whom it enters into contractual relationships, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations or covenants, other third-party claims that the Company’s products when used for their intended purposes infringe the intellectual property rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these indemnification obligations due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each claim.

From time to time, the Company is subject to various claims that arise in the ordinary course of business. Management believes that any liability of the Company that may arise out of or with respect to these matters will not materially affect the financial position, results of operations, or cash flows of the Company.

As of the date of this Annual Report, there is no known material litigation or claims against the Company.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

5458

Table of Contents

PART II

ITEM 5.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Market Information.

Our common stock is qualified for quotation on the OTCQX under the symbol “MDNC” and has been quoted on the OTC since March 2023. There currently is no liquid trading market for our common stock. There can be no assurance that a significant active trading market in our common stock will develop, or if such a market develops, that it will be sustained.

The ability of individual stockholders to trade their shares in a particular state may be subject to various rules and regulations of that state. A number of states require that an issuer’s securities be registered in their state or appropriately exempted from registration before the securities are permitted to trade in that state. Presently, we have no plans to register our securities in any particular state. Further, our shares are subject to the provisions of Section 15(g) and Rule 15g-9 of the Exchange Act, commonly referred to as the “penny stock” rule. Section 15(g) sets forth certain requirements for transactions in penny stocks and Rule 15g-9(d)(1) incorporates the definition of penny stock as that used in Rule 3a51-1 of the Exchange Act.

Holders

As of ~~July~~May 129, ~~2024~~2025, we had 6356 shareholders of common stock per transfer agent’s shareholder list.

Dividends

The Company has not paid any cash dividends to date and does not anticipate or contemplate paying any dividends in the foreseeable future. It is the present intention of management to utilize all available funds for the growth of the Registrant’s business.

Equity Compensation Plan Information

The Company does not currently have an equity compensation plan in place.

ITEM 6.

[RESERVED]

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations for the Years February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024

Revenue

~~The~~For the fiscal year ended February 28, 2025, the Consolidated Medinotec Group of Companies’ reported revenue ~~for~~of ~~the~~$9,113,607, ~~year~~an ~~ended~~increase ~~February~~of 29$4,093,216 ~~2024~~or ~~was~~81.5% compared to $5,020,391 ~~compared~~ toin ~~$999,579~~the ~~in revenue~~prior ~~being~~year. This ~~recorded~~growth inwas primarily driven by the full-year ~~ended~~impact ~~February~~of ~~28,~~newly ~~2023~~established distribution agreements, anthe ~~increase~~initial commercialization of a $4key product in the U.S. market,~~020,812~~ and continued expansion of our global sales footprint.

The reason for the higher sales growth was due to various new distribution agreements in the surgical specialty of cardiology the Company entered into. These agreements are short term in nature and can be cancelled on non-performance clauses by either party. It has a strong geographical country specific risk which is mainly concentrated to South Africa. This led to increased revenues in South Africa. The rapid sales growth is attributable to the fact that these distributors already have existing business as well as a reputation for quality product in South Africa. Disa Medinotec got awarded these contracts due to years of good relationships between the external third party distributors and the current executive management of Disa Medinotec. In addition, the Company realized sales for its Trachealator in the United States with no such sales inside the United States for the prior year period.59

Table of Contents

~~The~~Key ~~increase~~Drivers ~~for the sales~~ of ~~the~~Revenue Trachealator product, is substantiated by the roll out of this product as our lead product in the non-occlusive tracheal dilation market and the increase in its popularity and use within these territories.Growth

~~The~~• First Full Year Under New Distribution Agreements During the third quarter of fiscal 2024, the Company ~~recently~~entered ~~embarked on~~into ~~obtaining~~multiple ~~various~~new distribution agreements in the surgical cardiology segment, primarily concentrated in South Africa. Fiscal 2025 represents the first full year of revenue contribution under these agreements. The performance-based nature of these short-term contracts, ~~from~~while beneficial for flexibility, also introduces potential variability depending on distributor execution and market dynamics. • Geographic Concentration and Relationship-Driven Wins The revenue increase was concentrated in South Africa, where our distribution partners brought strong reputations and existing market presence. These contract awards were, in part, the result of long-standing relationships between distributor principals and current executive management. While this contributed to ~~ensure~~accelerated growth, the geographic concentration poses a ~~full~~potential risk in the event of contract changes, local disruptions, or economic volatility. • U.S. Market Commercialization of Trachealator In fiscal 2024, we began generating revenue in the United States through sales ~~basket~~of our Trachealator device. This represents the first year of U.S. commercialization for the product, which serves the non-occlusive tracheal dilation market. The rollout has been positively received and ~~cash~~forms ~~generation~~a tokey ~~sustain~~component of our growth ~~and~~strategy ~~product development~~going forward. • Expanded Product Portfolio The Company also secured several new distribution agreements with international principals late in the ~~near~~fiscal year to broaden its product offerings. These agreements are expected to support future revenue diversification, reduced concentration risk, and additional entry points into both existing and new markets.

NoSeasonality ~~revenue~~and ~~was~~Operating ~~generated by affiliations to related parties during the year ending February 29, 2024.~~Patterns

While our business is not subject to pronounced seasonality, we typically observe modest declines in sales during periods that coincide with regional holidays or extended breaks—particularly in markets like South Africa. These trends are known and budgeted for as part of our operating planning cycle.

Related Party Transactions

No revenue was generated from related party affiliations during the fiscal year ended February 28, 2025.

This table indicates the sales per revenue stream as a breakdown of the total revenue balance:

	Medinotec Inc Group Consolidated Years Ended
	Feb 29, 2024 $		Feb 28, 2023 $
	Feb 28, 2025 $		Feb 29, 2024 $
Outside of United States of America
Internally Designed/Manufactured Sales		~~976~~863,~~291~~337		~~978~~976,~~112~~291
Distribution Agreement Sales		37,~~490~~572,~~133~~165		—3,490,133
Sales Generated inside the United States of America
Internally Designed/Manufactured Sales		~~553~~678,~~967~~105		21553,~~467~~967
		5,020,391		999,579
		9,113,607		5,020,391

~~The following table sets forth financial information by reportable segment for the years ending February 29, 2024 and February 28, 2023:~~60

1. Income/(loss) from operations

	Inside the United States		Outside the United States		Total
	2024	2023	2024	2023	2024	2023
Revenue	$553,967	$21,467	$4,466,424	$978,112	$5,020,391	$999,579
Cost of goods sold	(47,708)	(1,746)	(2,530,214)	(416,011)	(2,577,922)	(417,757)
Gross profit	506,259	19,721	1,936,210	562,101	2,442,469	581,822
Selling expenses	(30,611)	(9,644)	(53,953)	(44,174)	(84,564)	(53,818)
Depreciation expense	—	—	(63,948)	(53,553)	(63,948)	(53,553)
General and administrative expenses	(477,226)	(259,487)	(1,193,802)	(388,685)	(1,671,028)	(648,172)
Research and development expenses	—	—	(22,351)	(64,866)	(22,351)	(64,866)
Income/(loss) from operations	$(1,578)	$(249,409)	$602,156	$10,822	$600,578	$(238,587)
Provision for impairment of note receivable	(642,012)	—	—	—	(642,012)	—

Table of Contents

The following table sets forth financial information by reportable segment for the years ending February 28, 2025 and February 29, 2024:

Income/(loss) from operations

	Inside the United States		Outside the United States		Total
	2025	2024	2025	2024	2025	2024
Revenue	$678,105	$553,967	$8,435,502	$4,466,424	$9,113,607	$5,020,391
Cost of goods sold	(87,826)	(47,708)	(4,164,995)	(2,530,214)	(4,252,821)	(2,577,922)
Gross profit	590,279	506,259	4,270,507	1,936,210	4,860,786	2,442,469
Selling expenses	(65,646)	(30,611)	(47,548)	(53,953)	(113,194)	(84,564)
Depreciation expense	-	-	(73,846)	(63,948)	(73,846)	(63,948)
General and administrative expenses	(725,834)	(477,226)	(665,280)	(1,193,802)	(1,391,114)	(1,671,028)
Research and development expenses	(50,000)	-	(41,133)	(22,351)	(91,133)	(22,351)
Income/(loss) from operations	$(251,201)	$(1,578)	$3,442,700	$602,156	$3,191,499	$600,578
Provision for impairment of note receivable	-	(642,012)	-	-	-	(642,012)

Total Assets

	Inside the United States		Outside the United States		Total
	2024	2023	2024	2023	2024	2023
	2025	2024	2025	2024	2025	2024
Total assets	$2,~~697~~181,~~502~~184	$32,~~248~~697,~~703~~502	$24,~~106~~627,~~777~~789	$12,~~241~~106,~~729~~777	$46,~~804~~808,~~279~~973	$4,~~490~~804,~~432~~279

The major component of total assets is "Cash" of $2,~~808~~769,~~910~~686 for the year ending February 2928, ~~2024~~2025 and $2,~~827~~808,~~457~~910 for the year ending February 2829, ~~2023~~ 2024. A significant portion of this is maintained ~~Inside~~inside the United States in USD of $2,~~478~~019,~~434~~628 for the year ending February 2928, ~~2024~~ 2025 and $2,~~582~~478,~~272~~434 for the year ending February 2829, ~~2023~~2024.

Cost of Goods

~~The~~For ~~Consolidated~~the ~~Medinotec~~fiscal year ended February 28, 2025, the Consolidated Medinotec Group of Companies recorded cost of goods sold (COGS) of $4,252,821, compared to $2,577,922 ~~constituting a gross profit percentage of 49%~~ for the year ~~ending~~ended February 29, 2024. ~~down~~This ~~from~~represents ~~$417,757~~a ~~for the~~ year-over-year ~~ending~~increase ~~February~~of 28$1,674,899, ~~2023~~in line with athe ~~gross~~significant ~~profit~~growth ~~percentage~~in ~~of 58%~~sales.

~~The~~Gross ~~most~~profit ~~material~~for fiscal 2025 was $4,860,786, representing ~~change~~a ingross ~~the~~margin ~~increase~~of in53%, ~~the~~compared ~~cost~~to a gross margin of ~~goods~~49% isin ~~that~~fiscal it2024. ~~functions~~The increase in agross ~~direct~~margin ~~correlation~~is primarily attributable to increased sales, together with manufacturing and ~~therefore~~sales ~~the~~processes ~~cost~~becoming ofmore ~~goods~~efficient ~~followed the~~as ~~same~~time ~~upward~~progresses, ~~trend~~as well as an improved sales mix favoring higher-margin products. The effect of exchange rate differences on imports and exports were also more stable during the year.

~~Due~~Key toFactors ~~the~~Affecting ~~fact that~~COGS ~~distribution~~and ~~revenues~~Gross are distributed at lower gross profit margins than internally designed products, there has been a substantial increase in the cost of goods, which has a direct correlation to the amount of distribution sales generated.Margin

No• Sales-Driven Increase ~~related~~in ~~party transactions~~COGS: ~~are~~The ~~recorded~~rise in ~~cost~~COGS ofis ~~sales~~consistent ~~for~~with ~~the~~higher ~~year~~product ~~ending~~sales, ~~February~~particularly 29under third-party distribution agreements, ~~2024~~which resulted in a proportional increase in associated costs.

• Operational Efficiencies: As the Group matures operationally, efficiencies in manufacturing and sales processes have improved. This ongoing operational refinement has contributed positively to gross margins through reduced unit costs and optimized workflows.

• Stabilization of Exchange Rates: The Group is exposed to foreign exchange fluctuations related to both imports and exports, which can materially affect margins due to timing differences between procurement and sales. During fiscal 2025, exchange rates remained relatively stable, with the South African Rand appreciating by approximately 4.6% against the U.S. Dollar. This stability helped mitigate currency-related margin volatility.

Related Party Transactions

No related party transactions were recorded in cost of sales for the fiscal year ended February 28, 2025.

Operating Expenses

~~The~~For ~~Consolidated~~the ~~Medinotec Group~~fiscal ofyear ~~Companies~~ended ~~operating~~February 28, 2025, operating expenses ~~were~~totaled $1,669,287, a decrease from $1,841,891 for the fiscal year ended February 29, 2024,. upThis ~~from~~decrease ~~$820~~was primarily due to reclassification adjustments,~~409~~ ~~for~~offsetting the ~~year~~increased ~~ended~~costs ~~February 28,~~related ~~2023~~to business expansion and product rollout.

~~Due~~One toof the ~~consistent~~major ~~growth of~~components that affect the ~~company~~operating expenses ~~and~~is the ~~popularity~~costs of compliance for the ~~product,~~business. ~~there~~Certain ~~was~~costs ~~also~~are anonce ~~increase~~off in ~~general~~nature ~~compliance~~and ~~costs~~others will be recurring. This will be determined after the markets were entered and all regulatory requirements met.

One of the major components that affects the operating expenses is the costs of compliance for the business. Certain costs are once off in nature and others will be recurring. This will be determined after the markets were entered and all regulatory requirements met.

The Consolidated Medinotec Group of Companies for the Years Ended

Feb 28,

2025

Feb 29,

2024

Compliance cost

526,603

186,338

	The Consolidated Medinotec Group of Companies for the Years Ended
	Medinotec Inc Group Consolidated Years Ended
	Feb 29, 2024 $		Feb 28, 2023 $
	Feb 28, 2025 $		Feb 29, 2024 $
Compliance cost		186,338		218,694
Depreciation and amortization expense		73,846		63,948
General and administrative expenses		1,391,114		1,671,028
Research and development expenses		91,133		22,351
Selling expenses		113,194		84,564
Total operating expenses		1,669,287		1,841,891

	Medinotec Inc Group Consolidated Years Ended
	Feb 29, 2024 $		Feb 28, 2023 $
Depreciation and amortization expense		63,948		53,553
General and administrative expenses		1,671,028		648,172
Research and development expenses		22,351		64,866
Selling expenses		84,564		53,818
Total operating expenses		1,841,891		820,409

Table of Contents

~~Limited R&D~~Key ~~activities~~Drivers ~~were~~of ~~conducted~~Operating inExpense 2024 due to the focus on rolling out the Trachealator in the United States which consumed all production and testing resources. R&D activities have resumed and are expected to increase in the next financial year.Trends

General and Administrative Expenses: General and administrative (G&A) expenses ~~showed~~decreased ~~significant~~significantly, ~~growth~~although ~~mainly~~this was partially due to ~~increases~~the inreclassification ~~independent~~of ~~contractor~~$327,950 ~~fees~~ in expenses to revenue in the first quarter of fiscal 2025, relating to activities outside the United States. ~~and~~Excluding ~~more~~this ~~staff~~reclassification, G&A ~~for~~expenses increased by $48,036, mainly driven by the ~~new~~addition ~~Cardiology~~of payroll costs related to new distribution ~~Revenues~~agreements and higher compliance costs as the Company expanded its market presence.

~~Other~~Research ~~costs~~and Development (R&D): The Company ~~included~~recorded ~~but~~R&D ~~not~~expenses asof ~~material:~~$91,133 ~~indemnity~~for ~~insurance~~the ~~and~~year ~~payments~~ended ~~made~~February to28, ~~service~~2025, ~~providers~~up asfrom ~~part~~$22,351 ofin ~~obtaining~~the prior year. However, R&D spending remains a relatively small portion of our ~~quotation~~overall operating expenses. This increase was primarily focused on ~~the~~perfecting ~~OTCQX~~existing manufacturing ~~markets~~processes to support the scaling of our Trachealator product and ~~costs~~other ~~relating~~potential toproduct integrations. Given the ~~quotation~~nature onof our operations, the ~~OTC~~majority ~~markets~~of our R&D efforts are directed toward refining production methods and ensuring that ~~will~~products ~~not~~can be ~~non-recurring~~efficiently manufactured within our current infrastructure. We only engage in ~~the~~R&D ~~future~~for ~~are~~products ~~estimated~~where ata ~~$30,000~~working prototype and proof of concept are already in ~~all~~hand, ~~other~~and we focus exclusively on products that align with our existing capabilities. This approach significantly reduces our R&D costs ~~will~~compared beto ~~repeated~~companies engaged in ~~the~~speculative ~~future~~or early-stage development.

Compliance Costs: A substantial portion of our operating expenses relates to compliance activities required to maintain international standards, including ISO certifications and CE/FDA product registrations. These compliance costs are essential for ensuring that our products meet regulatory requirements in the markets where we operate. Additionally, we incur costs for maintaining distribution licenses and product registrations with local health authorities in each country, such as the South African Health Products Regulatory Authority (SAHPRA) in South Africa. While some of these compliance costs are one-time in nature, many will be recurring as the Company enters new territories and ensures ongoing regulatory compliance. As we expand into more markets, particularly within the medical device industry, these compliance costs will likely increase.

Future Operating Expense Growth

Looking forward, we anticipate that future operating expenses will grow primarily in two areas:

	1.	Regulatory Compliance: As we expand into additional territories, we expect ongoing costs related to maintaining and obtaining product registrations, as well as adhering to the evolving regulatory standards in different jurisdictions. This includes the maintenance of certifications such as ISO, CE, and FDA approvals, as well as local health authority requirements in each market.
	2.	Sales and Marketing: As we increase our global footprint, particularly with the Trachealator and other products, we expect to allocate more resources toward sales and marketing efforts. These costs will be essential to drive product adoption, support new distribution agreements, and build brand awareness in new regions.

In addition, while R&D expenses will remain relatively modest, the Company's focus will remain on optimizing manufacturing processes, ensuring that production capabilities are aligned with increased product demand and the scalability of our operations.

Table of Contents

Non-operating income and expenses

Non-operating income and expenses for the fiscal year ended February 28, 2025, primarily consist of interest earned on free cash and the management of liquid assets. These amounts are immaterial relative to our core operating results and do not significantly affect the business’s overall financial performance. However, there were some key non-operating transactions that impacted both the balance sheet and income statement during the prior fiscal year.

Note Receivable

~~The~~On ~~Company~~November ~~decided~~30, to2023, ~~provide full~~the ~~impairment~~Company ~~against~~fully impaired ~~Innovative~~its ~~Outcomes~~ note receivable onfrom ~~November~~Innovative 30Outcomes, ~~2023~~ which ~~totaled~~amounted ~~S642~~to $642,012. This decision was made inprudently, ~~prudence due~~as to the ~~fact that the~~ receivable was isno ~~not~~longer ~~backed~~supported by any ongoing Trachealator revenue streams. ~~anymore~~While ~~and~~the receivable was impaired, it does not ~~change~~eliminate ~~that~~the future liability of Innovative Outcomes ~~will~~ ~~still~~to berepay ~~liable~~the ~~for~~amount. ~~payment~~No ofinterest ~~this~~income inis recognized on the ~~future~~note ~~Interest~~while ~~will~~it ~~accrue~~remains asimpaired. ~~normal~~The ~~until~~full recoverability ~~maturity~~of ~~date.~~the Noreceivable ~~impairment~~has ~~was~~not ~~recorded during~~yet ~~fiscal~~been ~~2023~~definitively tested.

Interest ~~expense~~Expense

Interest expense primarily relates ~~mostly~~ to the interest on the related party loan. ~~Another component~~ of ~~interest~~$141,748 ~~expense~~and ~~relates~~the to interest paid to our logistics service provider of $28,126. These expenses are recorded in line with the terms of the respective agreements and are consistent with prior periods.

Interest ~~income~~Income

Interest income ~~relates~~for tothe fiscal year ~~interest~~was earned from two main sources: the note receivable which was impaired and a tax refund receivable. No interest income is recognized on ~~notes~~the impaired note receivable, ~~for~~although interest continues to accrue contractually in accordance with the terms of the agreement, while interest on the tax refund receivable was earned during the prior fiscal year, ascontributing ~~well~~to asthe total interest income recognized. During the fiscal year ended February 28, 2025, no interest was recognized in respect of the note receivable; while an amount of $8,668 was earned on a tax refund receivable, ~~during~~representing a total of $8,668 interest income for the year.

Net ~~Loss~~Income

The Consolidated Medinotec Group of Companies reported a net profit of $2,159,473 for the year ending February 2928, ~~2024 showed total net loss of $404~~2025,~~688~~ compared to a net loss of $~~352~~404,~~735~~688 for the year ended February 2829, ~~2023~~2024.

~~The~~This ~~change~~increase in net income is ~~mainly~~primarily ~~attributable~~driven toby the higher sales ofgenerated from the new cardiology distribution business in South Africa, ~~and~~as well as the increased sales of the Trachealator, an internally designed and manufactured product, ~~sold~~ in the United States. The growth in both distribution revenues and the Trachealator's success in new markets were key factors in driving this positive shift in profitability.

The increased sales positioned the Company in a net profit, however, due to the impairment made on the note receivable, the Company showed an increase in net loss for the year ended February 29, 2024.

Liquidity and Capital Resources

As of February 29 28, ~~2024~~2025, the Company had total current assets of $46,~~379~~423,~~297~~186 and total assets ~~in the amount~~ of $46,~~804~~808,~~279~~973. Total current liabilities as of February 2928, ~~2024~~2025, were $~~827~~1,~~453~~505,047. The Company had working capital of $34,~~551~~918,~~844~~139 as atof February 2928, ~~2024~~2025. In comparison, as of February 28 29, ~~2023~~2024, the Company had total current assets of $34,~~369~~379,~~478~~297 and total assets ~~in the amount~~ of $4,~~490~~804,~~432~~279. Total current liabilities as of February 2829, ~~2023~~2024, ~~was~~were $71827,~~311~~453. Consolidated, we had working capital of $3,~~298~~551,~~167~~844 as of February 2829, ~~2023~~2024.

The research and development phase of the internally designed product lines ~~have~~has largely concluded. Therefore, we expect to see an increase in sales and marketing expenses, toprimarily for ~~build out of~~ the ~~territory~~rollout ofin the United States. ~~Combined~~and ~~with~~the expansion of the ~~Cardiology~~cardiology distribution contract business in South Africa.

5863

Table of Contents

AThe ~~private placement was completed in the wake of the successful research and development and subsequent regulatory approval in the prior financial year for $3,467,500 and therefore the~~ Company has ~~enough~~sufficient cash reserves and working capital to fund the roll -out in the market of the United States , including new research and development activities, ~~and~~as ~~Marketing~~well as marketing and ~~Sales~~sales functions.

We have cash available on hand and believe that this cash will be sufficient to fund operations and meet our obligations as they come due within one year from the date these Condensed Consolidated ~~financial~~Financial ~~statements~~Statements are issued. In the event that we do not achieve the revenue anticipated in ~~its~~ our current operating plan, management has the ability and commitment to reduce operating expenses as necessary. Our long-term success is dependent upon our ability to successfully raise additional capital, market our existing services, increase revenues, and, ultimately~~, to~~ achieve profitable operations.

~~Our~~As ~~audited~~of ~~Consolidated Financial~~February ~~Statements~~28, ~~have been prepared on a going-concern basis~~2025, ~~which~~we ~~contemplates~~have ~~the~~no ~~realization of assets and the satisfaction of~~material ~~liabilities~~capital inexpenditure ~~the normal course of business~~commitments. WeAll ~~received~~planned ~~FDA~~capital ~~510(k)~~projects ~~approval~~have ~~through~~been ~~the~~completed, ~~substantially~~and ~~equivalence~~there ~~process~~are ~~for~~no ~~Class II~~additional ~~medical~~contractual ~~devices~~ obligations for ~~our~~plant ~~main~~expansion ~~product~~or ~~being~~equipment ~~the Trachealator~~purchases. ~~During~~Our ~~the~~manufacturing ~~quarter~~facility ~~ending~~currently ~~November~~operates ~~30,~~below ~~2023,~~its ~~the~~maximum ~~Company also obtained cardiology distribution revenues in South Africa~~capacity, which ~~significantly~~allows ~~contributed~~ us to ~~the~~absorb ~~overall~~modest ~~profitability~~increases ofin ~~the~~production ~~Company.~~without ~~With~~significant ~~the research~~additional ~~and~~investment. ~~development~~This ~~phase~~available ofcapacity ~~most~~enables ~~products~~us ~~completed,~~to werespond ~~expect~~ efficiently to ~~see~~changes ~~an increase~~ in ~~sales~~customer ~~being~~demand ~~realized~~with ~~against~~minimal ~~the~~incremental ~~sales~~capital ~~expenditure incurred~~outlay.

We fund our operations and working capital needs primarily from cash generated by our ongoing business activities. Over the past two fiscal years, our operating cash flows have been positive and sufficient to meet our cash requirements, and we expect this trend to continue in the near future. We maintain strong operational controls that allow us to manage our working capital effectively, ensuring liquidity is available for daily operations and short-term commitments.

In the longer term, we may require additional capital to support strategic initiatives, including select product enhancements and potential expansion efforts. While we do not currently anticipate large-scale capital expenditures, the need for future funding to support ongoing business growth or research and development (R&D) efforts may arise. As a smaller reporting company with limited R&D activities, we continue to focus our research investments on incremental product refinements rather than early-stage or speculative development. These expenditures remain modest, as previously disclosed, and are primarily directed toward refining existing production processes. However, any significant future R&D initiatives or product development would likely require external funding, either through equity or debt financing.

Liquidity

In terms of liquidity, we currently have sufficient cash resources to meet our short-term obligations and continue day-to-day operations. We regularly evaluate cash needs based on forecasted operational demands and have identified no material trends or uncertainties that would cause a significant change in our liquidity position. Any potential changes in liquidity would likely arise from strategic decisions, such as expansion or increased investment in R&D, but we expect that cash flows from ongoing operations will continue to provide the necessary funds.

Capital Resources

As of the end of the latest fiscal period, our capital requirements are primarily focused on sustaining and optimizing existing operations, rather than large-scale growth or capital expansion. We have no material capital expenditures committed for the near term. However, as our business continues to evolve, we anticipate that we may seek external financing options, such as equity offerings or debt financing, should the need arise for larger investments in new products or significant capacity expansion.

While our current capital structure remains primarily equity-based, we are mindful of changing trends in the availability and cost of capital resources, including any shifts in equity or debt market conditions that may affect our financing strategy. We continue to explore opportunities to optimize our capital resources, balancing the need for flexibility with prudent financial management.

Table of Contents

Currency Fluctuations and Exchange Rate Risks

Given the Company’s exposure to various currencies, particularly the South African Rand and the U.S. Dollar, fluctuations in exchange rates could impact our working capital and cash reserves. We monitor foreign exchange risks and may take steps to hedge against significant adverse movements. While we have not implemented any hedging strategy at this time, we will continue to assess the impact of currency fluctuations on our financial position and operations.

Funding Strategy for Expansion

As part of our growth strategy, the Company continues to explore opportunities for alternative funding sources, including strategic partnerships, grants, and government incentives, to support expansion into new markets and product development initiatives. These options could provide additional capital if needed for larger-scale projects or unforeseen expenditures.

Future Plans and Financing Needs

Looking ahead, we anticipate that any major strategic initiatives, such as entering new markets or funding larger-scale projects, may require additional capital. We continue to explore all available financing options to ensure that we can access the necessary resources to fund future growth and innovation. This includes potential equity or debt offerings, as well as exploring potential partnerships or other arrangements that could provide non-dilutive funding.

Our audited Consolidated Financial Statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We received FDA 510(k) approval through the substantially equivalence process for Class II medical devices for our main product being the Trachealator. During the quarter ending November 30, 2023, the Company also obtained cardiology distribution revenues in South Africa, which significantly contributed to the overall profitability of the Company in the 2024 fiscal year. With the research and development phase of most products completed, we expect to see an increase in sales being realized against the sales expenditure incurred, as was the result in the current fiscal year.

Cash Flows

The following table summarizes our cash flows from continuing operations for the periods indicated:

	2024			2023
	2025			2024
Net cash provided by (used in):
Operating Activities		14877,~~242~~834			~~(490~~14,~~549~~242	)
Investing Activities		10(89,~~125~~013	)		~~(529~~10,~~723~~125	)
Financing Activities		(8894,~~092~~482	)		3(8,~~577,194~~092	)

Cash flows ~~from~~ provided by Operating Activities

~~The~~Net ~~increase in net~~ cash provided by operating activities from continuing operations increased significantly for the fiscal year ended February 2928, ~~2024~~2025. ~~over~~This ~~the~~improvement ~~prior year comparable period~~ was primarily due to a $512,~~953~~564,161 increase in ~~net loss~~profitability, aswith ~~well~~the asGroup ~~changes~~reporting innet ~~assets~~income ~~and~~of ~~liabilities~~$2,159,473, ~~that~~compared ~~had~~to a ~~current~~net ~~period~~loss ~~cash~~of ~~flow impact, such as~~ $~~500~~404,~~912~~688 ~~of changes~~ in ~~working capital. The change in non-cash charges compared to~~ the ~~change in the~~ prior year. ~~comparable~~This ~~period~~turnaround was ~~primarily~~ mainly driven by astrong ~~$642,012~~growth ~~impairment~~in ~~provision~~distribution ~~on notes receivable and a $34~~revenue,~~672~~ ~~increase~~particularly infrom ~~depreciation,~~the alaunch ~~$120,598~~of ~~variance~~the incardiology ~~deferred~~distribution ~~income~~business ~~taxes, a $139,712 change~~ in ~~provisions~~South Africa and aexpanded ~~bad~~U.S. ~~debt~~sales ~~write~~ of ~~amounting to $52,133 that was not present in~~ the ~~previous financial~~Trachealator ~~year~~product.

~~Cash~~Operational ~~flows~~cash flow also benefited from ~~Investing~~improved ~~Activities~~working capital management, including better receivables collection and inventory optimization. Operating expenses were carefully controlled, allowing the Group to support growth initiatives—especially in sales and marketing—while maintaining positive cash generation from operations. Management also notes customer concentration risk, with most customers situated within the South African segment, which should be considered in assessing the quality and stability of these cash flows.

~~The~~Management ~~increase~~believes inthat ~~net~~these improvements, ~~cash~~alongside ~~provided~~efficiencies byand ~~investing~~sustained ~~activities~~revenue ~~was~~momentum, ~~due~~position tothe aGroup ~~decrease~~for incontinued ~~the~~positive ~~issuance~~cash offlow ~~long~~generation. Non-~~term~~cash ~~debt~~adjustments, including ~~relating~~depreciation toand ~~the~~share-based ~~Innovative~~compensation, ~~Outcomes~~are ~~note receivable~~minimal in ~~2023~~our business.

~~Cash flow from Financing Activities~~65

Cash flow used in financing activities in 2024 consisted of the repayment of the related party loan. Cash flow provided by financing activities in 2023 consisted of a $3,577,194 private placement.

Off Balance Sheet Arrangements

As of February 29, 2024, there were no off-balance sheet arrangements.

Table of Contents

~~Critical~~Cash ~~Accounting~~flows ~~Policies~~used in Investing Activities

~~While~~Net ~~our~~cash ~~significant~~used ~~accounting~~in investing activities ~~policies~~increased ~~are~~for ~~described~~the infiscal year ended February 28, 2025. This change was primarily driven by the ~~notes~~absence toof ~~our~~inflows ~~consolidated~~from ~~financial~~a ~~statements~~note receivable, which wehad ~~believe~~generated ~~that~~positive cash flows through repayments in the ~~accounting~~prior ~~policies~~year. ~~below~~In ~~are~~contrast, ~~most~~during ~~critical~~the current year, the outstanding balance toof ~~understanding~~the ~~our~~note ~~financial~~receivable ~~condition~~increased and ~~historical~~was ~~and~~subsequently ~~future~~impaired, ~~results~~resulting ofin ~~operations~~no corresponding cash inflow.

~~Revenue~~Additionally, the Group increased its investment in property, plant, and equipment (PP&E), reflecting continued expansion and operational scaling. These capital expenditures contributed to higher cash outflows from investing activities compared to the prior year.

~~The Company~~Cash ~~generates~~flows ~~revenues~~used ~~through~~in ~~two~~Financing ~~distinct revenue sources:~~Activities

•Cash ~~From~~flows ~~the~~used ~~sale~~in offinancing ~~high-quality~~activities for ~~medical~~the ~~devices~~fiscal ~~which~~years ~~are~~ended ~~self-manufactured~~February ~~through~~28, ~~in-depth~~2025, ~~research~~ and ~~development;~~February ~~and~~29, •2024, ~~Through~~primarily related to the ~~distribution~~repayment of ~~finished~~a ~~products~~related onparty ~~behalf~~loan. ofIn ~~other~~fiscal 2025, ~~principals~~the ~~around~~Company repaid $895,279, an increase compared to $9,680 in the ~~world~~prior ~~into~~year. ~~pre-agreed~~This ~~territories~~increased ~~which~~repayment ~~are~~reflects ~~usually~~the ~~exclusive~~Company’s continued ~~territories~~efforts ~~granted~~to byreduce ~~such~~financial ~~principal~~liabilities and strengthen its balance sheet.

~~The Company~~Looking ~~applies~~ahead, the ~~following~~Company ~~five~~may ~~steps~~evaluate inadditional ~~order~~financing options—including topotential ~~determine~~debt ~~the~~or ~~appropriate~~equity ~~amount~~issuances—to ofsupport ~~revenue~~its tostrategic begrowth ~~recognized~~objectives. asThis itmay ~~fulfills~~include ~~its~~funding ~~obligations~~expansion ~~under~~into ~~each~~new ofmarkets, ~~its~~increasing ~~arrangements:~~production capacity, and scaling marketing and distribution efforts to drive long-term value creation.

•Off ~~identify~~Balance ~~the~~Sheet contract with a customer, • identify the performance obligations in the contract, • determine the transaction price, • allocate the transaction price to performance obligations in the contract, and • recognize revenue as the performance obligation is satisfied.Arrangements

~~Revenue~~As ~~from~~of ~~the~~February ~~sale~~28, of2025, ~~self~~there were no off-~~manufactured~~balance ~~products~~sheet arrangements.

~~These~~Critical ~~products~~Accounting ~~are~~Estimates ~~developed in-house.~~

~~The~~While ~~Company’s~~our ~~clients~~significant accounting policies are described ~~billed~~in ~~based~~the onnotes ato ~~pricelist~~our ~~that~~consolidated isfinancial ~~agreed~~statements, onwe inbelieve ~~each~~that ~~customer’s~~the ~~contract.~~accounting ~~Orders~~estimates below are ~~shipped~~most oncritical ato ~~per~~understanding our ~~order~~financial ~~basis~~condition ~~from~~and ~~the~~historical ~~Company’s warehouse~~and ~~with~~future ~~Free-On-Board~~results ~~Inco~~of ~~terms~~operations.

~~Revenues~~Allowance ~~relating~~for tocredit ~~the~~losses ~~self-manufactured products~~on ~~are~~loans recognized when control of the promised goods or services is transferred to a customer in an amount that reflects the consideration that the Company expects to receive in exchange for those products.receivable

Revenue from the distribution of products

The distribution products are sold via a network, which consists of a mixture of sub-distributors and in some instances a direct sales force. The Company’s clients are billed based on a pricelist that are agreed upon in each customer contract, orders are shipped on a per order basis from the Company’s warehouse with Free-on-Board Inco terms. The Company’s sub-distributors order from the Company on the same basis as its customers and have no preferential return rights on their inventory orders, therefore the client assumes the risk of the sale at point of invoice.

Revenues relating to the distribution of products are recognized when control of the promised goods or services are transferred to a customer in an amount that reflects the consideration that the Company expects to receive in exchange for those products.

Table of Contents

Goods delivered to a consignee pursuant to a consignment arrangement are not considered sales, and do not qualify for revenue recognition. Once it is determined that substantial risk of loss, rewards of ownership, as well as control of the asset have transferred to the consignee, revenue recognition would then be appropriate, assuming all other criteria for revenue recognition have been satisfied.

For both revenue streams

The Company has two operating segments, inside the United States and outside the United States. These sales are split by these territories and further segregated into the specific revenue streams sold into these territories.

The Company has no contract assets or liabilities representing accrued revenues that have not yet been billed to the customers due to certain contractual terms, because of the fact that orders are placed, invoiced, and shipped on a per order basis as and when the clients require additional inventory. All revenue is recognized at a specific point and time.

Under ASC Topic 606, the Company estimates the transaction price, including variable consideration, at the commencement of the contract and recognizes revenue at point of sale when risks and rewards are transferred to the customer. There are no contract revenue agreements that would need to be recognized over time and the point of risks and rewards being transferred is very clear.

Payment Terms

Our payment terms vary per segments; export sales made from within South Africa are subject to prepayment, where accounts are granted. They generally have payment terms of 30 days from statement and sales made inside the United States are 45 to 60 days. Terms can be extended by the Company when it deems the business case and credit worthiness of the customer is strong enough. The time between a customer’s payment and the receipt of funds is not significant. The Company’s contracts with customers do not result in significant obligations associated with returns, refunds, or warranties. Payment terms are generally fixed and do not include variable revenues.

Allowance for note receivable impairment

The Company records allowances for loan impairment when it is determined that the Company will be unable to collect all amounts due according to the terms of the underlying agreement. Interest income on impaired loans is recognized only when interest payments are received.

The Trachealator product obtained FDA approval in November 2021, which allowed the Company to sell this product into the United States of America. Since the Company had no prior sales channels or infrastructure in the United States, management found it prudent to plan a roll out of the product with a distributor that had an established network and infrastructure. For this business, the Company partnered with a company called Innovative Outcomes and entered into a revolving credit facility to a maximum of $750,000. Innovative Outcomes would use this to grow both their own distribution network and infrastructure and also allow for the Company to utilize this network and infrastructure. However, during the quarter ending November 30, 2023, there was a material change in strategic focus where the Company would require its products to be marketed to niche surgical units, Innovative Outcomes would be servicing the wound care clinic market only which meant that the future growth of the combined network and infrastructure would not be a strategic match between the two entities. It was therefore decided to separate the network and infrastructure developed and for each company to pursue its strategic focus. The note receivable will continue on the same terms and became payable in the 2024 fiscal year, but the Company decided to provide full impairment against this receivable on November 30, 2023. This decision was made in prudence due to the fact that the receivable is no longer backed by any Trachealator revenue streams. This does not change that Innovative Outcomes will still be liable for payment of this in the future. While impaired, no interest income will be recognized on the receivable. Should payments be received this provision will be reversed with the same amount of cashflow received.

Management believes that prior allowances for this note receivable were determined with appropriate assumptions and were as accurate as possible given the information available at the time. We continuously compare actual repayments and write-offs against our allowances and revise our estimate when subsequent events or newly obtained information indicate that adjustments are necessary.

There have been no material changes during the current year to the assumptions or methodologies used in estimating expected credit losses on the note receivable. Our approach to incorporating historical loss data, current borrower assessments and forward-looking information remains consistent with prior periods.

Table of Contents

Inventories

i. Valuation, costing and obsolescence

Inventories are stated at the lower of cost (weighted average) or net realizable value and consist of raw materials, work-in process and finished goods and include purchased materials, machine time, direct labor and manufacturing overhead.

Management evaluates the need to record adjustments to write down inventory to the lower of cost or net realizable value on an annual basis. The Company’s policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage.

The provision for stock obsolescence is assessed at the end of every reporting period. Due to the long shelf life of our products as well as the ability ~~the~~to ~~resterilize~~re-sterilize products to reset the shelf life, this provision, in ~~managements~~management’s opinion, will never increase significantly.

61Management believes that our historical inventory valuations, including weighted-average cost measurements and obsolescence provisions for raw materials, work-in-process and finished goods,were determined with appropriate assumptions and were as accurate as possible given the information available.

~~Table~~There ofhave ~~Contents~~ been no material changes during the current year to the key assumptions or methodologies applied to inventory valuation or obsolescence provisioning. Our approach to calculating weighted-average cost, assessing net realizable value for each inventory category and performing annual age-based obsolescence reviews remains consistent with prior periods.

Management does not anticipate any material changes to the methodologies or key assumptions used to determine inventory valuation or obsolescence provisions in future periods.

Deferred tax assets and liabilities

We identify temporary differences between the financial statement basis and tax basis of our assets and liabilities, as well as available loss and credit carryforwards. We apply the enacted statutory tax rates expected to be in effect when such differences reverse, pursuant to U.S. federal and state tax law and, where applicable, South African Income Tax Act provisions. We then assess positive and negative evidence—such as future taxable income projections, historical earnings patterns, tax-planning strategies and the expiration dates of carryforwards—to conclude whether it is “more likely than not” that DTAs will be realized. A valuation allowance is recorded against DTAs when realization is not deemed more likely than not.

Management believes that prior deferred tax asset estimates were prepared with appropriate assumptions and were as accurate as possible given the information available at the time. We continue to perform retrospective evaluations of those estimates against actual outcomes to confirm the reasonability of our methodologies, and we adjust valuation allowances when subsequent events or newly obtained information indicate that revisions are warranted.

There have been no material changes to the assumptions or estimates used in determining our deferred tax assets and liabilities during the current year. Our methodologies, including income forecasts, tax-law interpretations and valuation allowance assessments, remain consistent with those applied in prior periods.

Recently Issued Accounting Pronouncements

See Note 2 to our Consolidated Financial Statements included in Part IIIV, Item 15 of this Annual Report on Form 10-K for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one, of their potential impact on our financial condition and results of operations.

Table of Contents

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this Item because we are a smaller reporting company.

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements required by this Item 8 are included in this Annual Report following Item 15 hereof. As a smaller reporting company, we are not required to provide supplementary financial information.

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

OnIn ~~June 20~~July, ~~2023~~2024, we ~~dismissed~~replaced BDO South Africa Inc. with Mercurius & Associates LLP as our current independent registered public accounting firm.. ~~and,~~The onengagement ~~June~~of ~~20,~~the ~~2023,~~new weaccountant was ~~engaged~~approved ~~BDO~~by ~~South~~our ~~Africa~~Audit ~~Inc.~~Committee asof ~~our~~the ~~independent~~Board ~~registered public~~of ~~accounting firm~~Directors. ~~The~~For ~~engagement~~more ofinformation on the ~~new~~change ~~accountant~~in ~~was~~auditor, ~~approved~~see by our ~~Audit~~Current ~~Committee~~Report on ofForm 8-K filed with the ~~Board~~SEC ofon ~~Directors~~June 20, 2023.

For the years ended February 28, 2023 and 2022, and through the interim period ended June 20, 2023, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K of the rules and regulations of the U.S. Securities Exchange Commission (the “SEC”)) with the former accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the former accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.

For the years ended February 28, 2023 and 2022, and through the interim period ended June 20, 2023, there were the following “reportable events” (as such term is defined in Item 304 of Regulation S-K of the rules and regulations of the SEC). Our management determined that our internal controls over financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:

• The Company does not have written documentation of its internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act as of the period ending February 28, 2023. Management evaluated the impact of the Company’s failure to have written documentation of our internal controls and procedures on its assessment of the Company’s disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

• The Company does not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to the Company’s size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of its failure to have segregation of duties on the Company’s assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

• Effective controls over the control environment were not maintained. Specifically, a formally adopted written code of business conduct and ethics that governs the Company’s employees, officers, and directors was not in place. Additionally, management has not developed and effectively communicated to employees its accounting policies and procedures. This has resulted in inconsistent practices. Further, the Company’s Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

Other than as disclosed above, there were no reportable events for the years ended February 29, 2024 and February 28, 2023. Our Board of Directors discussed the subject matter of each reportable event with the former accountant. We authorized the former accountant to respond fully and without limitation to all requests of the new accountant concerning all matters related to the audited period by the former accountant, including with respect to the subject matter of each reportable event.

Table of Contents

ITEM 9A.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Based on the evaluation performed as of February 2928, ~~2024~~2025, as a result of the material weaknesses in internal control over financial reporting that are described below in Management’s Report on Internal Control Over Financial Reporting, our Chief Executive Officer and Chief Financial Officer determined that our disclosure controls and procedures were not effective as of such date.

Management’s Report on Internal Controls Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). A company’s internal control over financial reporting is a process designed by, or under the supervision of, its Chief Executive Officer and Chief Financial Officer, and effected by such company’s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

	•	pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
	•	provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
	•	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.68

As required by the SEC Rules 13a-15(b) and 15d-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of February 29, 2024, at the reasonable assurance level due to the material weaknesses described below.

Table of Contents

1.In Wedesigning doand ~~not~~evaluating ~~have~~the ~~written~~disclosure ~~documentation~~controls and ofprocedures, ~~our~~management ~~internal~~recognized ~~control~~that ~~policies~~any controls and procedures., ~~Written~~no ~~documentation~~matter how well designed and operated, can provide only reasonable and not absolute assurance of ~~key~~achieving ~~internal~~the ~~controls~~desired ~~over~~control ~~financial~~objectives. ~~reporting~~In isreaching a ~~requirement~~reasonable level of ~~Section~~assurance, ~~404~~management ofnecessarily was required to apply its judgment in evaluating the ~~Sarbanes~~cost-~~Oxley~~benefit ~~Act~~relationship ~~which~~of possible controls and procedures. In addition, the design of any system of controls is ~~applicable~~also tobased usin ~~for~~part upon certain assumptions about the ~~year~~likelihood ~~ended~~of ~~February~~future 29events, ~~2024~~and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. ~~Management~~Over ~~evaluated~~time, ~~the~~a ~~impact~~control may become inadequate because of ~~our~~changes ~~failure~~in toconditions ~~have~~or ~~written~~the ~~documentation~~degree of ~~our~~compliance ~~internal~~with ~~controls~~policies ~~and~~or procedures onmay ~~our~~deteriorate. ~~assessment~~Because of ~~our~~the ~~disclosure~~inherent ~~controls~~limitations in ~~and~~a ~~procedures~~cost-effective ~~and~~control ~~has~~system, ~~concluded~~misstatements ~~that~~due ~~the~~to ~~control~~error ~~deficiency~~or ~~represented~~fraud amay ~~material~~occur ~~weakness~~and not be detected.

As required by the SEC Rules 13a-15(b) and 15d-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of February 28, 2025, at the reasonable assurance level due to the material weaknesses described below.

We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the year ended February 28, 2025. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency represented a material weakness.

	2.	We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency represented a material weakness.

	3.	Effective controls over the control environment were not maintained. Specifically, a formally adopted written code of business conduct and ethics that governs our employees, officers, and directors was not in place. Additionally, management has not developed and effectively communicated to employees its accounting policies and procedures. This has resulted in inconsistent practices and represented a material weakness.

ToManagement ~~address~~is ~~these~~actively ~~material weaknesses, management~~ engaged ~~financial~~ ~~consultants,~~in ~~performed~~addressing ~~additional analyses and other procedures to ensure that~~ the ~~financial statements included herein fairly~~material ~~present,~~weaknesses in ~~all~~internal ~~material~~control ~~respects,~~over ~~our~~ financial ~~position,~~reporting ~~results~~identified as of ~~operations~~February ~~and~~28, ~~cash~~2025. ~~flows~~These ~~for~~weaknesses ~~the~~relate ~~periods~~to ~~presented.~~the Weabsence ~~have not~~of ~~remedied~~formal ~~the~~documentation ~~material weaknesses as~~ of ~~February~~internal 29control procedures, ~~2024.~~limited ~~The~~segregation ~~Company~~of ~~plans~~duties towithin ~~take~~accounting ~~remedial~~functions, ~~action~~and toan ~~address these weaknesses during~~underdeveloped ~~the~~control ~~fiscal year ending 2025~~environment.

While the Company’s size and structure present certain limitations, we recognize the importance of strengthening our internal controls and have initiated steps to improve our control framework. During the fiscal year ending February 28, 2026, we plan to:

	•	Begin formal documentation of key internal control processes and procedures, consistent with the COSO 2013 framework;
	•	Enhance segregation of duties within our finance function to the extent feasible, and implement additional review controls where full segregation is not practical;
	•	Adopt a formal Code of Business Conduct and Ethics and communicate it throughout the organization;
	•	Improve communication and documentation of our accounting policies and procedures.

We have also engaged external consultants to assist in evaluating and enhancing our internal control environment and to provide additional support during the remediation process.

These efforts are ongoing, and while the material weaknesses had not been fully remediated as of February 28, 2025, we are committed to making meaningful progress in the coming year. We will continue to assess the effectiveness of these actions and report on our remediation progress in future filings.

Table of Contents

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during our fourth quarter ended February 2928, ~~2024~~2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except for the ~~implementation~~planned ofremedial action toward the ~~controls~~control ~~identified~~deficiencies detailed above.

Limitations on Effectiveness of Controls and Procedures

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but there can be no assurance that such improvements will be sufficient to provide us with effective internal control over financial reporting.

ITEM 9B.

OTHER INFORMATION

~~None~~On February 19, 2025, we held our 2024 Annual Meeting of the shareholders, at which the shareholders voted on the matters disclosed in our Proxy Statement. The final voting results for the matters submitted to a vote of the shareholders were as follows:

Proposal No. 1 - Election of Directors

Our shareholders elected the persons listed below for a one-year term expiring at our 2025 Annual Meeting or until their respective successors are duly elected and qualified:

	FOR	AGAINST	ABSTAIN
Gregory Vizirgianakis	9,945,214	0	0
Pieter van Niekerk	9,945,214	0	0
Stavros G. Vizirgianakis	9,945,214	0	0
Joseph P. Dwyer	9,945,214	0	0
Athanasios Spirakis	9,945,214	0	0

Proposal No. 2 – Ratification of Independent Registered Public Accounting Firm

Our shareholders ratified the appointment of Mercurius & Associates LLP as our independent registered public accounting firm for fiscal 2025.

	FOR		AGAINST		ABSTAIN
	9,937,799		0		7,415

ITEM 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

None.

6470

Table of Contents

PART III

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

The following information sets forth the names, ages, and positions of our current directors and executive officers.

Name	Age		Position(s) and Office(s) Held
Gregory Vizirgianakis		4546	President, Secretary, CEO and Director
Pieter van Niekerk		3940	CFO, Treasurer and Director
Stavros G. Vizirgianakis		5253	Director
Joseph P. Dwyer		6869	Director
Athanasios Spirakis		6263	Director ~~(1)~~

(1) Appointed as Director on October 11, 2023.

Set forth below is a brief description of the background and business experience of our current executive officers and directors.

Gregory Vizirgianakis

The Company is led by Dr Vizirgianakis as the Chief Executive Officer, a qualified medical doctor, with a specialty interest in the field of neuroscience. He has many years of experience in the international and South African health markets. Dr Vizirgianakis is the founding ultimate shareholder of DISA Medinotec Proprietary Limited and has been involved in several successful entrepreneurial ventures. For the last five years, Dr. Vizirgianakis has been employed as CEO of Minoan Medical ndand DISA Medinotec Proprietary Limited.

Aside from that provided above, Dr. Vizirgianakis does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.

The Board believes that Dr. Vizirgianakis has the experience, qualifications, attributes and skills necessary to serve on the Board because of the fact that he held similar positions for more than 10 years and his designation as a medical doctor, he is also a founding shareholder in the company and has a long-standing track record in the industry.

Pieter van Niekerk

Mr. Pieter van Niekerk is a qualified Chartered Accountant and the Company's CFO and has been involved in multiple listings on various exchanges in the United States of America and South Africa. He has 10 years of executive management experience ~~and has been nominated as one of the “Top 35 under 35 Chartered Accountants” in South Africa for two consecutive years~~. For the last five years, Mr. van Niekerk has been employed as CFO of Minoan Medical and DISA Medinotec Proprietary Limited.

Aside from that provided above, Mr. van Niekerk does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.

The Board believes that Mr. van Niekerk has the experience, qualifications, attributes and skills necessary to serve on the Board because of the fact that he held similar positions for more than 10 years and his designation as a chartered accountant, he is also a founding shareholder in the company and has a long-standing track record in the industry.

6571

Table of Contents

Stavros G. Vizirgianakis

Mr. Vizirgianakis ~~became~~is an investor and strategic advisor to companies in the ~~Interim~~medical ~~Chief~~device ~~Executive~~field. ~~Officer~~He currently serves on the Board of ~~Misonix~~Directors inat ~~September~~Tally ~~2016~~Surgical, ~~and~~Inc., ~~the~~Theragenics Corporation, ~~full-time~~Xtant ~~President~~Medical ~~and~~Holdings, ~~Chief~~Inc. ~~Executive~~(NYSE ~~Officer~~American: inXTNT) ~~December~~and ~~2016~~Medinotec, Inc. (OTCQX:MDNC). Mr. Vizirgianakis ~~has~~previously aserved on ~~distinguished~~the ~~career~~Board inof ~~the~~Directors ~~medical~~at ~~devices~~Bioventus ~~field~~Inc. ~~having~~(Nasdaq: ~~worked~~BVS) ~~for~~and ~~United~~Tenaxis ~~States~~Medical. ~~Surgical~~Mr. ~~Corporation~~Vizirgianakis asis ~~director~~the former Chief Executive Officer of ~~sales~~medical ~~for~~device ~~sub-Saharan~~company, ~~Africa~~Misonix, ~~and~~Inc., ~~later~~which ~~Tyco~~he ~~Healthcare~~led infrom 2016 through the ~~capacity~~company’s ofacquisition ~~General~~by ~~Manager~~Bioventus ~~South~~Inc. ~~Africa~~in 2021. InHe previously ~~2006,~~served as Managing Director of the Medical Devices business at Ascendis Health Limited (JSE: ASC) from 2014 to 2016. Mr. Vizirgianakis co-founded Surgical Innovations, ~~which has become~~ one of the largest privately -owned medical device distributors in the African region, ~~and~~ ~~now~~which later became part of ~~the Johannesburg Stock Exchange listed entity~~ Ascendis Health. ~~In that capacity, Mr~~Limited. ~~Vizirgianakis~~His ~~acted~~career asin athe ~~distributor of~~medical ~~the~~device ~~Company’s~~industry ~~products.~~also ~~Mr.~~includes ~~Vizirgianakis~~experience ~~was~~serving ~~Managing~~as Director of ~~Ascendis~~Sales ~~Medical~~for sub-Saharan ~~from~~Africa ~~January~~at ~~2014~~United ~~through~~States ~~July~~Surgical ~~2016.~~Corporation ~~Mr. Vizirgianakis~~and ~~also~~as ~~served~~General onManager ~~the~~of ~~board~~South ofAfrica ~~Tenaxis~~at ~~Medical~~Tyco ~~and~~Healthcare. isMr. Vizirgianakis holds a ~~strategic~~degree ~~investor~~ in ~~and~~Commerce ~~advisor~~from tothe ~~numerous~~University ~~medical~~of ~~device~~South ~~startups and established companies in this field~~Africa.

Aside from that provided above, Mr. Vizirgianakis does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.

Mr. Vizirgianakis has a degree in commerce from the University of South Africa. The Board believes Mr. Vizirgianakis’ industry knowledge, sales and marketing experience and his international business relationships qualify him to serve as a director.

Joseph P. Dwyer

Mr. Dwyer has been serving as the Chief Financial Officer of Archive360, LLC since June, 2022. He served as Misonix’s Chief Financial Officer from August 2, 2017 through November 2021, and then as a financial consultant to Misonix’s acquirer, Bioventus, through April, 2022. From June 2015 to July 2017, Mr. Dwyer provided financial consulting and advisory services to various companies, through the firms Dwyer Holdings and TechCXO. Prior thereto, from November 2012 until June 2015, he was Chief Financial Officer of Virtual Piggy, Inc., a publicly traded technology company. Prior to joining Virtual Piggy, Mr. Dwyer served as chief financial officer of Open Link Financial, Inc., a privately held company, which provides software solutions for trading and risk management in the energy, commodity, and capital markets.

During 2011 and 2012, Mr. Dwyer was a member of the board of directors and chairman of the audit committee and served as interim chief administrative officer of Energy Solutions International, Inc., a privately held company providing pipeline management software to energy companies and pipeline operators. From 2010 through 2011, Mr. Dwyer served as chief administrative officer of Capstone Advisory Group, LLC, a privately held financial advisory firm providing corporate restructuring, litigation support, forensic accounting, expert testimony and valuation services. Mr. Dwyer served as a consultant to Verint Systems, Inc., a software company listed on the NASDAQ Global Market, from 2009 through 2010, assisting with SEC reporting and compliance.

From 2005 through 2009, Mr. Dwyer served as chief financial officer and executive vice president of AXS-One Inc., a publicly traded software company. During 2004, Mr. Dwyer served as chief financial officer of Synergen, Inc., a privately held software company providing energy technology to utilities. Prior to 2004, Mr. Dwyer also served as chief financial officer and executive vice president of Caminus Corporation, an enterprise application software company that was formerly listed on the NASDAQ National Market, chief financial officer of ACTV, Inc., a digital media company that was formerly listed on the NASDAQ National Market, and chief financial officer of Winstar Global Products, Inc., a manufacturer and distributor of hair care, bath and beauty products until its acquisition by Winstar Communications, Inc. in 1995 when Mr. Dwyer went on to serve as senior vice president, finance of Winstar Communications.

Aside from that provided above, Mr. Dwyer does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.

Mr. Dwyer received his BBA in Accounting from the University of Notre Dame in 1978 and is licensed as a Certified Public Accountant in the State of New York.

6672

Table of Contents

Athanasios Spirakis

Having received two Masters of Science degrees in Electromechanical & Computer Engineering as well as in Biomedical Engineering in 1984 and 1988 respectively, Mr. Spirakis embarked in an academic career in 1989 becoming a Senior Lecturer and the Head of the Biomechanics Group at the Department of Biomedical Engineering of the University of Cape Town.

During Mr Spirakis’ tenure, besides his academic outputs in the form of publications, conference presentations, post-graduate students’ supervision and lecturing, Mr. Spirakis undertook consulting research projects in total Knee and Hip Arthroplasty for Johnson & Johnson (DePuy) and designed ~~orthopaedic~~orthopedic implants which were subsequently manufactured by South African & international companies such as Zimmer (now Zimmer-Biomet).

In 1995, Mr. Spirakis left the academic world and assumed the responsibilities of Research & Development as well as Quality Assurance & Regulatory Affairs Directorships within Macmed Orthopaedics, a manufacturer of total joint prostheses and spinal implants till the end of 1999.

In 2000 Mr. Spirakis became the Business Development Director of two sister South African marketing and selling medical devices organizations, namely SA Biomedical and Orthomedics.

The former dealing in medical devices for a large variety of surgical specialties (Cardiac / Vascular / General Surgery / Arthroscopy / Urology / ENT) and the ~~later~~latter in total joint replacements. Orthomedics was acquired by J&J in 2008 and Mr. Spirakis continued his involvement as a business development director till 2011 when he became one of the founders and director of Advanced Orthopaedics.

In 2016 Mr. Spirakis accepted the Chief Executive Officer position within Elite Surgical, a South African medical devices manufacturer and held it till 2021 when he decided to join Minoan Medical / Disa Life Sciences as their Chief Operating Officer.

Aside from that provided above, Mr. Spirakis does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.

Term of Office

Our directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until they are removed from office in accordance with our bylaws. ~~Our~~ Our officers are appointed by our board of directors and hold office until removed by the board.

Significant Employees

We have no significant employees other than our officer and director.

Family Relationships

Aside from Gregory Vizirgianakis and Stavros G. Vizirgianakis, who are brothers, there are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

6773

Table of Contents

Involvement in Certain Legal Proceedings.

During the past 10 years, none of our current directors, nominees for directors or current executive officers has been involved in any legal proceeding identified in Item 401(f) of Regulation S-K, including:

1. Any petition under the Federal bankruptcy laws or any state insolvency law filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he or she was a general partner at or within two years before the time of such filing, or any corporation or business association of which he or she was an executive officer at or within two years before the time of such filing;

2. Any conviction in a criminal proceeding or being named a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

3. Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him or her from, or otherwise limiting, the following activities:

i. Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

ii. Engaging in any type of business practice; or

iii. Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

4. Being subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any type of business regulated by the Commodity Futures Trading Commission, securities, investment, insurance or banking activities, or to be associated with persons engaged in any such activity;

5. Being found by a court of competent jurisdiction in a civil action or by the SEC to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

6. Being found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

7. Being subject to, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

i. Any Federal or State securities or commodities law or regulation; or

ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

8. Being subject to, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

6874

Table of Contents

Audit Committee

On May 5, 2023, in connection with a requirement for quotation on the OTCQX markets, our Board of Directors authorized the creation of an Audit Committee. Gregory Vizirgianakis, Athanasios Spirakis and Joseph P. Dwyer currently serve on the Audit Committee.

Athanasios Spirakis and Joseph P. Dwyer have been determined by the Board to be independent directors within the meaning of NASDAQ Rule 5605. Mr. Dwyer was identified and designated by the Board as an “audit committee financial expert,” as defined by the SEC in Item 407 of Regulation S-K.

The Audit Committee approves the selection of our independent accountants and meets and interacts with the independent accountants to discuss issues related to financial reporting. In addition, the Audit Committee reviews the scope and results of the audit with the independent accountants, reviews with management and the independent accountants our annual operating results, considers the adequacy of our internal accounting procedures, including our internal control over financial reporting, and considers other auditing and accounting matters including fees to be paid to the independent auditor and the performance of the independent auditor.

For the fiscal year ending February 2928, ~~2024~~2025, the Audit Committee:

	•	Reviewed and discussed the audited financial statements with management, and
	•	Reviewed and discussed the written disclosures and the letter from our independent auditors on the matters relating to the auditor’s independence.

Based upon the Audit Committee’s review and discussion of the matters above, the board of directors authorized inclusion of the audited financial statements for the year ended February 2928, ~~2024~~2025 to be included in this Annual Report on Form 10-K and filed with the Securities and Exchange Commission.

At the ~~2023~~2024 annual meeting of the shareholders, our shareholders did not ratify the appointment of BDO South Africa Inc. as our independent registered public accounting firm for fiscal ~~2024~~ 2025. AsMercurius aand ~~result~~Associates ofLLP ~~the vote, our audit committee plans to conduct an inquiry into the reasons why ratification~~ was ~~not~~subsequently ~~approved~~appointed byas ~~the~~our ~~shareholders~~independent ~~and~~registered ~~report~~public ~~its~~accounting ~~findings to the board of directors for consideration~~firm.

ITEM 11.

EXECUTIVE COMPENSATION.

The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the years ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024.

SUMMARY COMPENSATION TABLE
Name and principal position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)~~(2)~~	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Gregory Vizirgianakis	~~2024~~2025	—	—	—	—	—	—	6,597	—
CEO	~~2023~~2024	—	—	—	—	—	—	—6,597	—
Peter van Niekerk	~~2024~~2025	—	—	—	—	—	—	3,958	—
CFO	~~2023~~2024	—	—	—	—	—	—	—3,958	—

Narrative Disclosure to the Summary Compensation Table

Although we do not currently compensate our officers with any regularity, we reserve the right to provide compensation at some time in the future. Our decision to compensate officers depends on the availability of our cash resources with respect to the need for cash to further business purposes.

6975

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

The table below summarizes all unexercised options, stock that has not vested, and equity incentive plan awards for each named executive officers as of February 2928, ~~2024~~2025.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

OPTION AWARDS

STOCK AWARDS

Name

Number of
Securities
Underlying
Unexercised
Options

Exercisable

Number of
Securities
Underlying
Unexercised
Options

Unexercisable

Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options

Option

Exercise

Price

($)

Option
Expiration
Date

Number
of
Shares
or Units
of
Stock That
Have
Not
Vested

Market
Value
of
Shares
or
Units
of
Stock
That
Have
Not
Vested
($)

Equity

Incentive

Plan

Awards:

Number

Unearned

Shares,

Units or

Other

Rights

That Have

Not

Vested

Equity

Incentive

Plan

Awards:

Market or

Payout

Value of

Unearned

Shares,

Units or

Other

Rights

That

Have Not

Vested

Gregory Vizirgianakis

Peter van Niekerk

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table sets forth, as of ~~July~~May 129, ~~2024~~ 2025, the beneficial ownership of our common and preferred stock by each executive officer and director, by each person known by us to ~~beneficially~~ beneficially own more than 5% of our common stock and by the executive officers and directors as a group. Unless otherwise noted, the address of each beneficial owner is located at Northlands Deco Park | 10 New Market Street | Stand 299 Avant Garde Avenue | North Riding | 2169.

Title of class	Name and address of beneficial owner ⁽¹⁾	Number of shares - Beneficial ownership	Percent of class ⁽²⁾
Common	Gregory Vizirgianakis⁽³⁾	4,750,179	40.5%
Common	Pieter van Niekerk	401,965	3%
Common	Stavros G. Vizirgianakis⁽⁴⁾	4,750,179	40.5%
Common	Joseph P. Dwyer	0	0%
Common	Athanasios Spirakis	0	0%
Total of All Directors and Executive Officers (5 persons):		9,902,323	84%
More Than 5% Beneficial Owners:
NONE

(1)	As used in this table, "beneficial ownership" means the sole or shared power to vote, or to direct the voting of, a security, or the sole or shared investment power with respect to a security (i.e., the power to dispose of, or to direct the disposition of, a security). In addition, for purposes of this table, a person is deemed, as of any date, to have "beneficial ownership" of any security that such person has the right to acquire within 60 days after such date.
(2)	The percent of class is based on 11,733,750 voting shares as of ~~July~~May 129, ~~2024~~2025.
(3)	Includes 14,~~108~~750,~~327~~179 shares ~~held~~of incommon ~~his~~stock ~~name and 3,641,852 shares~~ held inby ~~King~~Medisol ~~Style~~Pty ~~Investments,~~Ltd ~~formed~~that inMr. ~~Cyprus,~~Vizirgianakis ~~in which Gregory~~ has ~~beneficial~~sole ~~ownership~~voting ~~over~~and ~~43.39655%~~investment ~~of the shares held by King Style Investments~~power.
(4)	Includes 4,750,179 shares held in ~~King~~his ~~Style Investments, formed in Cyprus, in which Stavros has beneficial ownership over 56~~name.~~60345% of the shares held by King Style Investments.~~

7076

Table of Contents

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Other than as disclosed below and in “Executive Compensation,” there have been no transactions involving the Company since the beginning of the last fiscal year, or any currently proposed transactions, in which the Company was or is to be a participant and the amount involved exceeds $120,000 or one percent of the average of the Company’s total assets at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest.

Related Party Summary

Name	Relationship with the Medinotec Group of Companies	Related transactions with the Medinotec Group of Companies	Related Directors with the Medinotec Group of Companies	Related Owners with the Medinotec Group of Companies	Amount for the 2025 fiscal year
Minoan Medical Proprietary Limited	Medical investment company controlled by Dr Gregory Vizirgianakis	Related Party Loan	Dr Gregory Vizirgianakis ~~Pieter van Niekerk~~	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Loan payable - $940,001
Minoan Capital Proprietary Limited	Property investment company controlled by Dr Gregory Vizirgianakis	Related party loan Rental Expenses	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Loan payable - $276 Lease liability - $40,756
Medinotec Capital Proprietary Limited	The African holding company of the Medinotec Group of Companies	Related party loan payable to Minoan Capital	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity	n/a
DISA Vascular Distribution Proprietary Limited trading as DISA Life Sciences	Distributor appointed by DISA Medinotec Proprietary Limited for Africa	Sales Income	Pieter van Niekerk – Serves as independent non-executive according to distribution agreement Pieter van Niekerk resigned as a non-executive director on October 14, 2022 and therefore the related party relationship ceased to exist on the same date.	n/a external third party
DISA Medinotec Proprietary Limited	The African operating and manufacturing company	Related party loan with Minoan Medical Operational income and expenses with Minoan Medical	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity	n/a
DISA Medinotec Proprietary Limited	The African operating and manufacturing company	Related party loan with Minoan Medical Operational income and expenses with Minoan Medical	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity
Medinotec Incorporated Nevada	Ultimate parent of Medinotec Capital and DISA Medinotec	All of the above for its related subsidiaries	Dr Gregory Vizirgianakis Pieter van Niekerk Joseph P Dwyer Stavros Vizirgianakis Athanasios Spirakis	This is the entity owned by the shareholders and primarily controlled by Dr Gregory Vizirgianakis and his Brother Stavros Vizirgianakis	n/a
Medinotec Incorporated Nevada	Ultimate parent of Medinotec Capital and DISA Medinotec	All of the above for its related subsidiaries	Dr Gregory Vizirgianakis Pieter van Niekerk Joseph P Dwyer Stavros Vizirgianakis Athanasios Spirakis	This is the entity owned by the shareholders and primarily controlled by Dr Gregory Vizirgianakis and his Brother Stavros Vizirgianakis
Medinotec Group of Companies	The Consolidated group name of Medinotec Incorporated, Medinotec Capital Proprietary Limited and DISA Medinotec Proprietary Limited	above for its related subsidiaries	Dr Gregory Vizirgianakis Pieter van Niekerk Joseph P Dwyer Stavros Vizirgianakis Athanasios Spirakis	This is the entity owned by the shareholders and primarily controlled by Dr Gregory Vizirgianakis and his Brother Stavros Vizirgianakis	n/a

7177

Table of Contents

Medinotec Group of Companies The Consolidated group name of Medinotec Incorporated, Medinotec Capital Proprietary Limited and DISA Medinotec Proprietary Limited above for its related subsidiaries Dr Gregory Vizirgianakis Pieter van Niekerk Joseph P Dwyer Stavros Vizirgianakis Athanasios Spirakis This is the entity owned by the shareholders and primarily controlled by Dr Gregory Vizirgianakis and his Brother Stavros Vizirgianakis Pieter van Niekerk Chief financial officer of the Medinotec Group of Companies Transactions relating to mutual entities disclosed above Related directorships disclosed above Minority Shareholder in Medinotec Inc n/a Gregory Vizirgianakis Chief Executive officer of the Minoan Group of Companies Brother of Stavros Vizirgianakis Transactions relating to mutual entities disclosed above Related directorships disclosed above Shareholder in Medinotec Inc and Kingstyle investments. n/a Stavros Vizirgianakis Non-Executive director of the Medinotec Group of companies Brother of Gregory Vizirgianakis Transactions relating to mutual entities disclosed above No Related other Directorships in Medinotec Group of Companies n/a n/a Joseph Dwyer Non-Executive director of the Medinotec Group of companies Transactions relating to mutual entities disclosed above No Related other Directorships in Medinotec Group of Companies n/a n/a Athanasios Spirakis Independent director of the Medinotec Group of companies Transactions relating to mutual entities disclosed above No Related other Directorships in Medinotec Group of Companies n/a n/a

a. Rent

DISA Medinotec Propriety Limited leases commercial buildings from Minoan Capital Proprietary Limited (“Minoan Capital”). Minoan Capital is owned 100% by the Chief Executive Officer of the Medinotec Group of Companies, Dr. Gregory Vizirgianakis. ~~Pieter van Niekerk, CFO of the Medinotec Group of Companies, also serves as a director on Minoan Medical.~~

Set forth below is a table showing ~~the~~ the Consolidated entities’ rent paid for the year ended February 2928, ~~2024~~2025, with Minoan Capital and the Melville, New York Office:

	February 29, 2024		February 28, 2023
	February 28, 2025		February 29, 2024
Rent		3251,~~142~~759		3932,~~984~~142

Rent is comparable to rent charged for similar properties in the same relative area. The Consolidated entities do market research of a Minimum and a Maximum rental value within the area at every renewal of the rental agreement to ensure this is market related, this exercise is undertaken together with a registered property agent who has the appropriate knowledge of the area.

The Company leases office and warehouse spaces under a cancelable operating lease agreement with contractual terms from August 1, 2023, to July 31, 2026. The Company is required to pay property taxes, insurance, and normal maintenance costs for certain of these facilities and will be required to pay any increases over the base year of these expenses on the remainder of the Company’s facilities.

7278

Table of Contents

b. Loan

Loans payable ~~consists~~includes an unsecured loan of a $1940,~~769,957 unsecured~~001 ~~loan~~ from the prior parent entity of DISA Medinotec in South Africa called Minoan Medical. This loan originated to fund working capital and capex expansions of DISA Medinotec during the developmental and startup phase. After the acquisition of DISA Medinotec on March 2, 2022, the Company assumed this liability. The Company has a period of 3 years ~~after~~from the IPO date or afrom ~~date~~the date at which the Company starts trading on a ~~recognizable~~national exchange (as defined in Section 3(a)(1) of the Securities Exchange Act of 1934, as amended), to repay the loan. During these 3 years the loan will carry interest at the prevailing prime lending rate of the time.

The Minoan Medical loan decreased by $93829,~~109~~687 during the year ended February 2928, ~~2024~~2025.

The prevailing prime lending rate on the quarter ending February 2928, ~~2024~~2025 in South Africa is 11.7500%. The interest charged for the year was $~~236~~141,~~873~~748 and a 1% movement in the interest rates constitutes a value of $2012,~~159~~886. The interest rate chargeable is a guideline determined by the South African Reserve Bank and gets utilized by financial institutions to determine the financial gain they may derive from a loan. The Prime rate is therefore an arm’s length transaction and justifiable rate that can be applied to a loan within the borders of the Republic of South Africa.

The Consolidated entities, particularly Medinotec Inc. have the option to settle earlier and settlement can be in cash or any form of equivalent.

Minoan Medical’s ultimate ~~beneficial~~ beneficial owner is the CEO of the Medinotec Group of Companies Dr. Gregory Vizirgianakis and is used to hold his investments of which DISA Medinotec Proprietary Limited Incorporated was one before was got transferred into the Medinotec Group of Companies. ~~Pieter van Niekerk also serves as a director on Minoan Medical.~~

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES.

~~BDO~~Mercurius & Associates LLP served as our independent registered auditors for the year ended February 2928, ~~2024~~2025.

Audit Fees

Please refer below for the total audit fees for the Company’s fiscal years ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024, for professional services rendered by our independent auditors for the audit and review of our financial statements.

	February 29, 2024		February 28, 2023
	February 28, 2025		February 29, 2024
Audit Fees		~~166~~159,~~271~~620		~~120~~166,~~561~~271

Audit Related Fees

There were no fees for audit related services rendered by our independent auditors for the years ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024, respectively.

Tax Fees

For the Company’s fiscal years ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024, there were no fees for professional services rendered by our independent auditors for tax compliance, tax advice, and tax planning.

All Other Fees

For the Company’s fiscal years ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024, we were not billed any other fees by our auditors.

7379

Table of Contents

PART IV

ITEM 15.

EXHIBIT AND FINANCIAL STATEMENT SCHEDULES.

(a)(1)

FINANCIAL STATEMENTS.

The following documents are included on pages F-1 through F-23 attached hereto and are files as part of this Annual Report on Form 10-K. Reference is made to the Index to Consolidated Financial Statements on Page F-1.(a)(2) EXHIBITS.

(a)(2)

EXHIBITS

We have filed the exhibits listed on the accompanying Exhibit Index of this registration statement and below in this Item 15:

		Incorporated by
Exhibit		Reference		Filed or Furnished
Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
2.1	Share Exchange Agreement, dated March 2, 2022	S-1	2.1	6/2/2022
3.1	Articles of Incorporation	S-1	3.1	6/2/2022
3.2	Articles of Amendment	S-1	3.3	6/2/2022
3.3	Bylaws	S-1	3.3	6/2/2022
4.1	Unsecured Revolving Promissory Note, dated September 16, 2022	S-1/A	4.1	11/2/2022
4.2	Description of Registrant’s Securities	10-K	4.2	7/5/2024	X
10.1	Lease Agreement dated January 28, 2020 between Minoan Capital and DISA Medinotec Proprietary Limited	S-1/A	10.1	8/4/2022
10.2	Exclusive Distribution Agreement dated March 1, 2020 between Disa Life Sciences Proprietary Limited and DISA Medinotec Proprietary Limited	S-1/A	10.2	8/4/2022
10.3	Letter of Offer, dated April 26, 2021 with Gregory Vizirgianakis	S-1/A	10.3	8/30/2022
10.4	Letter of Offer, dated April 26, 2021 with Peter van Niekerk	S-1/A	10.4	8/30/2022
10.5	Letter of Offer, dated June 13, 2021 with Stavros Vizirgianakis	S-1/A	10.5	8/30/2022
10.6	Letter of Offer, dated June 13, 2021 with Joseph P Dwyer	S-1/A	10.6	8/30/2022
10.7	Loan Certificate dated Mary 1, 2017	S-1/A	10.7	8/30/2022
21.1	List of Subsidiaries Medinotec Capital Proprietary Limited and DISA Medinotec Proprietary Limited	10-K	21.1	5/30/2023
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.				X
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.				X
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350.				X
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema Linkbase Document.				X
101.CAL	Inline XBRL Taxonomy Calculation Linkbase Document.				X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.				X
101.LAB	Inline XBRL Taxonomy Label Linkbase Document.				X
101.PRE	Inline XBRL Taxonomy Presentation Linkbase Document.				X
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

ITEM 16.

10-K SUMMARY

None

7480

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DATE	SIGNATURE	TITLE
July 3, 2024	/s/ Gregory Vizirgianakis	Chief Executive Officer and Director
May 29, 2025	/s/ Gregory Vizirgianakis	Chief Executive Officer and Director
	Gregory Vizirgianakis	(Principal Executive Officer)

DATE	SIGNATURE	TITLE
July 3, 2024	/s/ Peter van Niekerk	Chief Financial Officer and Director
May 29, 2025	/s/ Pieter van Niekerk	Chief Financial Officer and Director
	Peter van Niekerk	(Principal Financial Officer and Principal Accounting Officer)
	Pieter van Niekerk	(Principal Financial Officer and Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

DATE	SIGNATURE	TITLE
July 3, 2024	/s/ Gregory Vizirgianakis	Chief Executive Officer and Director
May 29, 2025	/s/ Gregory Vizirgianakis	Chief Executive Officer and Director
	Gregory Vizirgianakis	(Principal Executive Officer)

DATE	SIGNATURE	TITLE
July 3, 2024	/s/ Peter van Niekerk	Chief Financial Officer and Director
May 29, 2025	/s/ Pieter van Niekerk	Chief Financial Officer and Director
	Peter van Niekerk	(Principal Financial Office and Principal Accounting Officer)
	Pieter van Niekerk	(Principal Financial Office and Principal Accounting Officer)

DATE	SIGNATURE	TITLE
July 3, 2024	/s/ Stavros G. Vizirgianakis and	Director
May 29, 2025	/s/ Stavros G. Vizirgianakis	Director
	Stavros G. Vizirgianakis

DATE	SIGNATURE	TITLE
July 3, 2024	/s/ Joseph P. Dwyer	Director
May 29, 2025	/s/ Joseph P. Dwyer	Director
	Joseph P. Dwyer

7581

Table of Contents

ITEM 15

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

MEDINOTEC, INC.

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED FEBRUARY 2928, ~~2024~~2025 AND FEBRUARY 2829, ~~2023~~2024

CONTENTS

		Page
Reports of Independent Registered Public Accounting Firms
Report for the year ended February 29, 2024 - BDO South Africa Inc. - Firm ID: 1368		F-1
Report for the year ended February 28, 2025 – Mercurius & Associates LLP - Firm ID: 3223		F-1
Report for the year ended February 28, 2023 – Mercurius & Associates LLP - Firm ID: 3223		F-2
Report for the year ended February 29, 2024 – BDO South Africa Inc. - Firm ID: 1368		F-2
Consolidated Balance Sheets as of February 29, 2024 and February 28, 2023		F-3
Consolidated Balance Sheets as of February 28, 2025 and February 29, 2024		F-3
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended February 29, 2024 and February 28, 2023		F-4
Consolidated Statements of Operations and Comprehensive Income/ (Loss) for the Years Ended February 28, 2025 and February 29, 2024		F-4
Consolidated Statements of Stockholders’ Equity / (Deficit) for the Years Ended February 29, 2024 and February 28, 2023		F-5
Consolidated Statements of Stockholders’ Equity for the Years Ended February 28, 2025 and February 29, 2024		F-5
Consolidated Statements of Cash Flows for the Years Ended February 29, 2024 and February 28, 2023		F-6
Consolidated Statements of Cash Flows for the Years Ended February 28, 2025 and February 29, 2024		F-6
Notes to Consolidated Financial Statements		F-7

7682

Table of Contents

		Tel: +27 011 488 1700 Fax: +27 010 060 7000 www.bdo.ca.za	Wanderers Office Park 52 Corlett Drive Illovo, 2196
			Private Bag X60500
			Houghton, 2041
			South Africa

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Medinotec Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of Medinotec Inc. and its subsidiaries (collectively, the “Company”) as of February 28, 2025, the related consolidated statement of operations and comprehensive income/(Loss), consolidated statement of stockholders’ equity and consolidated statements of cash flows for the year then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of February 28, 2025 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

Critical Audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. We determined that there are no critical audit matters.

Mercurius & Associates LLP

We have served as the Company’s auditor since 2024

New Delhi, India

May 29, 2025

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

Shareholders and Board of Directors

Medinotec Inc.

Johannesburg, South Africa

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of Medinotec Inc. (the “Company”) as of February 29, 2024, the related consolidated statements of operations and comprehensive loss, stockholders’ equity/(deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at February 29, 2024, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

/s/ BDO South Africa Inc.

BDO South Africa Incorporated

Registered Auditors

Jacques Barradas

We ~~have~~ served as the Company's auditor ~~since~~from 2023 to 2024.

Johannesburg, South Africa

July 033, 2024

BDO South Africa Incorporated

Registration number: 1995/002310/21

Practice number: 905526

VAT number: 4910148685

Chief Executive Officer: LD Mokoena

A full list of all company directors is available on www.bdo.co.za

The company’s principal place of business is at The Wanderers Office Park, 52 Corlett Drive, Illovo, Johannesburg where a list of directors’ names is available for inspection. BDO South Africa Incorporated, a South African personal liability company, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Medinotec Inc.

Opinion on the Financial Statements

We have audited the accompanying Consolidated Balance Sheets of Medinotec Inc. and its subsidiaries (collectively, the “Company”) as on February 28, 2023 and February 28, 2022, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the year ended February 28, 2023 and for the period from April 26, 2021 to February 28, 2022 and the related notes (collectively referred to as the "Financial Statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of February 28, 2023 and February 28, 2022 and the results of its operations and its cash flows for the year ended February 28, 2023 and for the period from April 26, 2021 to February 28, 2022, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of financial statement. We believe that our audits provide a reasonable basis for our opinion.

Emphasis of Matter

We draw attention to Note 2a(ii) to the consolidated financial statements which describes that the Consolidated Balance Sheet as on February 28, 2022 and the related consolidated statement of operations, changes in stockholders’ deficit and cash flow for the period from April 26, 2021 to February 28, 2022 and the related notes have been restated to consolidate the commonly controlled entities retrospectively, as if the transaction had occurred at the beginning of the previous period (i.e. formation date of registrant). Our opinion is not modified with respect to this matter.

Critical Audit Matter

The Critical Audit Matter are matters arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

Mercurius & Associates LLP

(Formerly known as AJSH & Co LLP)

We have served as the Company’s auditor since 2022

PCAOB #3223

New Delhi, India

May 30, 2023

F-2

Table of Contents

Consolidated Balance Sheets for the Medinotec Group of Companies as of February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024

	2024 $			2023 $
	2025 $			2024 $
Assets
Current Assets
Cash		2,~~808~~769,~~910~~686			2,~~827~~808,~~457~~910
Accounts receivable, net of allowances		~~589~~2,~~761~~612,440			21589,~~074~~761
Inventory		~~863~~988,~~452~~341			~~354~~863,~~304~~452
Other current assets		~~117~~52,~~174~~719			~~166~~117,~~643~~174
Total Current Assets		46,~~379~~423,~~297~~186			34,~~369~~379,~~478~~297
Note receivable		—			~~605,130~~—
Property, plant and equipment, net of accumulated depreciation		~~320~~348,~~122~~486			~~406~~320,~~873~~122
Deferred tax asset		~~42,881~~—			~~108~~42,~~951~~881
Operating right-of-use asset		6137,~~979~~301			—61,979
Total Assets	$	46,~~804~~808,~~279~~973		$	4,~~490~~804,~~432~~279
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable and accrued liabilities		~~801~~1,~~550~~476,987			71801,~~311~~550
Due to stockholders/Directors		~~1,587~~—			—1,587
Operating lease liability, current portion		2428,~~316~~060			—24,316
Total current Liabilities		~~827~~1,~~453~~505,047			71827,~~311~~453
Long Term Liabilities
Loans payable		1940,~~769,957~~277			1,~~863~~769,~~066~~957
Operating lease liability, net of current portion		39,698			—
Deferred tax liabilities		80,124			—
Total Liabilities		2,637,108			1,934,377
Operating lease liability, net of current portion		12,696			39,698
Total Liabilities		2,538,144			2,637,108
Equity
Capital stock		11,734			11,734
Capital stock additional paid in capital		3,296,391			3,296,391
Retained earnings (Accumulated deficit) - ending		(1918,~~241,325~~115	)		(~~836~~1,~~637~~241,325	)
Accumulated other comprehensive income		~~100~~44,~~371~~589			84100,~~567~~371
Total Equity		24,~~167~~270,~~171~~829			2,~~556~~167,~~055~~171
Total Liabilities and Equity	$	46,~~804~~808,~~279~~973		$	4,~~490~~804,~~432~~279

The accompanying notes are an integral part of these audited consolidated financial statements.

F-3

Table of Contents

Consolidated Statements of Operations and Comprehensive ~~Loss~~Income/ (Loss) for the Medinotec Group of Companies for the Years Ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024

	2024 $			2023 $
	2025 $			2024 $
Revenue		59,~~020~~113,~~391~~607			~~999~~5,~~579~~020,391
Cost of goods sold		(24,~~577~~252,~~922~~821	)		(~~417~~2,~~757~~577,922	)
Gross profit		24,~~442~~860,~~469~~786			~~581~~2,~~822~~442,469
Operating expenses
Selling expenses		(84113,~~564~~194	)		(5384,~~818~~564	)
Depreciation and amortization expense		(6373,~~948~~846	)		(5363,~~553~~948	)
General and administrative expenses		(1,~~671~~391,~~028~~114	)		(~~648~~1,~~172~~671,028	)
Research and development expenses		(2291,~~351~~133	)		(6422,~~866~~351	)
Total operating expenses		(1,~~841~~669,~~891~~287	)		(~~820~~1,~~409~~841,891	)
Income/(loss) from operations		600,578			(238,587	)
Income from operations		3,191,499			600,578
Non operating income and expenses
Interest income		608,~~590~~668			2260,~~507~~590
Interest expense		(~~277~~176,~~230~~416	)		(~~226~~277,~~814~~230	)
Other revenue/(expense)		4,304			51,417
Other revenue		387			4,304
Provision for impairment of note receivable		(642,012	)		—
Impairment of note receivable		—			(642,012	)
Total non-operating income and expenses		(~~854~~167,~~348~~361	)		(~~152~~854,~~890~~348	)
Loss before income taxes		(253,770	)		(391,477	)
Income/(loss) before income taxes		3,024,138			(253,770	)
Income taxes
Current income taxes		(81737,~~198~~389	)		—(81,198	)
Deferred income taxes		(69127,~~720~~276	)		38(69,~~742~~720	)
Net (loss)		(404,688	)		(352,735	)
Net income/(loss)		2,159,473			(404,688	)
Net loss per share, basic and diluted:		(0.03	)		(0.03	)
Net earnings/ (loss) per share, basic and diluted:		0.18			(0.03	)
Weighted average shares used in computing net loss per share, basic and diluted		11,733,750			11,733,750
Net (loss)		(404,688	)		(352,735	)
Net income/(loss)		2,159,473			(404,688	)
Other comprehensive income/(loss)
Foreign currency translation gain/(loss)		15(55,~~804~~815	)		8015,~~650~~804
Other comprehensive income/(loss)		15(55,~~804~~815	)		8015,~~650~~804
Comprehensive loss		(388,884	)		(272,085	)
Comprehensive income/(loss)		2,103,658			(388,884	)

The accompanying notes are an integral part of these audited consolidated financial statements.

F-4

Table of Contents

Consolidated Statements of Stockholders’ Equity ~~/ (Deficit)~~ for the Years Ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024

	Common Stock				Common Stock Additional Paid in Capital
	Shares		Amount $		Amount $			Retained Earnings/(Accumulated Deficit) $			Accumulated Comprehensive Income $			Total $
Balance, March 1,2022		10,000,000		10,000		—			483,902			3,917			(469,985	)
Balance, March 1, 2023		11,733,750		11,734		3,296,391			(836,637	)		84,567			2,556,055
Net (loss) for the period		—		—		—			(352,735	)		—			(352,735	)
Other comprehensive income / (loss)		—		—		—			—			80,650			80,650
Stock issued
Stock issued – pursuant to acquisitions @S2 per share		1,733,750		1,734		3,465,766			—			—			3,467,500
Raising fee capitalized		—		—		(169,375	)		—			—			(169,375	)
Balance February 28, 2023		11,733,750		11,734		3,296,391			(836,637	)		84,567			2,556,055
Net (loss) for the period		—		—		—			(404,688	)		—			(404,688	)
Other comprehensive income / (loss)		—		—		—			—			15,804			15,804
Balance, February 29, 2024		11,733,750		11,734		3,296,391			(1,241,325	)		100,371			2,167,171
Balance February 29, 2024		11,733,750		11,734		3,296,391			(1,241,325	)		100,371			2,167,171
Net income for the period		—		—		—			2,159,473			—			2,159,473
Other comprehensive income / (loss)		—		—		—			—			(55,815	)		(55,815	)
Reclassification adjustment		—		—		—			(33	)		33			—
Balance, February 28, 2025		11,733,750		11,734		3,296,391			918,115			44,589			4,270,829

The accompanying notes are an integral part of these audited consolidated financial statements.

F-5

Table of Contents

Consolidated Statements of Cash Flows for the Years Ended February 2928, 2025 ~~2024~~ and February 2829, ~~2023~~2024

	2024 $			2023 $
	2025 $			2024 $
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)		(404,688	)		(352,735	)
Net income/(loss)		2,159,473			(404,688	)
Depreciation		8873,~~225~~846			5388,~~553~~225
Foreign currency transaction gain (loss), unrealized		(35,~~916~~765	)		(803,~~643~~916	)
Deferred income taxes and tax credits		97127,~~273~~276			~~(23~~97,~~325~~273	)
Provisions		139,712			(169,375	)
Provision for income taxes		737,389			139,712
Interest		—			156,070
Impairment provision on notes receivable		—			642,012
Impairment provision on notes receivable		642,012			—
Bad debt write-off		—			52,133
Bad debt write-off		52,133			—
Operating lease liability		(32,030	)		(13,299	)
Operating lease liability		(13,299	)		—
(Increase)/Decrease in prepayments		(11,944	)		(10,674	)
(Increase)/Decrease in prepayments		(10,674	)		—
(Increase)/Decrease in receivables		(2,039,246	)		(631,248	)
(Increase)/Decrease in receivables		(631,248	)		(21,019	)
(Increase)/Decrease in inventories		(91,639	)		(480,640	)
(Increase)/Decrease in inventories		(480,640	)		84,619
Increase/(Decrease) in accounts payable and accrued expenses		226,855			621,650
Increase/(Decrease) in accounts payable and accrued expenses		621,650			(137,708	)
Net cashflow from/ (used in) operations		1,144,215			96,540
Net cashflow from / (used in) operations		96,540			(490,549	)
Accrued interest		—			(49,262	)
Accrued interest		(49,262	)		—
Tax paid		(266,381	)		(33,036	)
Tax paid		(33,036	)		—
TOTAL CASH FLOWS FROM/(USED IN) OPERATING ACTIVITIES		877,834			14,242
TOTAL CASH FLOWS FROM/(USED IN) OPERATING ACTIVITIES		14,242			(490,549	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments to acquire property, plant, and equipment		(289,~~255~~013	)		55(2,~~277~~255	)
Cash received from note receivable		~~12,380~~—			~~(585~~12,~~000~~380	)
TOTAL CASH FLOWS FROM/(USED BY) INVESTING ACTIVITIES		10(89,~~125~~013	)		~~(529~~10,~~723~~125	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt		~~1,588~~797			~~279~~1,~~069~~588
Repayment of debt		(9895,~~680~~279	)		—(9,680	)
Proceeds from issuance of common stock		—			3,298,125
TOTAL CASH FLOWS FROM/(USED BY) FINANCING ACTIVITIES		(894,482	)		(8,092	)
TOTAL CASH FLOWS FROM/(USED BY) FINANCING ACTIVITIES		(8,092	)		3,577,194
OTHER ACTIVITIES:
Effect of exchange rate on cash and cash equivalents		~~(34~~66,~~822~~437	)		~~138~~(34,~~958~~822	)
Net cash increase (decreases) in cash and cash equivalents		(1839,~~547~~224	)		2(18,~~695,880~~547	)
Cash and cash equivalents at beginning of period		2,~~827~~808,~~457~~910			~~131~~2,~~577~~827,457
Cash and cash equivalents at end of period		2,~~808~~769,~~910~~686			2,~~827~~808,~~457~~910
Supplemental disclosures
Interest income		6073,~~590~~468			2260,~~507~~590
Interest expense		(~~277~~176,~~230~~416	)		(~~226~~277,~~814~~230	)
Right-of-use Assets in exchange for lease liabilities		~~76,940~~—			—76,940

The accompanying notes are an integral part of these audited consolidated financial statements.

F-6

Table of Contents

Notes to Consolidated Financial Statements

1. Description of Business

Medinotec Inc. is a US-based company with a primary investment and operations in DISA Medinotec Proprietary Limited (“DISA Medinotec”), a South African medical device manufacturing and distribution company, which in management’s opinion is a global leader in tracheal non-occlusive airway dilation technology and medical device design. “The Company” consists of Medinotec Inc. in Nevada, which primary operations in the United States is in Long Island, New York. and its wholly owned subsidiaries, Medinotec Capital Proprietary Limited and DISA Medinotec, of which both are incorporated in South Africa. Combined, the Company has experience in establishing facilities for the manufacturing and design of niche medical devices and establishing international distribution networks to commercialize these devices.

The Company is seeking to expand sales and distribution operations into the United States of America and other markets.

The Company’s audited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company received FDA 510(k) approval through the substantial equivalence process for Class II medical devices for its main product, the Trachealator, in November 2021.

~~The reason for the higher sales growth was due to various new distribution agreements in the surgical speciality of cardiology the Company entered into~~2. Significant ~~These~~Accounting agreements are short term in nature and can be cancelled on non-performance clauses by either party. It has a strong geographical country specific risk which is mainly concentrated to South Africa. This led to increased revenues in South Africa. The rapid sales growth is attributable to the fact that these distributors already have existing business as well as a reputation for quality product in South Africa. Disa Medinotec got awarded these contracts due to years of good relationships between the external third party distributors and the current executive management of Disa Medinotec. In addition, the Company realized sales for its Trachealator in the United States with no such sales inside the United States for the prior year period.Policies

~~The Company recently embarked on obtaining various distribution contracts from principals to ensure~~ a. Nature ~~full~~of ~~sales basket and cash generation~~business/basis toof ~~sustain growth and product development in the near future.~~preparation

~~2. Significant Accounting Policies a. Nature of business/basis of preparation~~ Basis of presentation

The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States.

Emerging Growth Company (~~ECG~~EGC) status

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Prior period reclassification

Certain prior period amounts in the consolidated statements of operations and comprehensive loss and consolidated balance sheets have been reclassified to conform with the current period presentation.

F-7

Table of Contents

b. Foreign currency translation ~~i. Translation of foreign subsidiary~~

i. Translation of foreign subsidiary

The accounts of the foreign subsidiaries are translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates and income and expense accounts are translated at average exchange rates in effect during the year. Translation adjustments resulting from fluctuations in the exchange rates are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.

Exchange gains or losses incurred foreign exchange currency transactions conducted by one of the Company’s operations in a currency other than the operation’s functional currency are reflected in other revenue/(expense).

ii. Exposed to currency variations in subsidiary

The primary operations and functional currency of both Disa Medinotec (Pty) Ltd and Medinotec Capital (Pty) Ltd is in South African Rand. Due to the emerging market nature of this currency the spread volatility of the currency low and high can be material during a year. The conversion of the currency from Rand to reporting currency US Dollar can cause significant up or downward trends that are recorded in reserves under the heading accumulated comprehensive income.

The functional currency as well as the reporting currency for Medinotec Inc is the US Dollar.

c. Cash and cash equivalents ~~i. Highly liquid investments~~

i. Highly liquid investments

The Medinotec Group of Companies considers all highly liquid investments with a remaining maturity of three months or less at the time of purchase to be cash equivalents. These cash equivalents consist primarily of term deposits and certificates of deposit. Investments with maturities from greater than three months to one year are classified as short-term investments, while those with maturities in excess of one year are classified as long-term investments. Cash equivalents and short-term investments are stated at cost which approximates market value.

d. Accounts ~~Receivable i. Allowance based on a review and management evaluation~~Receivables

i. Allowance based on a review and management evaluation

Accounts receivables are presented on the consolidated balance sheets, net of estimated uncollectible amounts. The carrying amounts of trade accounts receivable represent the maximum credit risk exposure of these assets.

In accordance with FASB ASC 326, Measurement of Credit Losses on Financial Instruments ("ASC 326"), the Company evaluates the collectability of outstanding accounts receivable balances to determine an allowance for credit losses that reflects its best estimate of the lifetime expected credit losses.

One major client constitutes 8387% of the accounts receivable balance as at February 2928, ~~2024~~2025, compared to 083% on February 2829, ~~2023~~2024.

An allowance for credit losses is calculated taking into account all accounts older than ~~121~~91+ days.

F-8

Table of Contents

e. Property, plant and equipment ~~i. Depreciation rates~~

i. Depreciation rates

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided for using the straight-line method over the estimated useful lives as follows for the major classes of assets:


Plant and machinery	10 years
Laboratory equipment	5 years
Furniture and fixtures	6 years
Motor vehicles	5 years
Computer equipment	3 years
Office equipment	6 years
Computer software	2 years
Leasehold improvements	3 years
Small assets	1 year

f. Inventories

i. Valuation, costing and obsolescence

Management evaluates the need to record adjustments to write down inventory to the lower of cost or net realizable value on ana ~~annual~~quarterly basis. The Company’s policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage.

g. Impairment of long-lived assets

The Company assesses long-lived assets for impairment in accordance with the provisions of Financial Accounting Standards Board ASC 360, Property, Plant and Equipment. Long-lived assets (asset group), such as property and equipment subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value.

Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.

h. Leases

We determine if an arrangement is a lease at inception. We determine the classification of the lease, whether operating or financing, at the lease commencement date, which is the date the leased assets are made available for use. We use the non-cancelable lease term when recognizing the right-of-use (“ROU”) assets and lease liabilities, unless it is reasonably certain that a renewal or termination option will be exercised. We account for lease components and non-lease components as a single lease component. Modifications are assessed to determine whether incremental differences result in new contract terms and accounted for as a new lease or whether the additional right of use should be included in the original lease and continue to be accounted for with the remaining ROU asset.

F-9

Table of Contents

Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Lease payments consist of the fixed payments under the arrangement, less any lease incentives. Variable costs, such as common area maintenance costs and additional payments for percentage rent, are not included in the measurement of the ROU assets and lease liabilities, but are expensed as incurred. As the implicit rate of the leases is not determinable, we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments in determining the present value of the lease payments. Lease expenses are recognized on a straight-line basis over the lease term. We do not recognize ROU assets on lease arrangements with a term of 12 months or less.

i. Allowance for ~~loan~~credit ~~impairment~~losses on loans receivable

The Company ~~records~~maintains ~~allowances~~an allowance for ~~loan~~credit ~~impairment~~losses ~~when~~on itloans isreceivable ~~determined~~in ~~that~~accordance ~~the~~with ~~Company~~ASC ~~will~~326, beFinancial ~~unable~~Instruments—Credit toLosses. ~~collect~~This ~~amounts~~allowance ~~due~~reflects management’s toestimate of expected credit losses over the ~~Company~~contractual ~~according~~life toof the loans, considering historical loss experience, ~~terms~~current conditions, and reasonable and supportable forecasts. The estimate is developed using a combination of quantitative data and qualitative factors, including borrower creditworthiness, loan-specific risk characteristics, macroeconomic trends, and other relevant information. The allowance is adjusted through a provision for credit losses in the ~~underlying~~Company’s ~~agreement~~consolidated statements of operations, and loans are charged off against the allowance when deemed uncollectible.

j. Employee benefit plans The Company contributes 2.5% for eligible employees to a pension plan registered under the laws of South Africa. The Company also contributes a portion of the medical aid contribution for eligible employees to an approved medical insurance scheme. k. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. l. Financial instruments i. Fair Value Measurements

~~Fair value~~The ~~accounting~~Company iscontributes ~~applied for all assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually)~~2.5% ~~Fair value is defined as the exchange price that would~~of be basic ~~received~~salaries for aneligible ~~asset~~employees ~~or an exit price that would be paid~~ to ~~transfer~~ a ~~liability~~pension inplan ~~the~~registered ~~principal~~under ~~or most advantageous market for~~ the ~~asset~~laws orof ~~liability~~South inAfrica. anThe ~~orderly~~Company ~~transaction~~also ~~between~~contributes ~~market~~a ~~participants~~portion of on the ~~measurement~~medical ~~date.~~aid ~~The~~contribution ~~consolidated entities follow the established framework~~ for ~~measuring~~eligible ~~fair~~employees ~~value~~to ~~and~~an ~~expands~~approved ~~disclosures~~medical ~~about~~insurance ~~fair value measurements~~scheme.

k. Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.

F-10

Table of Contents

iil. Financial ~~Concentrations of Credit Risk~~instruments

i. Fair Value Measurements

Fair value accounting is applied for all assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The consolidated entities follow the established framework for measuring fair value and expands disclosures about fair value measurements.

ii. Concentrations of credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, trade accounts receivable and loans. The Company invests its excess cash in low-risk, highly liquid money market funds and certificates of deposit with a major financial institution.

iii. Exposed to currency variations in subsidiary

The primary operations and functional currency of a subsidiary's business is in South African Rand. Due to the emerging market nature of this currency the spread volatility of the currency low and high can be material during a year. The conversion of the currency from Rand to reporting currency US Dollar ~~can~~ can cause significant up or downward trends that is recorded in reserves under the heading accumulated comprehensive income. The effect on on the reserves for the year ended February 2928, ~~2024~~2025 was ($1555,~~804~~ 815) compared to $8015,~~650~~ 804 for the year ended February 2829, ~~2023~~2024.

iv. Interest rate ~~Risk~~risk

Market interest rate risk may result in loss from fluctuations in the future cash flows or fair values of financial instruments. Interest rate risk is managed principally through monitoring interest rate gaps and basis risk and by having pre-approved limits for repricing bands.

The interest rate risk relates solely to the related party loan.

m. Comprehensive income / loss ~~i. Comprehensive income / loss~~

i. Comprehensive income/loss

Comprehensive loss consists of net loss and other gains and losses affecting stockholders’ equity that, under GAAP, are excluded from net loss. Our other comprehensive loss represents foreign currency translation adjustment attributable to our operations. Refer to Consolidated Statements of Comprehensive Loss.

Total foreign currency transaction loss ~~gains~~ for the year ended February 2928, ~~2024~~2025 was $1555,~~804~~815, compared to gains of $8015,~~650~~ 804 for the year ended February 2829, ~~2023~~2024.

n. Revenue recognition

~~The~~Revenue represents the amount of ~~Company~~consideration ~~generates~~expected ~~revenues~~to ~~through~~be ~~two~~received ~~distinct~~from ~~revenue~~customers ~~sources:~~in exchange for the transfer of products. Net sales exclude value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. Shipping and handling costs charged to customers are included in net revenue.

	1.	From the sale of high-quality medical devices which are self-manufactured through in-depth research and development; and
	2.	Through the distribution of finished products on behalf of other principals around the world into pre-agreed territories which are usually exclusive territories granted by such principal.

F-11

Table of Contents

The Company generates revenues through two distinct revenue sources:

	1.	From the sale of high-quality medical devices which are self-manufactured through in-depth research and development; and

	2.	Through the distribution of finished products on behalf of other principals around the world into pre-agreed territories which are usually exclusive territories granted by such principal.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its arrangements:

	•	identify the contract with a customer,

	•	identify the performance obligations in the contract,

	•	determine the transaction price,

	•	allocate the transaction price to performance obligations in the contract, and

	•	recognize revenue as the performance obligation is satisfied.

Revenue from the sale of self-manufactured products

These products are developed in-house.

The Company’s clients are billed based on a pricelist that is agreed on in each customers contract. Orders are shipped on a per order basis from the Company’s warehouse with Free-On-Board Inco terms.

Revenues relating to the self-manufactured products are recognized when control of the promised goods or services is transferred to a customer in an amount that reflects the consideration that the Company expects to receive in exchange for those products.

Revenue from the distribution of products

Revenues relating to the distribution products are recognized when control of the promised goods or services are transferred to a customer in an amount that reflects the consideration that the Company expects to receive in exchange for those products. The transfer of control will typically be on the date of shipment.

F-12

Table of Contents

For both revenue streams

F-12

Table of Contents

Payment Terms

The Company sells a significant amount to DISA Life Sciences. For the year ending February 2928, ~~2024~~2025, 8688% of the Company's total revenue is derived from this single customer in the distribution environment in South Africa compared to 6286% for the year ending February 29, 2024. During fiscal 2025, a receivable was recognized for revenue earned from DISA Life Sciences. As of February 28, ~~2023~~2025, no sales taxes have been recorded, as no invoice has been issued. The related sales tax return will be finalized in accordance with standard invoicing timelines or adjusted as necessary upon invoice issuance.

o. Segment Reporting

This table indicates the sales per revenue stream as a breakdown of the total revenue balance:

	Medinotec Inc Group Consolidated Years Ended
	Feb 29, 2024 $		Feb 28, 2023 $
	Feb 28, 2025 $		Feb 29, 2024 $
Outside of United States of America
Internally Designed/Manufactured Sales		~~976~~863,~~291~~337		~~978~~976,~~112~~291
Distribution Agreement Sales		37,~~490~~572,~~133~~165		—3,490,133
Sales Generated inside the United States of America
Internally Designed/Manufactured Sales		~~553~~678,~~967~~105		21553,~~467~~967
		5,020,391		999,579
		9,113,607		5,020,391

The following table sets forth financial information by reportable segment for the years ending February 29, 2024 and February 28, 2023:

1. Income/(loss) from operations

	Inside the United States		Outside the United States		Total
	2024	2023	2024	2023	2024	2023
Revenue	553,967	21,467	4,466,424	978,112	5,020,391	999,579
Cost of goods sold	(47,708)	(1,746)	(2,530,214)	(416,011)	(2,577,922)	(417,757)
Gross profit	506,259	19,721	1,936,210	562,101	2,442,469	581,822
Selling expenses	(30,611)	(9,644)	(53,953)	(44,174)	(84,564)	(53,818)
Depreciation expense	—	—	(63,948)	(53,553)	(63,948)	(53,553)
General and administrative expenses	(477,226)	(259,487)	(1,193,802)	(388,685)	(1,671,028)	(648,172)
Research and development expenses	—	—	(22,351)	(64,866)	(22,351)	(64,866)
Income/(loss) from operations	(1,578)	(249,409)	602,156	10,822	600,578	(238,587)
Provision for impairment of note receivable	(642,012)	—	—	—	(642,012)	—

F-13

Table of Contents

Chief Operating Decision Maker (CODM)

The Company’s CODM is the Chief Executive Officer, who is responsible for strategic decision-making and resource allocation. The CEO, with support from the executive leadership team, regularly reviews financial and operational results segmented by geographic region. These reports form the basis for internal decision-making and operational management.

The Company has determined that it operates in two reportable geographic segments: Inside the United States and Outside the United States. These segments reflect the manner in which the Chief Operating Decision Maker (CODM) assesses financial performance and allocates resources.

Basis of Segmentation

Operating segments are determined based on the internal reports regularly reviewed by the CODM. Geographic segmentation reflects the Company's internal management structure and reporting lines, as operations within the United States and internationally are subject to distinct market, regulatory, and customer dynamics.

Performance Measures Reviewed by CODM

The CODM evaluates segment performance primarily using income/loss from operations, which includes revenues, cost of goods sold, and major operating expenses. This measure is reviewed regularly and is considered the most relevant indicator of segment profitability and operating efficiency. Segment results are prepared on a basis consistent with the Company’s consolidated financial statements, with no adjustments for intersegment transactions.

Granular Segment Expense Reporting

To support effective decision-making, the CODM reviews segment-level performance at a more detailed level than presented in the consolidated financial statements. Specifically, the CODM receives and evaluates reports that disaggregate significant expenses such as:

	•	Selling Expenses
	•	Depreciation
	•	General and Administrative Expenses
	•	Research and Development Expenses

This level of detail enables the CODM to evaluate cost drivers and profitability more effectively across geographic segments.

The following table sets forth financial information by reportable segment for the years ending February 28, 2025 and February 29, 2024:

Income/(Loss) from operations


	Inside the United States		Outside the United States		Total
	2025	2024	2025	2024	2025	2024
Revenue	678,105	553,967	8,435,502	4,466,424	9,113,607	5,020,391
Cost of goods sold	(87,826)	(47,708)	(4,164,995)	(2,530,214)	(4,252,821)	(2,577,922)
Gross profit	590,279	506,259	4,270,507	1,936,210	4,860,786	2,442,469
Selling expenses	(65,646)	(30,611)	(47,548)	(53,953)	(113,194)	(84,564)
Depreciation expense	-	-	(73,846)	(63,948)	(73,846)	(63,948)
General and administrative expenses	(725,834)	(477,226)	(665,280)	(1,193,802)	(1,391,114)	(1,671,028)
Research and development expenses	(50,000)	-	(41,133)	(22,351)	(91,133)	(22,351)
Income/(loss) from operations	(251,201)	(1,578)	3,442,700	602,156	3,191,499	600,578
Other income/(expenditure)	-	-	-	-	(1,032,026)	(1,005,266)
Net income/(loss)	-	-	-	-	2,159,473	(404,688)

Other income/(expenditure) includes items not considered by the CODM at segment level, and consist of items such as interest income, interest expense, current income taxes and deferred income taxes.

F-14

Table of Contents

Total Assets

	Inside the United States		Outside the United States		Total
	2024	2023	2024	2023	2024	2023
	2025	2024	2025	2024	2025	2024
Total assets	2,~~697~~181,~~502~~184	32,~~248~~697,~~703~~502	24,~~106~~627,~~777~~789	12,~~241~~106,~~729~~777	46,~~804~~808,~~279~~973	4,~~490~~804,~~432~~279

The major component of total assets is "Cash" of $2,~~808~~769,~~910~~686 for the year ending February 2928, ~~2024~~2025 and $2,~~827~~808,~~457~~910 for the year ending February 2829, ~~2023~~2024. A significant portion of this is maintained ~~Inside~~inside the United States in USD of $2,~~478~~019,~~434~~628 for the year ending February 2928, ~~2024~~2025 and $2,~~582~~478,~~272~~ 434 for the year ending February 2829, ~~2023~~2024.

op. Cost of goods sold

Cost of goods sold consists primarily of raw material purchases, manufacturing costs and employee benefits paid to operational personnel associated with the production of our medical devices.

pq. General and administrative expenses

General and administrative expenses consist ~~consists~~ mostly of personnel costs, consulting fees as well as audit fees.

qr. Research and development

All research and development expenses are expensed as incurred and are included in operating expenses. Our research and development efforts are limited in scope and primarily focused on enhancing existing production processes. We undertake R&D projects only when a working prototype and proof of concept exist, and after assessing economic viability. Projects that cannot be efficiently integrated into our current manufacturing infrastructure are not pursued.

rs. Interest expense

Interest expense relates mostly to is an unsecured loan from Minoan Medical which is repayable over the next 2 years. The loan carries interest at the prevailing prime lending rate of the time. The prevailing lending rate in South Africa was 11.7500% at year end. The terms of this loan are deemed to be market related.

st. Earnings per share

Basic earnings (loss) per share are computed based on the weighted average number of ordinary shares outstanding during each year.

The diluted ~~net~~ earnings/(loss) per share is computed by giving effect to all potentially dilutive securities outstanding for the period, by applying the treasury stock method. For periods in which we report net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. There were no potentially dilutive securities outstanding during the fiscal year ended February 28, 2025; accordingly, no additional shares have been included in the diluted earnings per share calculation.

tu. Principles of consolidation ~~i. Consolidated - all intercompany transactions eliminated~~

~~The consolidated financial statements include the accounts of Medinotec Inc~~i.~~, Medinotec Capital Proprietary Limited and the financial statements of DISA Medinotec Proprietary~~ Consolidated ~~Limited,~~- ~~known~~all ~~as “the Company”. All significant~~ intercompany transactions ~~have been~~ eliminated.

~~F-14~~The consolidated financial statements include the accounts of Medinotec Inc., Medinotec Capital Proprietary Limited and the financial statements of DISA Medinotec Proprietary Limited, known as “the Company”. All intercompany transactions have been eliminated.

F-15

Table of Contents

uv. Use of estimates ~~i. Actual results could differ~~

The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periodi. Actual results could differ ~~from those estimates and may have an impact on future periods.~~

vThe preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. ~~Recently~~Actual ~~issued~~results could differ from those estimates and may have an impact on future periods. As detailed in the Critical Accounting Estimates section above, the key accounting ~~standards~~estimates are as follows:

	•	Allowance for credit losses on loans receivables
	•	Inventory: Valuation, costing and obsolescence
	•	Deferred tax assets

w. Recently issued accounting standards

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU is intended to enhance transparency of income statement disclosures primarily through additional disaggregation of relevant expense captions. The standard is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, with prospective or retrospective application permitted. The Company is currently evaluating the impact of this guidance on its disclosures in the consolidated financial statements.

In August 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-05, Business Combinations-Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement (“ASU 2023-05”), which addresses the accounting for contributions made to a joint venture, upon formation, in a joint venture’s separate financial statements. The amendments require certain joint ventures to apply a new basis of accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The objectives of the amendments are to provide decision-useful information to investors and other allocators of capital in a joint venture’s financial statements and also to reduce diversity in practice. ASU 2023-05 is effective for both public and private joint venture entities with a formation date on or after January 1, 2025. Early adoption is permitted. Entities may elect to apply the guidance retrospectively to joint ventures with a formation date prior to January 1, 2025. The Company does not expect the adoption of this standard to have a material impact on its condensed consolidated financial statements and related disclosures.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions to clarify that a contractual restriction on the sale of an equity security is not considered part of a unit of account of the equity security, and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments also require the following disclosures for equity securities subject to the contractual sale restrictions.

1. The fair value of equity securities subject to the contractual sale restrictions reflected on the balance sheet.

2. The nature and remaining duration of the restriction(s).

3. The circumstances that could cause a lapse in the restriction(s).

This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those financial years. The Company does not expect the adoption of this standard to have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

~~In September 2022, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) ASU 2022~~F-04, Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, which enhances transparency surrounding the use of supplier finance programs. The new guidance requires qualitative and quantitative disclosure sufficient to enable users of the financial statements to understand the nature, activity during the period, changes from period to period and potential magnitude of such programs. The amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the ASU to determine its impact on the Company’s disclosures.16

F-15

Table of Contents

In ~~November 2023~~September 2022, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) ~~2023~~ASU 2022-0704, ~~"Segment~~Liabilities ~~Reporting~~- Supplier Finance Programs (~~Topic~~Subtopic ~~280~~405-50): ~~Improvements~~Disclosure toof ~~Reportable~~Supplier ~~Segment~~Finance ~~Disclosures"~~Program Obligations, which ~~amends~~ enhances transparency surrounding the ~~disclosure~~use toof ~~improve~~supplier finance ~~reportable~~programs. ~~segment~~The new guidance requires qualitative and quantitative disclosure ~~requirements,~~sufficient ~~primarily~~to ~~through~~enable ~~enhanced~~users ~~disclosures~~of ~~about~~the ~~significant~~financial ~~segment~~statements ~~expenses~~to onunderstand anthe ~~annual~~nature, ~~and~~activity ~~interim~~during ~~basis~~the ~~for~~period, tochanges ~~enable~~from ~~investors~~period to ~~develop~~period ~~more~~and ~~decision-useful~~potential ~~financial~~magnitude ~~analyses.~~of ~~All~~such ~~public~~programs. ~~entities~~The amendments ~~will~~are beeffective ~~required~~for tofiscal ~~report~~years ~~segment~~beginning ~~information~~after inDecember ~~accordance~~15, ~~with~~2022, ~~the~~including ~~new~~interim ~~guidance~~periods ~~starting~~within inthose ~~annual~~fiscal ~~periods~~years, ~~beginning~~except ~~after~~for ~~December~~the ~~15,~~amendment ~~2023.~~on ~~The~~roll ~~Company~~forward information, which is ~~currently~~effective ~~assessing~~for ~~potential~~fiscal ~~impacts~~years ofbeginning ~~ASU~~after ~~2023-06~~December ~~and~~15, ~~does~~2023. ~~not~~The ~~expect~~Company has evaluated the ~~adoption~~effect of this ~~guidance~~standard ~~will have~~on aits ~~material~~operations ~~impact~~and onhas ~~its~~determined ~~condensed~~that ~~consolidated~~it ~~financial~~has ~~statements~~no ~~and~~material ~~disclosures~~impact.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures", which amends the disclosure to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an annual and interim basis for to enable investors to develop more decision-useful financial analyses. All public entities will be required to report segment information in accordance with the new guidance starting in annual periods beginning after December 15, 2023. The Company has implemented this standard for the current fiscal year.

In December 2023, the FASB issued ASU 2023-09, " Income Taxes (Topic 740): Improvements to Income Tax Disclosures", which amends the disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness of income tax disclosures. For entities other than public business entities, the requirements will be effective for annual periods beginning after December 15, 2025. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently assessing potential impacts of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its condensed consolidated financial statements and disclosures and the Company is in a loss position and not incurring any tax expenses.

3. Fair Value Measurements

The Consolidated entities report all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3—Inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement in its entirety.

At February 2928, ~~2024~~2025 and February 28 29, ~~2023~~2024, all of the Company’s cash and cash equivalents, trade accounts receivable and trade accounts payable were short term in nature, and their carrying amounts approximate fair value. Our current and long-term debt arrangements are classified as level 2 financial instruments.

F-1617

Table of Contents

4. Property, plant and equipment

a. Accounts by year end

Property, plant and equipment consist of the following:

	Feb 29, 2024 $			Feb 28, 2023 $
	Feb 28, 2025 $			Feb 29, 2024 $
Leasehold improvements		—			19,134
Computer software		1,133			—
Computer software		—			58,551
Office equipment		—			—
Office equipment		—			7,273
Motor vehicles		11,889			11,889
Motor vehicles		11,889			12,446
Small assets		—			—
Small assets		—			14,146
Plant and machinery		1,144,371			1,056,830
Plant and machinery		1,056,830			1,104,182
Furniture and fittings		99,098			99,098
Furniture and fittings		99,098			103,578
Computer equipment		146,437			145,891
Computer equipment		145,891			152,731
Laboratory equipment		239,834			238,799
Laboratory equipment		238,799			249,995
Total cost		1,642,762			1,552,507
Total cost		1,552,507			1,722,036
Foreign currency adjustment		38,373			35,626
Foreign currency adjustment		35,626			90,379
Total accumulated depreciation		(1,332,649	)		(1,268,011	)
Total accumulated depreciation		(1,268,011	)		(1,405,542	)
Total		348,486			320,122
Total		320,122			406,873

Depreciation of property, plant and equipment totaled approximately $8895,~~225~~ 734 for the period ending February 2928, ~~2024~~2025 compared to $5388,~~553~~ 225 for the period ending February 2829, ~~2023~~ 2024.

The Company has not acquired any property and equipment under capital leases.

Depreciation Allocation to Cost of Goods Sold:

A portion of the depreciation expense related to Property, Plant, and Equipment has been allocated to the Cost of Goods Sold. This practice is in accordance with the company's accounting policy, which recognizes a portion of the depreciation expense as part of the cost of producing goods.

The allocation of depreciation to Cost of Goods Sold is based on the estimation of the assets' usage in the production process. This method is employed to better match the cost of assets with the revenue generated during the period.

Depreciation of $2421,~~277~~888 was ~~allocated~~ allocated to Cost of Goods Sold for the year ending February 2928, ~~2024~~2025, compared to $2624,~~777~~ 277 for the year ending February 2829, ~~2023~~2024.

5. ~~Inventories a.~~ Accounts receivable, bynet ~~period~~of allowances

~~Inventory consists~~a. ofAccounts ~~the~~receivable ~~following:~~by period

	2024 $			2023 $
Stock on hand		861,451			381,390
Less provisions for obsolescence		(10,221	)		(27,086	)
Goods in transit		12,223			—
Total		863,452			354,304

Accounts receivable consist of the following:

F-17


	2025 $			2024 $
Trade accounts receivable		2,682,361			641,367
Allowance for expected credit losses		(69,921	)		(51,606	)
Total		2,612,440			589,761

Table of Contents

6. Note receivable

	2024 $		2023 $
Note receivable		—		605,130
Total		—		605,130

The Trachealator product obtained FDA approval in November 2021, which allowed the Company to sell this product into the United States of America. Since the Company had no prior sales channels or infrastructure in the United States, management found it prudent to plan a roll out of the product with a distributor that had an established network and infrastructure. For this business, the Company partnered with a company called Innovative Outcomes and entered into a revolving credit facility to a maximum of $750,000. Innovative Outcomes would use this to grow both their own distribution network and infrastructure and also allow for the Company to utilize this network and infrastructure. However, during quarter ending November 30, 2023, there was a material change in strategic focus where the Company would require its products to be marketed to niche surgical units, Innovative Outcomes would be servicing the wound care clinic market only which meant that the future growth of the combined network and infrastructure would not be a strategic match between the two entities. It was therefore decided to separate the network and infrastructure developed and for each company to pursue its strategic focus. The note receivable will continue on the same terms and become payable later in the 2024 financial year, but the Company decided to provide full impairment against this receivable on November 30, 2023. This decision was made in prudence due to the fact that the receivable is not backed by any Trachealator revenue streams anymore. This does not change that Innovative Outcomes will still be liable for payment of this in the future Interest will accrue as normal until maturity date. Should payments be received this provision will be reversed with the same amount of cashflow received.

7. Loans Payable a. Loans from related parties

	2024 $			2023 $
Minoan Medical Proprietary Limited
Opening balance		1,862,793			1,583,672
Interest		236,873			178,584
Received/Issued		2,076,257			3,329,201
Repayments		(2,323,089	)		(3,228,716	)
Foreign exchange difference		(83,326	)		232
Closing balance		1,769,688			1,862,793
Minoan Capital Proprietary Limited
Opening balance		273			325
Foreign exchange difference		(4	)		(53	)
Closing balance		269			273
Total debt		1,769,957			1,863,066

F-18

Table of Contents

6. Inventories

a. Accounts by period

Inventory consists of the following:


	2025 $			2024 $
Raw materials		261,899			291,389
Work in progress		306			—
Finished goods		731,788			570,061
Less provisions for obsolescence		(10,494	)		(10,221	)
Goods in transit		4,842			12,223
Total		988,341			863,452

7. Other current assets

a. Other current assets by period

Other current assets consist of the following:


	2025 $		2024 $
Prepayments		48,405		39,959
Deposits paid		2,681		2,612
Other receivables		1,633		74,603
Total		52,719		117,174

8. Note receivable


	2025 $		2024 $
Note receivable		—		—
Total		—		—

The Trachealator product obtained FDA approval in November 2021, which allowed the Company to sell this product into the United States of America. Since the Company had no prior sales channels or infrastructure in the United States, management found it prudent to plan a roll out of the product with a distributor that had an established network and infrastructure. For this business, the Company partnered with a company called Innovative Outcomes and entered into a revolving credit facility to a maximum of $750,000. Innovative Outcomes would use this to grow both their own distribution network and infrastructure and also allow for the Company to utilize this network and infrastructure. However, during quarter ending November 30, 2023, there was a material change in strategic focus where the Company would require its products to be marketed to niche surgical units, Innovative Outcomes would be servicing the wound care clinic market only which meant that the future growth of the combined network and infrastructure would not be a strategic match between the two entities. It was therefore decided to separate the network and infrastructure developed and for each company to pursue its strategic focus. The note receivable will continue on the same terms and become payable later in the 2024 financial year, but the Company decided to provide full impairment against this receivable on November 30, 2023. This decision was made in prudence due to the fact that the receivable is no longer backed by any Trachealator revenue streams. This does not change that Innovative Outcomes will still be liable for payment of this in the future. Should payments be received this provision will be reversed with the same amount of cashflow received. We have taken legal action in order to recover the amount outstanding.

F-19

Table of Contents

9. Loans Payable

a. Loans from related parties

	2025 $			2024 $
Minoan Medical Proprietary Limited
Opening balance		1,769,688			1,862,973
Interest accrued		141,748			236,873
Received/Issued⁽¹⁾		1,664,939			2,076,257
Repayments⁽¹⁾		(2,701,966	)		(2,323,089	)
Foreign exchange difference		65,592			(83,326	)
Closing balance		940,001			1,769,688

Minoan Capital Proprietary Limited
Opening balance		269			273
Foreign exchange difference		7			(4	)
Closing balance		276			269

Total debt		940,277			1,769,957

(1) During the fiscal year ended February 29, 2024, the Company entered into a non-cash settlement arrangement involving its loan payable to Minoan Medical. Under this arrangement, a third-party trading partner settled a portion of the loan balance directly with Minoan Medical on behalf of Medinotec. The net impact of this arrangement was a non-cash offset of $339,209. During the fiscal year ended February 29, 2024, the Company made cash loan payment in the amount a $9,680, which is included in the financing cash outflows in the consolidated statement of cash flows.

Minoan Medical Proprietary Limited:

Loans payable consists of a $1940,~~769,688~~ 001 unsecured loan from the prior parent entity of DISA Medinotec in South Africa called Minoan Medical. This loan originated to fund working capital and capex expansions of DISA Medinotec during the developmental and startup phase. After the acquisition of DISA Medinotec on March 2, 2022, the Company assumed this liability. The Company has a period of 3 years after the IPO date of 31 March 2023 or a date at which the Company starts trading on a ~~recognizable~~a national exchange (as defined in Section 3(a)(1) of the Securities Exchange Act of 1934, as amended) to repay the loan. During these 3 years the loan will carry interest at the prevailing prime lending rate of the time.. The prevailing lending rate in South Africa was 11.7500% at year end compared to 1011.75% on February 2829, ~~2023~~2024. The terms of this loan are deemed to be market related.

The Minoan Medical loan decreased by $93829,~~105~~ 687 during the year ended February 2928, ~~2024~~2025 as detailed in the table above.

The interest charged for the year was $~~236~~141,~~873~~ 748 and a 1% movement in the interest rates constitutes a value of $2012,~~159~~886.

The Company has the option to for early settlement in cash or any form of equivalent.

Minoan Medical Proprietary Limited’s ultimate beneficial owner is the CEO of the Medinotec Group of Companies Dr. Gregory Vizirgianakis and is used to hold his medical investments and exports of which DISA Medinotec Proprietary Limited Incorporated was one of these investments before it got transferred into the Medinotec Group of Companies. ~~Pieter van Niekerk also serves as a director on Minoan Medical Proprietary Limited.~~

Minoan Capital Proprietary Limited:

This is an unsecured, interest free loan with no fixed terms of repayment.

Minoan Medical and Minoan Capital are related parties of the Group as the CEO Dr Gregory Vizirgianakis has common control.

~~8. Accounts payable and accrued expenses a. Accounts payable by period~~F-20

Accounts payable consist of the following:

	2024 $		2023 $
Trade accounts payable		588,640		53,615
Accrued payroll, payroll taxes and leave pay		11,684		6,995
Provision for professional fees		92,000		—
Royalties payable		35,139		10,701
Tax liability		53,646		—
Other payables		20,441		—
Total		801,550		71,311

One major European Cardiac supplier constitutes 61% (0% in prior period) of the total trade accounts payable

F-19

Table of Contents

910. ~~Commitments~~Accounts payable and accrued expenses a. ~~Leases~~Accounts ~~and~~payable ~~deferred~~by ~~rent~~period

~~The~~Accounts ~~Company~~payable ~~leases~~consist office and warehouse spaces under a cancelable operating lease agreement with contractual terms from August 1, 2023 to July 31, 2026. The Company is required to pay property taxes, insurance, and normal maintenance costs for certain of ~~these facilities and will be required to pay any increases over~~ the ~~base year of these expenses on the remainder of the Company’s facilities.~~following:

Rental expense for operating leases for the period ended February 29, 2024 was $32,432compared to $39,984 for the period ended February 28, 2023


	2025 $		2024 $
Trade accounts payable		1,198,953		588,640
Accrued payroll, payroll taxes and leave pay		9,656		11,684
Provision for professional fees		—		92,000
Royalties payable		16,462		35,139
Tax liability		195,037		53,646
Other payables		56,879		20,441
Total		1,476,987		801,550

One major European Cardiac supplier constitutes 74% (61% in prior period) of the total trade accounts payable

11. Commitments
a. Leases and deferred rent

The Company accounts for leases under ASC 842, Leases. The Company leases office and warehouse spaces under a cancelable operating lease agreement with contractual terms from August 1, 2023 to July 31, 2026 from a third-party entity that is considered a related party due to mutual directorship with a member of the Company’s Board. The Company is required to pay property taxes, insurance, and normal maintenance costs for certain of these facilities and will be required to pay any increases over the base year of these expenses on the remainder of the Company’s facilities. Management believes the terms of the lease are consistent with market rates and were entered into at arm’s length.

Operating lease right-of-use (ROU) assets and corresponding lease liabilities are recognized on the consolidated balance sheet at the commencement date based on the present value of future lease payments. The Company uses its incremental borrowing rate to discount lease payments, as the implicit rate is not readily determinable. Lease expense is recognized on a straight-line basis over the lease term. Short-term leases (terms of 12 months or less) are not capitalized and are expensed as incurred.

Rental expense for operating leases for the period ended February 28, 2025 was $32,031 compared to $32,142 for the period ended February 29, 2024.

Lease cost associated with operating leases is charged to general and administrative expenses in our consolidated financial statements. The exercise of lease renewal options is at our sole discretion. No extension period has been included in the determination of the right of use asset or the lease liability, as we concluded that it is not reasonably certain that we would exercise such option.

Maturities of our operating lease liability as of February 2928, ~~2024~~2025 was as follows:

Years ending February 28:	Amounts
Years ending February 26/27:	Amounts
2025		30,556
2026		31,370
2026		30,556
2027		13,071
2027		12,731
Total undiscounted lease payments:		44,441
Total undiscounted lease payments:		73,843
Less: Imputed Interest		(3,685	)
Less: Imputed Interest		(9,829	)
Present value of operating lease liabilities		40,756
Total operating lease liabilities		64,014
Operating lease liabilities, current portion		28,060
Operating lease liabilities, current portion		24,316
Operating lease liabilities, net of current portion		12,696
Operating lease liabilities, net of current portion		39,698

~~b. Litigation~~F-21

Table of Contents

The carrying amount of the operating right-of-use asset as of February 28, 2025 was as follows:

	Amounts

Opening balance at March 1, 2024		61,979
Accumulated depreciation		(24,678	)
Closing balance at February 28, 2025		37,301

From time to time, the Company may become involved in various legal proceedings in the ordinary course of its business and may be subject to third-party infringement claims.

In the normal course of business, the consolidated entities my agree to indemnify third parties with whom it enters into contractual relationships, including customers, lessors, and parties to other transactions with the Consolidated entities, with respect to certain matters. The Consolidated entities has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations or covenants, other third-party claims that the Group’s products when used for their intended purposes infringe the intellectual property rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these indemnification obligations due to the Consolidated entities limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each claim.

From time to time, the Consolidated entities are subject to various claims that arise in the ordinary course of business. Management believes that any liability of the consolidated entities that may arise out of or with respect to these matters will not materially affect the financial position, results of operations, or cash flows of the Consolidated entities.

At the reporting date there is no known material litigation or claims against the Group.

~~F-20~~12. Stockholders' equity/(deficit) a. Authorized and issued stock by period

Table of Contents

10. Stockholders' equity/(deficit) a. Authorized and issued stock by period

Authorized:

As of February 2928, ~~2024~~2025 the Company had 188,266,250 shares of common stock authorized and available to issue for purposes of satisfying conversion of preferred stock, the exercise and future grant of common stock options, and for purposes of any future business acquisitions and transactions.

As of February 2928, ~~2024~~2025, Medinotec Inc., the parent Company had 20,000,000 shares of preferred stock authorized and available to issue.

This has remained unchanged from the previous financial year ending February 2829, ~~2023~~2024.

Issued and outstanding shares

	2024		2023
	2025		2024
Common shares		11,733,750		1011,~~000~~733,~~000~~750
Stock issued		—		~~1,733,750~~—
Total		11,733,750		11,733,750

Amount of shares

	2024 $		2023 $
	2025 $		2024 $
Common shares		11,734		1011,~~000~~734
Stock issued		—		~~1,734~~—
Total		11,734		11,734

~~11. Income taxes a. Provision for income taxes~~F-22

The components of income tax expense are as follows:

	2024			2023
Current expense from income taxes:
Federal		(47,753	)		—
State		(5,892	)		—
Foreign		(27,553	)		—
Total current expense from income taxes		(81,198	)		—
Deferred benefit (expense) from income taxes
Federal		—			—
State		—			—
Foreign		(69,720	)		38,742
Total deferred benefit (expense) from income taxes		(69,720	)		38,742
Total	$	(150,918	)	$	38,742

F-21

Table of Contents

13. Income taxes
a. Provision for income taxes

The components of income tax expense are as follows:


	2025			2024
Current expense from income taxes:
Federal		17,666			(47,753	)
State		1,525			(5,892	)
Foreign		(756,580	)		(27,553	)
Total current expense from income taxes		(737,389	)		(81,198	)

Deferred benefit (expense) from income taxes
Federal		—			—
State		—			—
Foreign		(127,276	)		(69,720	)
Total deferred benefit (expense) from income taxes		(127,276	)		(69,720	)

Total	$	(864,665	)	$	(150,918	)

The following table sets forth a reconciliation from the U.S statutory federal income tax rate to the effective income tax rate:

	2024			2023
	2025			2024
Federal income tax rate		21	%		21%	%
Permanent differences		(184	%)		—(18	%)
State taxes		(20	%)		—(2	%)
Valuation allowance		~~(52~~5	%)		—(52	%)
Foreign rate differential		(7	%)		(~~11%)~~7	%)
Other		(10	%)		—(1	%)
Effective rate		~~(59~~29	%)		~~10%~~(59	%)

F-23

Table of Contents

b. Deferred taxes/Future income tax assets and valuation allowance

The following table sets forth the significant components of deferred tax assets and liabilities:

	2024 $			2023 $
	2025 $			2024 $
Deferred tax assets
Provision for Professional fees		~~24,840~~—			—24,840
Leave pay provision		~~973~~1,244			~~3,102~~973
Provision for stock obsolescence		2,~~110~~166			—2,110
Provision for bad debt		1317,~~792~~504			—13,792
Provision for royalties		9,487			—
Unrealised profit inventory		24,503			—
Commission accrual		3,731			—
Provision for royalties		4,445			9,487
Impairment of note receivable		167,574			—
Commission accrual		383			3,731
Assessed losses		—			105,849
Impairment of note receivable		173,803			167,574
Lease liabilities		17,283			—
Foreign tax credits		264,820			—
Total deferred tax assets		236,790			108,951
Net operating loss - State		6,066			—
Less valuation allowance		(177,175	)		—
Advanced income		12,661			—
Deferred tax assets, net		59,615			108,951
Lease liabilities		38,234			17,283
Total deferred tax assets		545,829			236,790
Less valuation allowance		(462,576	)		(177,175	)
Deferred tax assets, net		83,253			59,615
Deferred tax liabilities:
Right-of-use assets		(1637,~~734~~302	)		—(16,734	)
Total deferred tax liabilities		(16,734	)		—
Uninvoiced revenue GAAP adjustment		(126,075	)		—
Deferred tax assets, net		42,881			108,951
Total deferred tax liabilities		(163,377	)		(16,734	)
Deferred tax assets/(liabilities), net		(80,124)			42,881

Deferred tax assets refer to assets ~~that~~ that are attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets in essence represent future savings of taxes that would otherwise be paid in cash. The realization of the deferred tax assets is dependent upon the generation of sufficient future taxable income, including capital gains. If it is determined that the deferred tax assets cannot be realized, a valuation allowance must be established, with a corresponding charge to net income. It is management’s estimate that ~~the~~certain deferred tax assets will be utilized in full in the next 12 months.

F-22

Table of Contents

c. Other

The geographic components of income/(loss) before income taxes consisted of the following for the years ended February 2928, ~~2024~~2025 and February 28 29, ~~2023~~2024:

	2024			2023
	2025			2024
United States operations	$	(~~594~~248,~~328~~501	)	$	(~~239~~594,~~782~~328	)
International operations		~~340~~3,~~558~~272,639			~~(151~~340,~~695~~558	)
(Loss) income before taxes	$	~~(253~~3,~~770~~024,138	)	$	(~~391~~253,~~477~~770	)

No U.S. federal tax has been provided on the undistributed earnings of the foreign subsidiaries as of February 29, 2024 as the company intends to permanently reinvest the earnings. As of February 28, 2024, the Company has no liabilities for uncertain tax positions. It is the Company’s policy to record interest and penalties as a component of tax expense. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and South Africa. With few exceptions, the fiscal years that remain subject to examination are February 28, 2023 through February 29, 2024.

12. Business acquisitions

a. Acquisition of Disa Medinotec Proprietary Limited

On March 2, 2022 the Medinotec Inc. and Medinotec Capital Proprietary Limited acquired 100 percent of the issued and outstanding shares of DISA Medinotec Proprietary Limited. The consideration payable was $11 for the outstanding equity and the Group assumed the responsibility of the loan account ($1,583,661) payable to Minoan Medical Proprietary Limited. Due to the control of businesses being in principal 95% the same between the Group and the previous ultimate beneficial owner of DISA Medinotec Proprietary Limited the transaction would be deemed a common control transaction. Due to common control being established on April 26, 2021 (the incorporation date of the registrant) the effective date is deemed to be at this date.

The Group acquired the assets and liabilities:

	$
Cash		80,975
Accounts and other receivables		41,742
Inventory		424,810
Property, plant and equipment		507,956
Deferred tax assets		22,449
Accounts payable and accrued liabilities		(120,987	)
Long-term debt		(1,316,848	)
Common control reserve		(359,903	)

To properly account for the transfer of the membership interests of DISA Medinotec Proprietary Limited, the Company reviewed the ownership structure of all of the entities involved in the contribution transaction, as contemplated in the Registration Statement, and concluded that in accordance with ASC 805-50-25-2, the contribution of such membership interests will qualify as a transfer of ownership between entities under common control.

“When accounting for a transfer of assets or exchange of shares between entities under common control, the entity that receives the net assets or the equity interests shall initially measure the recognized assets and liabilities transferred at their carrying amounts in the accounts of the transferring entity at the date of transfer. If the carrying amounts of the assets and liabilities transferred differ from the historical cost of the parent of the entities under common control, for example, because pushdown accounting had not been applied, then the financial statements of the receiving entity shall reflect the transferred assets and liabilities at the historical cost of the parent of the entities under common control.”

F-23

Table of Contents

ASC 805-50-15-6 states that the guidance in the Transactions Between Entities Under Common Control Subsections applies to combinations between entities or businesses under common control in which an entity charters a newly formed entity and then transfers some or all of its net assets to that newly chartered entity. If the guidance in the subsection applies, then in accordance with ASC 805-50-30-5, the Company will initially measure the recognized assets and liabilities transferred at their carrying amounts (historical cost) in the accounts of the transferring entity at the date of transfer.

The Company believes the financial information of DISA Medinotec Proprietary Limited is properly presented based on the carryover basis of accounting because the transfer of the ownership qualifies as a reorganization of entities under common control.

In ASC 805, “control” has the same meaning as “controlling financial interest” in ASC 810-10-15-8. A “controlling financial interest” is generally defined as ownership of a majority voting interest by one entity, directly or indirectly, of more than 50 percent of the outstanding voting shares of another entity. U.S. GAAP does not define the term “common control.”

The accounting treatment for the contribution of the membership interests of DISA Medinotec Proprietary Limited into the structure of Medinotec Inc Nevada was based upon the following facts:

At the date of incorporation of Medinotec Inc in Nevada April 26, 2021, Gregory Vizirgianakis (CEO) was the 100% ultimate beneficial owner of DISA Medinotec Proprietary Limited and owned 95% of Medinotec Inc in Nevada.

Based upon the facts as outlined above, the Company applied the guidance outlined in ASC 805-50 which deals with transactions between entities under common control.

Transactions between entities under common control are accounted for in a manner similar to the pooling of-interest method. Thus, the financial statements of the commonly controlled entities would be combined, retrospectively, as if the transaction had occurred at the beginning of the period. However, ASC 805-50-45-5 states that prior years’ comparative information is only adjusted for periods during which the entities were under common control. In addition, ASC 805-50-45-2 requires that the “effects of intra-entity transactions on current assets, current liabilities, revenue, and cost of sales for periods presented and on retained earnings at the beginning of the periods presented shall be eliminated to the extent possible.”

DISA Medinotec Proprietary Limited was deemed to be under common control prior to March 2, 2022 share transfer date and therefore the acquisition was retrospectively applied from April 26, 2021, the formation date of registrant.

The proforma information as disclosed in this note have been prepared to present this.

	Proforma 2022 $
Revenue	$	1,215,905
General and administration	$	601,094
Net loss		(167,764	)

F-24

Table of Contents

13No U. ~~Transactions~~S. federal tax has been provided on the undistributed earnings of the foreign subsidiaries as of February 28, 2025 as the company intends ~~with~~to ~~related~~permanently ~~parties~~reinvest the earnings. As of February 28, 2024, the Company has no liabilities for uncertain tax positions. It is the Company’s policy to record interest and penalties as a component of tax expense. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and South Africa. With few exceptions, the fiscal years that remain subject to examination are February 29, 2024 through February 28, 2025.

Name	Relationship with the Medinotec Group of Companies	Related transactions with the Medinotec Group of Companies	Related Directors with the Medinotec Group of Companies	Related Owners with the Medinotec Group of Companies
Minoan Medical Proprietary Limited	Medical investment company controlled by Dr Gregory Vizirgianakis	Related Party Loan	Dr Gregory Vizirgianakis Pieter van Niekerk	Dr Gregory Vizirgianakis is the ultimate beneficial owner
Minoan Capital Proprietary Limited	Property investment company controlled by Dr Gregory Vizirgianakis	Related party loan Rental Expenses	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Dr Gregory Vizirgianakis is the ultimate beneficial owner
Medinotec Capital Proprietary Limited	The African holding company of the Medinotec Group of Companies	Related party loan payable to Minoan Capital	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity
DISA Vascular Distribution Proprietary Limited trading as DISA Life Sciences	Distributor appointed by DISA Medinotec Proprietary Limited for Africa	Sales Income	Pieter van Niekerk – Serves as independent non-executive according to distribution agreement Pieter van Niekerk resigned as a non-executive director on October 14, 2022 and therefore the related party relationship ceased to exist on the same date.	n/a external third party
DISA Medinotec Proprietary Limited	The African operating and manufacturing company	Related party loan with Minoan Medical Operational income and expenses with Minoan Medical	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity

In October 2021, the Organisation for Economic Co-operation and Development (OECD)/G20 Inclusive Framework released a two-pillar solution to address the tax challenges of the digital economy. Pillar Two introduces a global minimum corporate tax regime that applies to multinational enterprises (MNEs) with annual consolidated revenue of €750 million or more.

The Company operates manufacturing and distribution activities in several jurisdictions, including the United States and South Africa. Although South Africa has announced its intention to implement a Qualified Domestic Minimum Top-Up Tax (QDMTT) beginning in 2024 under Pillar Two, the Group’s consolidated revenue for the past two fiscal years has not exceeded the €750 million threshold. As such, the Group is not currently within the scope of the Pillar Two global minimum tax rules.

The Company continues to monitor developments related to Pillar Two in the jurisdictions in which it operates, including the United States and South Africa. If future changes to revenue thresholds or group composition bring the Company into scope, the potential tax impacts will be assessed in accordance with ASC 740, Income Taxes.

Based on the current scope criteria and the absence of substantively enacted legislation in the United States, no amounts have been recognized in the consolidated financial statements related to Pillar Two. Any future obligations arising from the implementation of these rules, should the Group become subject to them, will be accounted for as current-period tax expenses, consistent with the FASB staff guidance issued in 2023.

14. Transactions with related parties

Name	Relationship with the Medinotec Group of Companies	Related transactions with the Medinotec Group of Companies	Related Directors with the Medinotec Group of Companies	Related Owners with the Medinotec Group of Companies	Amount for the 2025 fiscal year
Minoan Medical Proprietary Limited	Medical investment company controlled by Dr Gregory Vizirgianakis	Related Party Loan	Dr Gregory Vizirgianakis	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Loan payable - $940,001
Minoan Capital Proprietary Limited	Property investment company controlled by Dr Gregory Vizirgianakis	Related party loan Rental Expenses	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Dr Gregory Vizirgianakis is the ultimate beneficial owner	Loan payable - $276 Lease liability - $40,756
Medinotec Capital Proprietary Limited	The African holding company of the Medinotec Group of Companies	Related party loan payable to Minoan Capital	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity	n/a
DISA Medinotec Proprietary Limited	The African operating and manufacturing company	Related party loan with Minoan Medical Operational income and expenses with Minoan Medical	Dr Gregory Vizirgianakis Pieter van Niekerk	Medinotec Incorporated in Nevada is the 100% ultimate parent entity	n/a

F-25

Table of Contents

Medinotec Incorporated Nevada Ultimate parent of Medinotec Capital and DISA Medinotec All of the above for its related subsidiaries Dr Gregory Vizirgianakis Pieter van Niekerk Joseph P Dwyer Stavros Vizirgianakis Athanasios Spirakis This is the entity owned by the shareholders and primarily controlled by Dr Gregory Vizirgianakis and his Brother Stavros Vizirgianakis n/a Medinotec Group of Companies The Consolidated group name of Medinotec Incorporated, Medinotec Capital Proprietary Limited and DISA Medinotec Proprietary Limited above for its related subsidiaries Dr Gregory Vizirgianakis Pieter van Niekerk Joseph P Dwyer Stavros Vizirgianakis Athanasios Spirakis This is the entity owned by the shareholders and primarily controlled by Dr Gregory Vizirgianakis and his Brother Stavros Vizirgianakis n/a Pieter van Niekerk Chief financial officer of the Medinotec Group of Companies Transactions relating to mutual entities disclosed above Related directorships disclosed above Minority Shareholder in Medinotec Inc n/a Gregory Vizirgianakis Chief Executive officer of the Minoan Group of Companies Brother of Stavros Vizirgianakis Transactions relating to mutual entities disclosed above Related directorships disclosed above Shareholder in Medinotec Inc and Kingstyle investments. n/a Stavros Vizirgianakis Non-Executive director of the Medinotec Group of companies Brother of Gregory Vizirgianakis Transactions relating to mutual entities disclosed above No Related other Directorships in Medinotec Group of Companies n/a n/a Joseph Dwyer Non-Executive director of the Medinotec Group of companies Transactions relating to mutual entities disclosed above No Related other Directorships in Medinotec Group of Companies n/a n/a Athanasios Spirakis Independent director of the Medinotec Group of companies Transactions relating to mutual entities disclosed above No Related other Directorships in Medinotec Group of Companies n/a n/a

F-26

Table of Contents

a. Rent

DISA Medinotec Propriety Limited ~~leases~~ leases commercial buildings from Minoan Capital Proprietary Limited (“Minoan Capital”). Minoan Capital is owned 100% by the ~~Chief~~ Chief Executive Officer of the Medinotec Group of Companies, Dr. Gregory Vizirgianakis. ~~Pieter van Niekerk, CFO of the Medinotec Group of Companies, also serves as a director on Minoan Medical Proprietary Limited.~~ We are currently also renting storage and office space in the US on a 12-month lease agreement.

Set forth below is a table showing ~~the~~ the Consolidated entities' rent paid for the year ended February 2928, ~~2024~~2025 and February 2829, ~~2023~~2024 with Minoan Capital and for the Melville, New York office:

	2024 $	2023 $
	2025 $	2024 $
Rent	3251,~~142~~759	3932,~~984~~142

Rent is comparable to rent charged for similar properties in the same relative area. The company does market research of a Minimum and a Maximum rental value within the area at every renewal of the rental agreement to ensure this is market related, this exercise is undertaken together with a registered property agent who has the appropriate knowledge of the area.

b. Loan

This is an unsecured loan from the prior parent entity of DISA Medinotec Proprietary Limited incorporated in South Africa called Minoan Medical Proprietary Limited (a related party). This loan originated to fund working capital and capex expansions of DISA Medinotec Proprietary Limited Incorporated during the developmental and startup phase.

The Consolidated entities, particularly Medinotec Inc. has the option to settle earlier in cash or any form of equivalent.

1415. Subsequent events

~~There were~~We noobtained ~~subsequent~~FDA ~~events~~clearance for the ~~year~~Aortic Valve ~~ending~~Dilatation ~~February~~Balloon 29Catheter (OutFlo) on March 11, ~~2024~~2025.

There were no other subsequent events for the year ending February 28, 2025.

F-27

Filing Compare · Medinotec Inc.